ypsomed holding ag – annual report 2011/12 · “diabetes care” and broaden our customer base....

Ypsomed Holding AG – Annual Report 2011/12

Ypsomed Holding AG

Brunnmattstrasse 6Postfach3401 BurgdorfSchweiz

Telefon +41 34 424 41 11Fax +41 34 424 41 22

[email protected]

Ypso

med

Hol

ding

AG

– A

nnua

l Rep

ort 2

011/

12

Annual Report 2011/12

Ypsomed Holding AG

Ypsomed – Better Life

All over the world, there are manypeople who live their lives independentlyand with great enjoyment despitetheir condition, such as having diabetes.And all over the world, there are large numbers of people who are committedto achieving a better life for patients:family members, doctors, nurses, pharma-ceutical researchers, developers and Ypsomed staff. All of them have their own personal story.


Patrick Martinsson was in a serious car accident. Damage to his pancreas meant that he would suffer from type 1 diabetes for the rest of his life. His doctor recommended conventional insulin syringes for the daily injections. While he did not have a problem performing the injec-tions at home, he found the sy-ringes too unwieldy to have with him all the time when he was out and about and not sufficiently discreet for use in his everyday activities. At Ypsomed he came up with a revolutionary new so-lution that is available today as mylife™ DailyDose™ and that has made many people’s daily lives easier.

Patrick Martinsson Insulution, Inventor of mylife™ DailyDose™

As Senior Product Manager, Adrian Gerber is expected to always be right up to date when it comes to the latest innova-tions for self-injection. One of these innovations is the launch of mylife™ DailyDose™ as an alternative for diabetes sufferers who need injections before meals. mylife™ Daily- Dose™ allows them to reach a new level of freedom. The world’s smallest syringe can be easily tucked away in a jacket pocket and makes for a discreet, virtually invisible injection at any time.

Adrian GerberSenior Product Manager


Ulrike Bauer and her team work closely with pharmaceutical and biotech partners from different parts of the world. In joint pro-jects, platform products are adapted to the specific needs of user groups. This allows more and more patients to benefit from the convenience of simple, safe, self-medication in the form of Ypsomed’s high-quality pens. After their market launch Ypsomed’s specialists make sure that the products are always available for delivery and that the quality stays consistently high.

Ulrike Bauer Vice President Customer & Product Management

At the beginning of every new development there has to be an idea. Inspired by genu-ine issues affecting customers, Jürg Hirschel is constantly on the hunt for this idea. By com-bining technical innovations and a good understanding of the market, Jürg Hirschel and his team develop new products that make patients’ lives easier. Jürg Hirschel and his depart-ment make the link between sufferers’ needs and the techni-cal possibilities, always aiming at the perfect solution.

Jürg HirschelTechnical Leader Product Development


As International Product Mana-ger, Annika Baumann ensures that the innovative mylife™

Orbit® infusion set is available to patients around the world. Together with her team, she works every day to make the mylife™ Orbit® offering even more attractive and more suited to people’s needs. Thanks to the sophisticated 360° freely rotating connection, this pioneering infusion set gives diabetics lots of freedom of movement and hence a greater quality of life.

Annika Baumann International Product Manager

mylife™ Orbit® provides patients with an infusion set that offers a high degree of convenience when it comes to self-medication. One of the key tasks of a Logistics department is to ensure a well-oiled procurement chain. As Head of Supply Chain Management, Konrad Indermitte and his team invest all their energies, every day, into making all mylife™

Diabetescare products available to the markets in the best possi-ble quality, and into ensuring as secure a supply as possible.

Konrad IndermitteHead of Supply Chain Management


Ypsomed is committed to ensur-ing that, worldwide, self-medica-tion becomes a matter of course for sufferers. To achieve this goal, it needs all its employees at every level to have both a high level of specialist expertise and the will-ingness to make constructive use of their skills. As Human Resources Manager, Erwin Ryser is good at spotting talented people. His balanced approach to human resources management ensures that everyone is deployed in a way that matches his or her specialist, methodological and social skills and can therefore develop his or her talent in the best way possible.

Erwin Ryser Human Resources Manager

Heike Grum and her team provide Ypsomed’s management with management information that serves as a basis for impor-tant corporate decisions. As Head of Controlling, she is an advisor for operational issues and ensures that planning principles are created for corporate goals. Business cases are drawn up for new investment projects, mean-ing the financial framework is also strong and that Ypsomed can continue to provide its customers with high-quality products.

Heike GrumHead of Controlling


Life with diabetes is different – but not that different. In spite of his illness, Stephan Stempfel does not have to do without anything. Having his blood sugar level un-der control at all times, be this in sport, at work or in his free time, allows him to have a normal life. Precise blood sugar testing is par-ticularly important here. Only by being sure that he has everything under control can he deal easily with his everyday life, and mylife™ Diabetescare gives him this certainty.

Stephan StempfelType 1 diabetic

As a salesperson in the field, Natacha Boquet is particularly reliant on a comprehensive prod-uct portfolio. Salespeople can only be successful if they are convinced they are offering cus-tomers the best possible product. Thanks to the mylife™ Diabetes-care product range, she doesn’t need to worry about this. The well-balanced offering of inno-vative and high-tech products means this is always guaranteed.

Natacha Boquet Key Account Manager France

Ypsomed – Annual Report

Contents

17 Ypsomed key figures at a glance

18 Letter to the shareholders

21 Annual Report

YDS Ypsomed Delivery Systems 21 Injection systems – A worldwide growth market

22 YDS Ypsomed Delivery Systems – Complete portfolio of injection systems 24 YDS Custom Products – Individual platform products ready for use

29 YDS Contract Development – Customer-specific order development 30 YDS Contract Manufacturing – A flexible service

31 YDS Drug & Device Assembly – One-stop shop for injection systems and drug packaging

mylife™ Diabetescare 32 Strategic Diabetes Care business segment extended further 34 Ypsomed worldwide 37 Ypsomed extends the mylife™ Diabetescare product range 40 mylife™ – Pen needles and safety pen needles 41 mylife™ Pura® – The blood glucose monitoring system that is highly accurate and easy to use 42 mylife™ OmniPod® – The insulin patch pump proves popular

45 Sustainability Report 45 Employees 48 Environment

49 Financial Report 49 Comments on the consolidated financial statement 2011/12 53 Consolidated financial statement 2011/12 77 Financial statement of Ypsomed Holding AG 2011/12 84 Five-year overview

85 Corporate Governance Report 85 Corporate Governance 105 Information policy

106 Glossary

17


An

nual

Rep

ort

Key figures and share price development

Key figures at a glanceIn thousand CHF 1 April 2011

31 March 20121 April 2010

31 March 2011(Adjusted*)

Change in %

Sales of goods and services 248 593 261 822 –13 228 –5.1

thereof delivery devices 153 404 173 917 –20 513 – 11.8

thereof diabetes direct business 78 186 72 584 5 602 7.7

thereof others 17 003 15 321 1 683 11.0

Gross profit 56 373 60 987 –4 615 –7.6

Gross profit in % 22.7% 23.3%

Operating profit 5 140 8 817 –3 677 –41.7

Operating profit in % 2.1% 3.4%

Net profit 8 500 5 468 3 032 55.5

Net profit in % 3.4% 2.1%

Earnings per share (in CHF) 0.67 0.43 0.24 55.5

Research and development expenditures, total 25 201 27 464 –2 263 –8.2

Investments in fixed assets 7 501 14 734 –7 233 –49.1

Equity ratio in % 66.6% 63.6%

Employee headcount (as of 31 March) 1 026 1 097 –71 –6.5

Employees fulltime equivalents (as of 31 March) 980 1 056 –76 –7.2

Audited IFRS figures. In thousand CHF. Earnings per share in CHF.

*The figures have been adjusted due to the change to Swiss GAAP FER.

– –

Share Price Development

250

200

150

100

50

0

Ypsomed Holding AG SPI Index

CHF

22.9.2004 2006 2007 2008 2009 2010 2011 31.3.2012

18


Net profit rises – currency effects impact negatively on sales and operating result

Dear shareholders

In the 2011/12 business year, the Ypsomed Group posted consolidated sales of CHF 248.6 million. Adjusted by CHF 10.8 million for currency effects occasioned by the strong Swiss franc, Ypsomed would have increased sales of delivered goods by 2.5% compared to the year before. Net profit in this business year was able to be increased by CHF 3.0 mil-lion to CHF 8.5 million thanks to the capital gains made from selling financial assets. Operating profits had a margin of 2.1%, lower than the previous year (3.4%). Here, too, cur-rency effects had a major impact, cutting profitability by some CHF 3.0 million in the business year. A further negative fac-tor was an amortization on a pen project of CHF 1.0 million because of an impairment. By sticking rigorously to its strat-egy and thanks to appropriate cost management, the sales base and profitability have been strengthened in the mid-term in a sustainable manner.

Major cost savings realized

The cost analysis launched by the Board of Directors at the start of the business year revealed new areas in which savings could be made. The targeted action taken enabled the Ypsomed Group to cut personnel costs by a total of CHF 8.5 million and reduce expenditure on investments by more than CHF 7.0 million in the 2011/12 business year compared with the previous year. Areas not contributing directly to production were cut back and management structures were streamlined, while existing capacities were utilized more efficiently and customer-focused activities were stepped up. Stringent cost management remains a high priority for us and we remain committed to improving our business processes continuously and achieving more with the resources available. The substan-tial investments over the past few years in innovative technol-ogy platforms and cutting-edge production infrastructure for injection systems and in cultivating the market for the new mylife™ Diabetescare products were made quite deliberately and are now gradually beginning to have a positive financial impact.

Ypsomed’s strategy is the right one

Ypsomed’s strategy is built around “self-care solutions,” focus-ing on solutions that allow patients to self-inject drugs and in particular on products and services for people with diabetes who need to treat themselves with insulin. Our aim is to further expand our two business segments “Injection Systems” and “Diabetes Care” and broaden our customer base. In terms of diabetes care, Ypsomed markets products and services directly to diabetics, doctors and health insurance providers such as our patented mylife™ pen needles or the extremely successful mylife™ OmniPod®, the world’s first tubing-free insulin pump. You can read more on the extensive mylife™ Diabetescare product range and the new second-generation mylife™ OmniPod®, which is now two-thirds of its former size, from page 32 of this Annual Report onward. In the Injection Systems segment, Ypsomed’s YDS Ypsomed Delivery Systems offer a complete range of products for pharmaceutical and biotech companies looking to deploy ready-to-use injection systems to administer their drugs or to develop and manufacture them in line with customer require-ments and package them together with the drugs. More information on Ypsomed Delivery Systems, the injection sys-tem platforms available and Ypsomed’s comprehensive service portfolio for pharmaceutical customers can be found from page 22 of this Annual Report onward.

“We are pursuing the right strategy and have successfully expanded our customer base, both in diabetes care and injection systems.”

Letter to the shareholders

19


An

nual

Rep

ort

Ypsomed launches new products and expands its customer base

In the 2011/12 business year, the Ypsomed Group diversified its sales base further. In the Injection Systems segment, we succeeded in winning several new customers for our high-quality ServoPen® insulin pen, including two more Asian in-sulin providers in the shape of Square Pharmaceuticals Ltd. and Incepta Pharmaceuticals Ltd. More and more pharma-ceutical companies are turning to ergonomic, patient-friendly injection systems that can be produced at low cost and in high quality and quickly brought to market. Over the past few years, Ypsomed has succeeded in being considered for most of the relevant invitations to tender issued by pharmaceutical companies for pen systems and autoinjectors, which has se-cured the Group a number of key customer projects.Other particularly pleasing developments have included the growth in sales of ServoPens® achieved with Tonghua Dong-bao Pharmaceutical Co. Ltd. in China and the extremely reli-able supply service for Amylin Pharmaceuticals Inc, which honored Ypsomed with its “Supplier of the Year Award” in 2011. Ypsomed was able to partially offset the decline in sales recorded by the OptiPen® Pro and the OptiSet®, which is no longer to be produced, with contract manufacturing

work for components for the SoloStar® Pen. The share of sales attributable to Sanofi, formerly a major customer, is currently 20.5%. Because the OptiSet® Pen is no longer being manu-factured, sales with Sanofi will further reduce by some 40% in the 2012/13 business year. However, in the Diabetes Care segment, Ypsomed has also broadened its geographic cus-tomer base for mylife™ Diabetescare and has launched new products. For instance, a new distribution company was set up in Austria late last year and the mylife™ Orbit® infusion set, which offers 360 degrees of freedom of movement, was already brought onto the market in summer 2011. In addition, the launch of mylife™ DailyDose®, the insulin syringe in credit card format, will take place soon, and distribution of the second generation of mylife™ OmniPod® insulin patch pumps is set to begin in summer 2012.

Strategically important acquisition in the highly profitable infusion set business Ypsomed made a strategically important acquisition in No-vember 2011, purchasing the patents and infusion set business of the US company ICU Medical Inc. By taking over manu-facturing processes and relocating production from the USA to Mexico, costs can be optimized and the gross profit mar-gins achieved by these products increased in future. The market for infusion sets for insulin pumps is extremely prom-ising and is already worth over a billion US dollars. The Orbit® infusion sets are providing Ypsomed with potential for growth and are of great strategic importance in light of the launch of a self-developed, low-cost, user-friendly insulin pump, which is planned for early 2014.

Ypsomed keeps executive responsibility in the family As founder and major shareholder and as a family, we are convinced that we at Ypsomed are pursuing the right strategy and we are implementing it with great consistency. We are acting in a targeted manner and taking extensive measures to diversify our sales base and cut our costs. With CEO Richard Fritschi moving to a start-up company in the dental sector, in August 2011 we once again assumed responsibil-ity for the operational management of the company. We accept our responsibility and are ourselves keen to ensure Ypsomed’s lasting positive development. The top-level man-agement of the Ypsomed Group is in future to remain in the hands of the family, ensuring continuity for customers, partners and employees. The plan is for Simon Michel, currently re-

Ypsomed's strategy

20


sponsible for Marketing & Sales and a member of the man-agement, to take over as CEO in two years’ time. As a father and son team, our commitment in terms of time and personal effort is great, and we are both firmly intent on increasing Ypsomed’s sales and improving its profitability through strin-gent cost management in order to boost the share price once again in the medium term. We would like to take this op-portunity to thank all our employees for their loyalty and hard work as well as you, our shareholders, for the trust you have placed in us.

“We intend to increase Ypsomed’s profitability through strict cost management and thus boost the share price once again.”

Outlook

Injection systems for self-medication and diabetes care are both attractive markets with potential for growth at interna-tional level, in the USA, Europe and particularly in Asia. With mylife™ Diabetescare, Ypsomed is further expanding an extensive range of diabetes care products, with many prom-ising customer projects for injection systems also in the pipeline. This makes us fundamentally very confident for the future, although the cultivation of the diabetes care market will continue to require substantial resources, and experience has shown us that new customer projects for injection systems take time to implement. Another challenge is compensating for the downward trend in former Sanofi products. Other challenges include increasing cost pressure in the healthcare sector as well as the global debt crisis and the associated currency trends. The strong Swiss franc is curbing Ypsomed’s sales growth and eating into profit margins of individual products. As an export-oriented Swiss medical technology

company, we are taking all the countermeasures we can and are committed to strengthening Ypsomed’s competitiveness on the international stage. Because of existing expertise and internationally recognized Swiss quality, the development and manufacture of high-technology products in large quan-tities will remain in Switzerland. However, for new injection systems that are primarily produced manually or are very sensitive to price fluctuations, Ypsomed will in future be forced to consider moving manufacturing activities abroad.The loss of the OptiSet® Pen will mean that the first quarter of 2012/13 will be muted in terms of both sales and income, while the second semester, thanks to compensatory transac-tions, will have a result better than expected. As a whole, we are cautiously optimistic for the 2012/13 business year and are expecting sales and income to be at the same level as in the previous year.

Dr. h. c. Willy Michel Simon Michel

Chief Executive Officer, CEO Senior Vice President Marketing & Sales and Chairman of the Board of Directors

21


An

nual

Rep

ort

Injection systems – A worldwide growth market

Innovative injection systems enable safe and cost-effective self-medication

Modern injection systems, such as those that Ypsomed has been developing and supplying to pharmaceutical customers for more than 25 years, are a worldwide growth market. The medications that are produced using biotechnology today (such as peptide hormones and monoclonal antibodies) are administered almost exclusively subcutaneously, i.e. they are injected under the skin. Pen systems and autoinjectors are used primarily to treat diseases such as diabetes, growth disorders, infertility, thrombosis prophylaxis, osteoporosis, hepatitis C or anemia in the case of kidney disorders. How-ever, they are also used for cancer, and various autoimmune diseases such as arthritis, multiple sclerosis, psoriasis or Crohn’s disease. Because of the unchecked increase in diabetes around the world, the administration of insulin is one of the largest and most interesting markets for Ypsomed. Particularly prom-ising here is the growth potential for insulin pens in emerging markets, and with new insulin suppliers.

“Innovative injection systems enable safe self-medication, and contribute to improving the success of treatment, while simultaneously reducing costs in the healthcare sector.”

Cost pressures in the healthcare sector and in pharmaceutical companiesThe trend towards self-medication has increased further in recent years, not least because of the ever- growing pressure on costs in the healthcare sector. Innovative injection systems such as pen systems or autoinjectors enable successful treat-ment by the patients themselves, thus helping to avoid expen-sive hospital stays and visits to doctors, and lowering the costs of treatment overall. But the established pharmaceutical companies too are subject to cost pressures, as more and more patents for their original preparations are running out.

Because of this so-called “patent cliff”, pharmaceutical com-panies are implementing savings in the development, manu-facture and marketing of drugs. In addition, generic products and biosimilar drugs, which are being developed both by the large US and European pharmaceutical groups as well as by up-and-coming pharmaceutical companies from India, China, Korea, Latin America and eastern Europe, are gaining in importance.

Challenging market environment with numerous opportunitiesFor the use of biosimilars, a market worth billions that will experience strong growth in the future, just as for the numer-ous new biotech drugs, there will be a demand for ergo-nomic, safe and economical pen systems or autoinjectors for pre-filled syringes, such as Ypsomed offers in its product portfolio. Small and medium-sized pharmaceutical companies that have little or no expertise in injection systems are there-fore working today – just as the large pharmaceutical com-panies have been doing for years already – with independent developers and manufacturers of injection systems, or with contract developers and contract manufacturers. Pharmaceu-tical companies wish to offer their drugs either with new and innovative injection systems as a premium product, or to compete with original preparations with very simple and economical injection systems at significantly lower prices. Thus the pressure on costs not only leads to takeovers among pharmaceutical companies, but also leads to consolidation at the level of contract manufacturers and component manu-facturers, as well as in the filling and packaging of drugs.

22


Complete portfolio of injection systems with extended service provisionWithin the industry, Ypsomed is regarded as the world’s larg-est independent developer and producer of injection systems for subcutaneous administration of drugs in liquid form by patients. Ypsomed not only has an extensive patent portfolio and a comprehensive range of products, but also many years of experience in the development and manufacture of high-quality injection systems. In order to be able to market the existing range of innovative injection systems and all the specialized services for pharmaceutical companies even bet-ter, Ypsomed has created a new umbrella brand with YDS Ypsomed Delivery Systems.

Amylin names Ypsomed “Supplier of the Year”For more than 10 years, Ypsomed has been successfully working with Amylin Pharmaceuticals Inc., a leading US pharmaceutical group. Ypsomed has developed the SymlinPen® for Amylin, for the administration of a liquid medication for better control of blood glucose, and has built up the production of the pen system in Switzerland. Ypsomed has been supplying the SymlinPen® since 2007 and will soon be in a position to manufacture a further pen system for Amylin in Switzerland. Ypsomed is delighted that Amylin has awarded Ypsomed the accolade of “Supplier of the Year” for 2011. Amylin operates a professional supplier manage-ment system with quarterly assessments using the most diverse criteria relating to the supplier relationship. With the nomina-tion as Supplier of the Year, Amylin particularly recognizes Ypsomed’s delivery reliability, quality, flexibility, good part-nership both during projects as well as product life and Ypsomed’s will to continually improve.

YDS Ypsomed Delivery Systems

Ypsomed Delivery Systems covers the following four service provision areas:

• Custom Products• Contract Development• Contract Manufacturing • Drug & Device Assembly

“Pharmaceutical customers can rely on the products, expertise and experience of Ypsomed Delivery Systems, and are thereby more successful on the market.”

23


An

nual

Rep

ort

More confidence – more success – with Ypsomed Delivery SystemsYpsomed Delivery Systems offer a complete range of products and services for injection systems, ranging from development, through the manufacture of injection systems, to packaging them with the drug.

Drug & deviceassembly

Contractmanufacturing

Contractdevelopment

Custom products

YDS Ypsomed Delivery Systems

Competent and flexible, at the service of pharmaceutical customersWith YDS Ypsomed Delivery Systems, Ypsomed intends to further extend its leading market position as a comprehensive supplier of injection systems for original preparations and biosimilars from both large and smaller pharmaceutical and biotech companies, in both highly regulated markets as well as in emerging markets. The needs of the individual pharma-ceutical and biotech companies vary, and the YDS offering from Ypsomed is accordingly flexible. Ypsomed can, as a full-service provider, manufacture already developed and industrialized pen systems, and also package and deliver them ready-filled with the drug. Ypsomed can, however, also provide individual services, and for example develop new injection systems on behalf of customers, or as a contract manufacturer can manufacture sophisticated components of medical technology products in high quality, at attractive prices.

“Ypsomed sees itself as a comprehensive service provider for pharmaceutical and biotech companies.”

Innovative portfolio of injection systems

24 25

Ypsomed – Annual Report Ypsomed – Annual Report

An

nual

Rep

ort

Ypsomed provides the swift manufacture of smaller quantities for immediate use in clinical trials, through to complete indus-trialization and high-quality production of large volumes for market launches.Ypsomed is of course continually developing further new and innovative pen systems, autoinjectors for pre-filled syringes, as well as pen needles and safety pen needles. On average, every year Ypsomed invests some 10% of sales in basic research and product development.

“The injection systems from Ypsomed can be adapted to suit the specific cus-tomer, and are available for immediate use in clinical trials and for market launches.”

ServoPen® YpsoPen® Twist UnoPen™ Memo UnoPen™ Fix LyoTwist™ Trio LyoTwist™ Vario LyoTwist™ Trio S LyoTwist™ Vario S

3 ml cartridge

1 ml dual chamber cartridge

1 ml long prefilled syringe

Reusable

Disposable

Automatic injection

Multi dose

Single dose

Variable dose

Fixed dose

Min dose (ml) 0.01 0.01 0.01 0.01 0.1 0.1 0.1 0.1

Max dose (ml) 0.6 0.6 0.6 0.6 1.0 1.0 1.0 1.0

Built in needle safety

Optional needle safety

Developed and tested pen systems and autoinjectors ready for useWith YDS Custom Products, Ypsomed offers pharmaceutical and biotech companies a complete product portfolio of already developed and tested pen systems and autoinjectors, which can be adapted to suit individual customer wishes with respect to design, drug dosing or functionality. Over and above that,

YDS Custom Products – Individual platform products ready for use

26


Benefits of YDS Custom Products for pharmaceutical and biotech customersPharmaceutical and biotech companies look for standardized injection system platforms for the application of their new drugs, in other words: devices that have already been developed, have been tested in handling studies with patients, and have been largely industrialized and are thereby suitable for cost-effective production. Pharmaceutical companies also want to use injection systems in which the patent issues have been

successfully dealt with, and where use of the devices is guar-anteed not to infringe any other patents (freedom to operate). By proceeding in this way, in contrast to new development, pharmaceutical companies avoid unnecessary risk and make considerable savings on upfront investment and development costs. When they use YDS Custom Products, they also make drastic savings on the time until use in clinical trials (time to clinic) and the time until market introduction (time to market). It is not only large pharmaceutical groups that benefit from the numerous advantages of YDS Custom Products, but also small and medium-sized pharmaceutical and biotech companies.

UnoPen™ YpsoJect® YpsoMate® VarioJect™

3 ml cartridge

1 ml dual chamber cartridge

1 ml long prefilled syringe

Reusable

Disposable

Automatic injection

Multi dose

Single dose

Variable dose

Fixed dose

Min dose (ml) 0.01 0.1 0.1 0.05

Max dose (ml) 0.6 1.0 1.0 1.5

Built in needle safety

Optional needle safety

27


An

nual

Rep

ort

“With YDS Custom Products, pharmaceutical customers make considerable savings in terms of time and costs.”

The right injection system to suit every requirementBoth reusable and disposable pen systems are suitable for drugs that need to be injected by the patient either once or even several times a day, such as insulin, GLP-1 and growth or fertility hormones. Cost-effective injection systems are in demand particularly in emerging markets if the drug is offered within the context of tender procedures or generally at very low prices. Dual-chamber pen systems are used for drugs that are unstable or cannot be stored for long in a liquid state. With these pen systems, the substance in its freeze-dried form is mixed with the diluent in a special ampule just before use. In addition, autoinjectors with a pre-filled syringe tend to be used where even inexperienced patients need to administer the required substance easily, safely and in the required quantity, or where drugs need to be injected less frequently as a depot formulation e.g. weekly or monthly.

Several insulin suppliers have opted for the ServoPen® from the YDS Custom Products rangeYpsomed is particularly pleased that, in Square Pharmaceu-ticals Ltd., Incepta Pharmaceuticals Ltd., Pharmastandard and B. Braun, several insulin suppliers opted for the high-quality ServoPen® insulin pen from Ypsomed from the YDS Custom Products product portfolio in the 2011/12 business year. The ServoPen®, which has been developed by Ypsomed, is part of the YDS Custom Products portfolio, and has received the internationally renowned “red dot design award.” Ypsomed manufactures the ServoPen® in Switzerland, utilizing existing production capacities.

Ypsomed wins new pharma-ceutical customers in Asia

Ypsomed is particularly proud that following Tonghua Dong-bao from China, Square Pharmaceuticals Ltd. and Incepta Pharmaceuticals Ltd., two insulin manufacturers in Bangladesh, have opted for a Swiss quality product, the ServoPen® insulin pen. Both companies will be launching the ServoPen® with their respective insulins in 2012.

“For our clients in Bangladesh the ServoPen®’s great user-friendliness and the swift availability for the market launch were important decision criteria, along with the renowned Swiss quality.”

28


New YpsoPen® Twist insulin penYpsomed has developed the existing platforms further, and in the last business year it has aroused great interest among potential customers with both the YpsoPen® Twist, a simple and economical insulin pen, and the YpsoMate® autoinjector. The YpsoPen® Twist is ideal for markets where there is price pressure, or where insulin is marketed within the context of tender procedures (including China and India).

“The YpsoPen® Twist is a simple, reusable pen, and together with the reusable, automatic ServoPen® and the disposable UnoPen®, it completes Ypsomed’s range of insulin pens.”

YpsoMate® 2-step autoinjectorThe two-step YpsoMate® autoinjector was presented at the 2011 PDA conference in Basel, and is the latest autoinjector from Ypsomed for pre-filled syringes with a volume of up to 1 ml. The YpsoMate® offers ergonomic handling and enables the convenient, safe and automatic release of the medicine as soon as the autoinjector is pressed against the skin (so-called “push-on-skin” release). Several easily audible clicks and a large viewing window onto the syringe with the medi-cine provide the patient with a high degree of assurance in use, and confirmation that the full dose has been injected. The YpsoMate® has an extremely slimline design, and offers numerous possibilities for individual customisation. More and more pharmaceutical companies are realizing that patients want autoinjectors for the application of drugs, and are not content with pre-filled syringes.

YpsoPen® Twist YpsoMate®

Individual contract development for injection systems is re-quested by certain customers if none of the available platform products adequately meets their requirements, or if customers wish to implement their own ideas and claim the rights to the results of development, as well as to newly obtained patents. Large pharmaceutical companies in particular very often develop injection systems with contract developers, because they are thus not dependent on a specific manufacturer, and for reasons of risk they can split the production between several contract manufacturers.

Comprehensive patent portfolio and proven development processesWithin the framework of YDS Contract Development, Ypsomed makes available to the customer its many years of expertise in development, as well as its comprehensive patent portfolio for pen systems and autoinjectors. Depending on the custom-ers’ needs, existing patents held by Ypsomed can be used on an exclusive or non-exclusive basis. The development process takes place in the form of collaboration with the customer, and fulfills all the ISO and cGMP guidelines, right through to the correct documentation to conform to regula-tions. During the development phase, concepts are continu-ally tested and monitored by experts. Thanks to the in-house tool manufacturing department and available production capacities, prototypes can be produced quickly and cost-effectively even in larger quantities, and are available for trials with patients within a short space of time. Thanks to its many years of experience as a manufacturer, Ypsomed takes into account the economical manufacture of components and their ease of assembly, right from the start when developing new injection systems.

YDS Contract Development – Customer-specific order development

Successful development of innovative injection systems for more than 25 yearsWith YDS Contract Development for pharmaceutical and bio-tech companies, Ypsomed offers customer-specific contract development of injection systems and all the corresponding services. Since the mid-1980s, Ypsomed has built up an out-standing reputation in the industry as an innovative developer of user-friendly and safe injection systems. Many systems have won high-profile design awards and received excellent feedback from patients in handling studies.

“Injection systems developed by Ypsomed have won numerous high- profile design awards because they are innovative, user-friendly and safe.”

ServoPen®

29


An

nual

Rep

ort

30


With YDS Contract Manufacturing, Ypsomed offers a complete range of services for the contract manufacture of injection systems, medical technology components and assemblies. The YDS Contract Manufacturing range furthermore includes con-sultancy, project management and expert support in the context of challenging industrialization and rapid upgrading of produc-tion capacities.

Flexible contract manufacturing of small and large volumesThe production facilities at Ypsomed are designed to be flex-ible, and allow the partially-automated manufacture of small volumes through to mass production of several hundred million parts with fully automated high-performance plants. Ypsomed has over 25 years’ experience in the manufacture of medical technology products, and has the necessary expertise in the corresponding manufacturing processes and technology. These include injection molding, printing, semi- and fully automatic parts assembly, country-specific labeling and packaging. Ypsomed also has its own tool manufacturing department, thus guaranteeing the flexible and swift manu-facture of tools, as well as a high degree of precision and quality in the manufacture of high-specification injection-molded parts.

Proven Swiss quality on attractive termsYpsomed’s excellently trained workforce and their expertise, as well as its modern production infrastructure, guarantee the highest quality. The Ypsomed Group and its quality manage-ment system are certified in accordance with ISO 13485:2003 and are regularly audited by international pharmaceutical

YDS Contract Manufacturing – A flexible service

customers and by the FDA. Ypsomed operates several produc-tion sites in Switzerland and in the Czech Republic. Where necessary, Ypsomed has access to manufacturing capacities in the Far East and Mexico through trusted partners. By utiliz-ing existing production infrastructure and partnerships, Yp-somed can offer competitive contract manufacturing, and rapidly adjust the production volumes to meet the needs of customers and markets.

“With YDS Contract Manufacturing, pharmaceutical companies can have devices and components that they have developed themselves manufactured by Ypsomed in a cost-effective way, and can adjust their production volumes swiftly and flexibly to meet market requirements.”

Components for Solostar® by Sanofi

31


An

nual

Rep

ort

One-stop shop for injection systems and drug packaging

For pharmaceutical and biotech companies, the manufacture and packaging of drugs together with the injection systems in conformity with FDA requirements is an absolutely critical process, and demands not only a great deal of expertise, but also major investment in infrastructure. In order that pharma-ceutical and biotech companies, particularly small and medium-sized firms, do not have to build up this expensive infrastructure and these processes themselves, with YDS Drug & Device Assembly, Ypsomed offers the integrated assembly of pen components or autoinjector components with the ampule, or of the pre-filled syringe that contains the medication. Ypsomed has received corresponding inquiries from customers, and can make available its tried and tested production and assembly plants for injection systems, as well as the relevant packaging and logistics infrastructure, right through to distribution specific to the country in question. The final assembly of injection systems and packaging together with the drugs can be considerably simplified by this, enabling pharmaceutical companies to save time and costs. The multilingual country of Switzerland, in the heart of Europe, offers not only logistical benefits, but also tax ben-efits for pharmaceutical and biotech companies.

“With YDS Drug & Device Assembly, Ypsomed extends the value-creation chain and provides an important additional service for pharmaceutical customers.”

YDS Drug & Device Assembly – One-stop shop for injection systems and drug packaging

32


Strategic diabetes care business segment extended further Over the last 25 years, Ypsomed has made a name for itself around the world as a competent diabetes expert, and in recent years it has made substantial investments in building up the strategic Diabetes Care business segment. Ypsomed has ex-tended its international marketing presence through its own subsidiaries and distribution partners to more than 50 countries, and furthermore in 2009 it launched the new mylife™ Diabetes-care umbrella brand. With mylife™ Diabetescare, Ypsomed offers a complete product range for diabetes care, specifically for type 1 and type 2 diabetics who are treated with insulin. In the 2011/12 business year, Ypsomed extended the mylife™ Diabe-tescare range of products still further, and introduced numerous new products to the market, including the mylife™ Orbit® infusion set, with 360-degree freedom of movement, the new mylife™ Clickfine® 4.5 mm pen needles with extra-short needles, and the mylife™ Clickfine® AutoProtect™ safety pen needles. mylife™ DailyDose®, a self-injection system in credit card format compris-ing three small syringes that are pre-filled with the daily require-ment of insulin, will be launched in the next business year.

“No other company in the world offers such a complete product range for comprehensive diabetes care under one umbrella brand as Ypsomed does with mylife™ Diabetescare.”

Success in diabetes treatment with mylife™ Diabetescare

Sustained strong increase in diabetes

With the strategic Diabetes Care business segment, Ypsomed is active in a market that is experiencing sustained growth, as the worldwide increase in diabetes shows. The World Health Organization (WHO) estimates that currently almost 300 million people are suffering from diabetes. Expert estimates predict that in the year 2030, around the world roughly 440 million people will be living with diabetes. The USA, which currently has the most diabetics, will be overtaken in the next few years by China, India and other countries in Asia and the Middle East. The reasons for the sustained increase in diabetes are on the one hand the rising world population (from approx. 7 billion people today to over 8 billion in 2030), and increased life expectancy, with a continually growing proportion of older people in need of care, and on the other hand the increase in standards of living along with the associated changes in nutri-tional habits and lifestyle. Excessive intake of calories, coupled with lack of movement, is widespread not only in the industrial-ized countries but also in emerging countries in Asia, Central and South America, as well as the Middle and Near East.

Diabetes care – a global market worth billionsAlong with the rising numbers of diabetics, the costs of treating diabetes also increase. Today, diabetes care is a global market worth billions, with further high growth potential in the future. In view of the enormous costs however, the cost pressure on suppliers, which is exerted by the authorities, politicians and the cost payers such as health insurance providers, insurance companies and patients, is also increasing. This leads to a preference for products that tend to be cheap, and new products are reimbursed only if they are demonstrated to improve treat-ment or can be offered cheaper. To some extent, the choice of products is restricted for doctors and patients, or only a flat rate reimbursement is paid, instead of reimbursing individual products and services as previously. Increasing harmonization is also being observed of prices that are still heterogeneous in individual countries, both internationally and specifically within Europe. The price war puts the large and established suppliers under pressure and opens up fresh opportunities for lower-priced competitors. Although the pressure on prices is continually increasing and demands a corresponding adjustment of the cost structures and the products offered, diabetes care will remain an attractive and growing market for Ypsomed for years to come.

33


An

nual

Rep

ort

The best products under one umbrella brand: “mylife™ Diabetescare”For the care of people with diabetes mellitus, Ypsomed has created the mylife™ Diabetescare umbrella brand, under which it offers not only products manufactured by Ypsomed itself, such as mylife™ Penfine, mylife™ Optifine®, mylife™ Clickfine® and the mylife™ Clickfine® AutoProtect™ safety needles, but also diabetes products from partners. To this end, Ypsomed has established several partnerships with the best suppliers in the respective product categories, and has included their products in the mylife™ Diabetescare product family as private labels. Thus, for example, Ypsomed has since 2009 been working closely with the Taiwanese company Bionime Corp., which produces one of the most accurate blood glucose test strips in the world, and distributes the mylife™ Pura® blood glucose monitoring system exclusively in Europe, through its own subsidiaries. At the start of 2010, Ypsomed acquired from Insulet Corp. the exclusive distribution rights outside North America for OmniPod®, the first and – until now – only insulin patch pump, and introduced the tubing-free, user-friendly insulin pump to the market in numerous countries under the name mylife™ OmniPod®. In November 2011, Ypsomed also acquired the Orbit® product line from the US medical technology company ICU Medical Corp., and has thus become a manufacturer of infusion sets for conventional insulin pumps (see page 38 of the Annual Report). The reason for the acquisition is that wherever possible, Ypsomed wishes to own and manufacture the products that are distributed under mylife™ Diabetescare itself. For Ypsomed, it is also strategically important to be able to influence product devel-opment and ensure quality.

“With the mylife™ Diabetescare umbrella brand, Ypsomed makes a decisive contribution to the market success of partner products.”

mylife™ Diabetescare – Complete product range for diabetics

Diabetes expertise and access to markets as a benefit for “mylife™ Diabetescare” partnersThanks to mylife™ Diabetescare, Ypsomed is of interest to partners with innovative diabetes products for several reasons. First of all, Ypsomed has an undisputed reputation and ex-pertise in the field of diabetes, and secondly, Ypsomed ena-bles direct access to markets for the partners’ diabetes products under the mylife™ Diabetescare brand through its own subsidiaries in Europe and India, via direct distribution through DiaExpert, as well as through local distribution part-ners in more than 50 countries. Furthermore, the partners also benefit from the high credibility and quality of the mylife™ Diabetescare brand. With mylife™ Diabetescare, Ypsomed has built up a brand that enjoys the trust of patients, doctors, diabetes specialists and health insurance providers alike. Ultimately, with mylife™ Diabetescare Ypsomed can also offer a complete product range, which companies that have only one diabetes product cannot do. Depending on the needs of the health insurance providers, flat-rate offers or individual product categories can be combined with one another and offered at attractive prices (so-called bundling), such as for example infusion sets and pump accessories, or blood glucose test strips and pen needles.

“With mylife™ Diabetescare, Ypsomed wants to become the partner of choice for patients, doctors and health insur-ance providers, and at the same time contribute towards lowering the overall costs of diabetes treatment.”

1

2

4

6

7

8

9

11

12

13

14

16

17

18 21

24

23

26

27

29

31

34

35

36

37

38

39

40

41

42

43

25

5

15

1922

30

44

33

32

3

10

20

28

45

46

34 35

Ypsomed – Annual Report Ypsomed – Annual Report

An

nual

Rep

ort

Ypsomed Germany

Population: 81 600Number of diabetics: 5 022Estimated growth by 2022: 6%

Ypsomed Sweden

Population: 9 400Number of diabetics: 386Estimated growth by 2022: 6%

Ypsomed Denmark


Ypsomed Finland


Ypsomed IndiaPopulation: 1 210 000

Number of diabetics: 30 629Estimated growth by 2022: 30%

Ypsomed AustriaPopulation: 8 440Number of diabetics: 706Estimated growth by 2022: 10%

37 SingaporePopulation: 5 184Number of diabetics 2012: 448Estimated growth by 2022: 29%

39 SpainPopulation: 46 196Number of diabetics 2012: 3 105Estimated growth by 2022: 12%

40 TunisiaPopulation: 10 674Number of diabetics 2012: 236Estimated growth by 2022: 34%

41 TurkeyPopulation: 74 724Number of diabetics 2012: 4 046Estimated growth by 2022: 31%

42 UkrainePopulation: 45 655Number of diabetics 2012: 1 634Estimated growth by 2022: 0.3%

43 HungaryPopulation: 9 986Number of diabetics 2012: 350Estimated growth by 2022: 4%

45 USAPopulation: 311 485Number of diabetics 2012: 22 115Estimated growth by 2022: 20%

46 VenezuelaPopulation: 26 841Number of diabetics 2012: 887Estimated growth by 2022: 42%

31 PortugalPopulation: 10 562Number of diabetics 2012: 75Estimated growth by 2022: 10%

34 RussiaPopulation: 142 914Number of diabetics 2012: 1 208Estimated growth by 2022: 5%

35 Saudi ArabiaPopulation: 27 137Number of diabetics 2012: 1 370Estimated growth by 2022: 43%

36 Serbia/MontenegroPopulation: 7 741Number of diabetics 2012: 351Estimated growth by 2022: 7%

38 SloveniaPopulation: 2 056Number of diabetics 2012: 74Estimated growth by 2022: 10%

33 RomaniaPopulation: 19 042Number of diabetics 2012: 4 870Estimated growth by 2022: 9%

32 QatarPopulation: 1 699Number of diabetics 2012: 53Estimated growth by 2022: 34%

44 United Arab EmiratesPopulation: 8 264Number of diabetics 2012: 462Estimated growth by 2022: 26%

1 AlgeriaPopulation: 37 100Number of diabetics 2012: 654Estimated growth by 2022: 43%

2 EgyptPopulation: 81 455Number of diabetics 2012: 3 873Estimated growth by 2022: 38%

3 ArgentinaPopulation: 40 117Number of diabetics 2012: 1 786Estimated growth by 2022: 21%

6 BelgiumPopulation: 10 840Number of diabetics 2012: 370Estimated growth by 2022: 14%

7 Bosnia-HerzegovinaPopulation: 3 840Number of diabetics 2012: 136Estimated growth by 2022: 18%

8 BulgariaPopulation: 7 365Number of diabetics 2012: 466Estimated growth by 2022: n/a

9 ChinaPopulation: 1 339 725Number of diabetics 2012: 27 873Estimated growth by 2022: 28%

10 ColombiaPopulation: 36 355Number of diabetics 2012: 1 341Estimated growth by 2022: 42%

11 Czech RepublicPopulation: 10 562Number of diabetics 2012: 3 760Estimated growth by 2022: 10%

4 AustraliaPopulation: 22 814Number of diabetics 2012: 1 194Estimated growth by 2022: 22%

12 EstoniaPopulation: 1 340Number of diabetics 2012: 45Estimated growth by 2022: n/a

13 GreecePopulation: 10 788Number of diabetics 2012: 939Estimated growth by 2022: 8%

14 IrelandPopulation: 4 581Number of diabetics 2012: 110Estimated growth by 2022: 23%

16 IcelandPopulation: 318Number of diabetics 2012: 8Estimated growth by 2022: 27%

17 IsraelPopulation: 7 836Number of diabetics 2012: 338Estimated growth by 2022: 26%

18 ItalyPopulation: 60 757Number of diabetics 2012: 468Estimated growth by 2022: 8%

20 CanadaPopulation: 34 278Number of diabetics 2012: 2 538Estimated growth by 2022: 22%

21 CroatiaPopulation: 4 291Number of diabetics 2012: 165Estimated growth by 2022: 5%

23 LatviaPopulation: 2 068Number of diabetics 2012: 85Estimated growth by 2022: 3%

24 LebanonPopulation: 4 259Number of diabetics 2012: 216Estimated growth by 2022: 39%

25 LithuaniaPopulation: 3 199Number of diabetics 2012: 126Estimated growth by 2022: 9%

26 MalaysiaPopulation: 28 334Number of diabetics 2012: 1 406Estimated growth by 2022: 40%

27 MoroccoPopulation: 32 447Number of diabetics 2012: 641Estimated growth by 2022: 40%

28 MexicoPopulation: 112 337Number of diabetics 2012: 3 343Estimated growth by 2022: 43%

30 OmanPopulation: 2 773Number of diabetics 2012: 178Estimated growth by 2022: 47%

Countries with distributors (in 1000)

Ypsomed France


Ypsomed UK


Ypsomed Netherlands


Ypsomed Norway


Ypsomed Switzerland (head office)Population: 7 900Number of diabetics: 424Estimated growth by 2022: 10%

Countries with subsidiaries (in 1000)

Source: WHOhttp://www.who.int/diabetes/facts/world_figures/en

22 KuwaitPopulation: 3 582Number of diabetics 2012: 165Estimated growth by 2022: 47%

5 BahrainPopulation: 1 235Number of diabetics 2012: 55Estimated growth by 2022: 40%

29 PolandPopulation: 38 092Number of diabetics 2012: 1 287Estimated growth by 2022: 11%

19 JordanPopulation: 6 284Number of diabetics 2012: 327Estimated growth by 2022: 54%

15 IranPopulation: 33 330Number of diabetics 2012: 1 054Estimated growth by 2022: 46%

Ypsomed worldwide

Under the brand mylife™ Diabetescare Ypsomed offers patients worldwide an extensive range of products for the treatment of diabetes.

DiaExpert shop

36


Specialized diabetes sales force in EuropeIn Europe, Ypsomed has its own sales force that specializes in diabetes, as well as subsidiaries in Germany, France, England, Switzerland, the Netherlands, Sweden, Denmark, Norway, Finland and, as a new addition since December 2011, also in Austria. With the establishment of the new subsidiary that is headquartered in Vienna, Ypsomed par-ticularly wants to exploit the promising market potential for the tubing-free mylife™ OmniPod® insulin patch pump, and strengthen the marketing of the other products from the mylife™ portfolio in Austria. Since 2007, Ypsomed has also had a subsidiary and representation in New Delhi, India.

International sales via local distribution partnersIn addition to distribution through its own subsidiaries, Ypsomed also has an international network of strong, locally established partners with expertise in diabetes. Today, Ypsomed has a presence in over 50 countries, and with mylife™ Diabetescare it can offer distributors an attractive range of diabetes prod-ucts that includes more than just pen needles.

Global presence with www.mylife-diabetescare.comVia the web portal www.mylife-diabetescare.com, mylife™

Diabetescare has a worldwide presence on the market round the clock. People with diabetes and diabetes experts can obtain information on the subject of diabetes and on the mylife™ Diabetescare product portfolio. In addition to a news-letter and practical tips on dealing with diabetes on a day-to-day basis, advice can also be obtained by telephone or e-mail.

International market presence and marketing expertise for mylife™ Diabetescare

Expansion in the diabetes mail order businessIn Germany, through its subsidiary DiaExpert, Ypsomed has been successfully active in the diabetes mail order business for over twenty years. In Germany, DiaExpert is the country’s largest diabetes mail order business, and supplies over half of all insulin pump users. DiaExpert serves several tens of thousands of customers with more than 1 500 high-quality diabetes products. The products that are ordered are delivered directly to customers’ homes within 24 hours. The advice available also includes a telephone hotline and the “Feel Free” customer magazine with specialist articles and up-to-date product information on the subject of diabetes. Market access is decisive for the success of diabetes products. In 2012, Ypsomed will start up a diabetes direct mail order service, similar to DiaExpert, in Norway and Switzerland too. Where regulations permit, from 2013 onwards a diabetes direct mail order service will also be set up in other countries in Europe.

mylife™ Diabetescare product portfolio expansion

2009 2011 20122010

37


An

nual

Rep

ort

Ypsomed extends the “mylife™ Diabetescare” product range

The complete mylife™ Diabetes-care product rangeSince 2009, Ypsomed has continually expanded the mylife™ Diabetescare product portfolio. Currently, mylife™ Diabetescare covers a complete range and comprises the following products for diabetes care.

Pen needles

Blood glucose meters

Insulin pumps andinfusion sets

Accessoires

38


The new mylife™ Orbit®

infusion set with 360-degree freedom of movementIn April 2011, Ypsomed started the market introduction of a new infusion set for insulin pumps, and in the 2011/12 busi-ness year it thus expanded the mylife™ Diabetescare portfolio with an additional, extremely attractive product. mylife™ Orbit® is a new infusion set for patients who use an insulin pump with a Luer lock connection. The system offers much greater freedom of movement than conventional catheters, as the tube rotates around 360 degrees. The new infusion set is available with a flexible Teflon catheter (mylife™ Orbitsoft®) and with a particularly fine steel cannula (mylife™ Orbitmicro®).

The mylife™ Orbit® infusion set offers numerous benefitsBecause the tape is semi-transparent and the set is very flat, with a height of just six millimeters, mylife™ Orbit® can be worn discreetly and is hardly noticeable. For patients, using the set is very simple and user-friendly. The choice of infusion site is just as easy as connecting and disconnecting the set in any position. A click signals that everything is fitting cor-rectly, and gives patients the necessary assurance. Moreover, the mylife™ Orbit® infusion set is attached with an innovative, heat-activated tape, which ensures secure positioning.

Acquisition of the infusion set business of ICU Medical Inc.

With this acquisition, Ypsomed has become a manufacturer of infusion sets, and at the same time secures the ownership of important patents in the area of infusion sets. The purchase contract was signed in November 2011. The transfer of pro-duction is under way, and will be concluded in the third quarter of 2012.

“With the acquisition of the mylife™ Orbit® infusion set, Ypsomed is strengthening the strategic Diabetes Care business segment.”

Increased profit marginWith this acquisition, Ypsomed is strengthening the strategic Diabetes Care business segment and sees the opportunity to increase its market share in the extremely promising growth market for infusion sets. For Ypsomed, the acquisition is also beneficial because as the manufacturer of the infusion sets, Ypsomed can achieve a clearly better margin than the previ-ous retail margin. Ypsomed has also made preparations for transferring the production of the infusion sets from the USA to Mexico. Ypsomed thus benefits from synergies with the strategic partner AdvalTech Group, and can use the existing production site of AdvalTech’s subsidiary Omni Group in Queretaro, Mexico. Moreover, with a view to the launch of its own economical and user-friendly insulin pump, Ypsomed has also secured the availability of this important accessory.

mylife™ Orbit®

39


An

nual

Rep

ort

Ypsomed launches new mylife™

DailyDose® – the world’s smallest insulin syringeThe most recent addition to the mylife™ family is mylife™

DailyDose®, an innovative self-injection system in credit card format, which comprises three small syringes that are pre-filled to cover the insulin requirement for a day. This handy product enables an active and independent lifestyle, and ideally suits the motto of mylife™ Diabetescare: “More freedom. More confidence. With mylife™!” Thanks to its compact size, mylife™

DailyDose® can be tucked away discreetly and carried any-where, and can be used immediately where necessary. The packaging sleeve is transparent, making it possible to tell at a glance how much insulin is still available, or how much has already been dispensed. With these benefits, mylife™ Daily-Dose® is particularly suitable for children, and gives parents a great sense of security. Ypsomed has signed a distribution contract for mylife™ DailyDose® with the Swedish manufac-turer Insulution AB, and will be presenting mylife™ DailyDose® at the German Diabetes Congress in May 2012. It will then be introduced gradually on the market in Switzerland, Germany, England, Norway, Austria and the Netherlands.

mylife™ DailyDose®

Pleasing progress in the product development of the new insulin pumpIn the 2011/12 business year, Ypsomed once again invested substantially in the product development of a new insulin pump and achieved pleasing progress. Thanks to a new type of design and construction, the insulin pump can be produced economically and is easy for patients to operate. The new pump from Ypsomed will, however, above all be lower priced than conventional insulin pumps, which cost between CHF 5 000 and CHF 6 000 per device alone, and are associated with additional annual costs of CHF 1 500 to CHF 2 000 for accessories such as catheters and batteries. The new pump from Ypsomed will yield clear savings, to the benefit of health insurance providers, and at the same time will enable optimum insulin treatment with an insulin pump for more diabetics.

“The new insulin pump from Ypsomed will change the market, because it gen-erates considerably fewer costs than conventional insulin pumps. In future, more diabetics will therefore be able to benefit from the advantages of insulin pump treatment.”

The market introduction of the new insulin pump is planned for the start of 2014Although the development of the new insulin pump is more complex than was originally assumed, in the 2011/12 business year Ypsomed reached important milestones. Based on current project progress, a market introduction at the start of 2014 appears realistic. Thanks to the low manufacturing costs, Ypsomed plans to market the new insulin pump in emerging and developing countries too.

40


Ypsomed has been producing pen needles in Switzerland for 20 yearsThe development and production of pen needles has a tradi-tion at Ypsomed. Over the last 20 years, Ypsomed has devel-oped a wide range of pen needles, with complete production in Switzerland. Ypsomed thus has the necessary experience, and has full control over the sophisticated fully automated production of sterile disposable products. In the last 20 years, Ypsomed has produced and sold several billion pen needles, without ever having had a single recall.

“The high quality of Ypsomed’s patented pen needles is known around the world among patients and doctors, as well as distributors.”

Rising demand and expansion of production capacitiesThe growing number of insulin-dependent diabetes patients, coupled with Ypsomed’s efforts in international marketing, has led to a continuous rise in demand for pen needles. Particularly pleasing are the volume increases in the USA, France, China and India. In order to be able to supply the higher quantities of pen needles, in recent years Ypsomed has continually optimized the existing pen needle production in Burgdorf, and has additionally set up a new production facility in Solothurn. Ypsomed currently has a capacity of 500 million pen needles a year, and will increase this to 1 billion within the next 24 months. When extending the production facilities further, Ypsomed has opted for a tried and tested German supplier, following considerable ejection problems with an Italian machine manufacturer, which have now largely been resolved.

mylife™ pen needles and safety pen needles

Comprehensive range of pen needles

In addition to its reputation for high-quality pen needles, acknowledged across the industry, Ypsomed is the supplier with the most comprehensive product range worldwide. Ypsomed offers five different needle lengths, ranging from 4.5 mm, 6 mm, 8 mm, 10 mm through to 12 mm. Patients can thus select the ideal length of pen needle depending on their physical constitution. Ypsomed markets the different pen needles – which, thanks to the patented click mechanism, fit all conventional insulin pens – as a private label and under the mylife™ Diabetescare umbrella brand. The mylife™ pen needle range includes the mylife™ Penfine, mylife™ Clickfine® and, in Germany, the mylife™ Optifine® needles, as well as the mylife™ Clickfine® AutoProtect™ safety pen needle, for which Ypsomed also gained approval in the USA last year. The mylife™ Clickfine® AutoProtect™ is equipped with a special locking mechanism that prevents a second injection and thus also prevents accidental needle-stick injuries, infections and the transmission of life-threatening diseases.

mylife™ pen needles

41


An

nual

Rep

ort

High level of measurement accuracy and precision with HDST technologyThe mylife™ Pura® blood glucose monitoring system, produced by our Taiwanese partner Bionime Corp., and which Ypsomed has been distributing on an exclusive basis in Europe since 2009, stands apart from conventional devices through its measurement accuracy. mylife™ Pura® features the innovative High Definition Signal Transmission (HDST) technology, which ensures interruption-free signal transmission and thus very accurate measurement results. With conventional test strips with a long signal path and corrosion-prone conductive material, faults in measurement can occur, thus resulting in inaccurate measurement results. Not so with mylife™ Pura®: thanks to the innovative design of the test strip with lateral test strip insertion, in the mylife™ Pura® the signal path is around 10 times shorter than for conventional test strips with insertion at the front. Moreover, with mylife™ Pura®, high-quality gold electrodes are used for optimum signal transmission in test strips and in the meter.

Ease of use and innovative designThe unique design of the mylife™ Pura® test strip brings additional benefits, by making the blood glucose monitoring system easier and safer to use. mylife™ Pura® is the first blood glucose monitoring device with insertion of the test strips from the side, thus allowing hygienic measurement without contact with blood. Of course, mylife™ Pura® also has autocoding and autostart functions. The mylife™ Pura® blood glucose monitor-ing system also includes an innovative lancing device for gentle blood sampling. The mylife™ Softlance lancing device, which was developed in Switzerland, has vibration-reducing fins to aid precise guidance of the lancet, and has seven puncture depths that can be set. In the 2011/12 business year, in addition to the tried and tested mylife™ Pura®, Ypsomed has successfully marketed a Limited Edition mylife™ Pura® X with an unusual design. The mylife™ Pura® blood glucose monitor-ing system is marketed by Ypsomed in Germany, France, the Netherlands, Switzerland, Sweden, Denmark, Finland, England and India.

mylife™ Pura® – The blood glucose monitoring system that is highly accurate and easy to use

Further development of the next generation of mylife™ Pura® blood glucose monitoring devicesIn the 2011/12 business year, Ypsomed has intensively driven forward the product development of a new blood glucose monitoring system together with the Taiwanese partner Bionime Corp. and a Swiss design partner. The results from customer surveys and focus groups that were conducted in Switzerland and Germany have been fed into the development of a new, very small and high-performance blood glucose monitoring system. The meter has been designed specifically for insulin-dependent patients, and is easy to operate, through modern menu guidance and an LCD display. Moreover, the newly developed system will set new standards in precision and accuracy. The new system already effortlessly meets the latest ISO standards and the most recent, even stricter, specifications of the FDA in the USA. For the new system, Ypsomed has itself developed a new lancing aid. Ypsomed plans to introduce it on the market in Germany, France, Aus-tria, the Netherlands and Switzerland from fall 2012 onwards.

“As several studies have shown, mylife™ Pura® is one of the most accurate blood glucose monitoring systems on the market.”

mylife™ Pura® and Pura® X

42


Pleasing growth in sales with the mylife™ OmniPod® insulin patch pumpIn the 2011/12 business year, it was particularly pleasing to note the disproportionately large growth in sales of the mylife™

OmniPod® insulin patch pump in comparison with the same period in the previous year. The numerous benefits of the innovative mylife™ OmniPod® insulin patch pump have won over both doctors and patients. Ypsomed’s presence at numer-ous European and international diabetes conferences, as well as the training of specialist staff and the certification of dia-betes centers for the mylife™ OmniPod®, have proved worth-while. In Germany alone, Ypsomed has certified over 300 specialist practices and pump centers for the patch pump.

“In Germany, one in three new pump users chooses the tubing-free mylife™ OmniPod® insulin pump.”

Successful market introduction of the mylife™ OmniPod®

Ypsomed has invested considerable funds in the rapid market introduction of the mylife™ OmniPod®, and has expanded the sales force and enhanced its specialist expertise at the sub-sidiaries in Europe. The mylife™ OmniPod® insulin patch pump has been on the market in Germany, England and the Netherlands since 2010, and in Switzerland since 2011. In the 2011/12 business year, Ypsomed made preparations for its market introduction in Scandinavia, France and China. There were both unexpected and unwelcome problems with the registration of the mylife™ OmniPod® in France, where the launch is now not anticipated before the end of 2013 because of a trial required by the authorities.

mylife™ OmniPod® – The insulin patch pump proves popular

Extension of cooperation with Insulet

In the coming business year, Ypsomed intends to further in-tensify its successful cooperation with Insulet. The cooperation was extended early by one year and in addition the tubing-free insulin patch pump can be distributed in 14 new countries. These include, among others, countries such as Denmark, India, Poland, Hungary, the Czech Republic and countries from the Middle East. The launch in the additional countries is planned for the 2012/13 business year and will be imple-mented on a rolling basis.

High level of acceptance among patients and diabetes expertsIn the market, Ypsomed’s mylife™ OmniPod® insulin patch pump is being met with enthusiasm by both patients and leading diabetes experts. In contrast to conventional insulin pumps, the unique patch pump for type 1 diabetes patients offers a very high degree of freedom and flexibility in how they manage their everyday life. Using the mylife™ OmniPod® is extremely simple: the small pod with insulin that is required for up to 3 days is stuck directly onto the skin, and is acti-vated and controlled wirelessly via the Personal Diabetes Manager. The cannula is inserted automatically, invisibly and almost painfree for the patients. The flat, lightweight pod can be worn very discreetly on many different places on the body. The pod is also watertight, and does not need to be removed for showers or swimming. Users of the tubing-free mylife™

OmniPod® patch pump therefore no longer need any infusion sets, and can also use the Personal Diabetes Manager as a blood glucose monitoring device. The used pods are collected by Ypsomed and recycled in a proper, environ-mentally friendly way. The costs for the mylife™ OmniPod® are comparable with the costs of conventional insulin pump treatment, and are reimbursed by the health insurance providers.

“The tubing-free mylife™ OmniPod® patch pump can be worn very discreetly, and operating it is child’s play.”

NEWNEW

43


An

nual

Rep

ort

Second-generation mylife™ OmniPod® – flatter and even more compactIm September 2011, Ypsomed presented the second genera-tion of the mylife™ OmniPod® at the largest European diabetes conference, EASD (European Association for the Study of Diabetes), which was held in Lisbon. This product innovation stimulated great interest among the diabetes specialists who were present, as the second-generation pod is one third smaller in volume, and at just 1.4 cm it is even flatter than the first-generation pod, which itself was small. The new pod has the same fill quantity for insulin (200 units), but weighs only 27 grams when the insulin reservoir is full. The further devel-opment of the new pod has taken account of experience gained so far from over four years of use in the market, and has implemented numerous improvements. Thus for example the distance for secure wireless communication has been extended to 7.5 meters, the skin-friendly adhesive patch has been strengthened, and the number of batteries has been reduced. Ypsomed is currently undertaking supplementary studies with the new pod, and is planning its gradual introduc-tion to the market from summer 2012 onwards.

“The refined second-generation pod is one third smaller in volume and significantly flatter than the previous pod.”

Sustainability and social responsibility

For Ypsomed, acting in a sustainable and socially aware manner is part of our corporate responsibility. That is why economic, environmental and social aspects are all taken into account in decision-making. Accordingly, starting out from the vision and the mission, Ypsomed has defined uniform values and management principles that ensure this for the whole Group.

As a medical technology enterprise, Ypsomed focuses on the needs of patients and customers, such as pharmaceutical companies, doctors and specialist medical staff. Innovative products and high-quality services are possible above all thanks to the above-average commitment, great loyalty and many years of experience of Ypsomed’s employees. Em-ployee education and training are therefore important to Ypsomed, as are an innovation-driving and family-friendly corporate culture. As the explanations below show, in spite of a difficult economic environment, even in the 2011/12 business year Ypsomed has lived up to its social responsibil-ity to employees and to society.

“In its actions and decision-making, Ypsomed takes account of economic, environmental and social aspects.”

Employee education and training

Ypsomed offers interesting apprenticeships In the 2011/12 business year, Ypsomed trained a total of 43 apprentices in six different vocational areas. Since the company was floated on the stock exchange in 2004, the number of trainees has more than tripled from the 14 ap-prentices we had then. In summer 2011, 11 new apprentices started their training. Because of the site closure, Ypsomed has also taken on two apprentices from Roche Diabetes Care AG in Burgdorf. Of 12 apprentices who completed their basic vocational training this year with very good results, Ypsomed has kept six of them on as employees.For August 2012, Ypsomed has the following apprenticeships to offer: design engineers, polymechanics, plastics technolo-gists, logistics assistants, computer scientists, business assis-tants.

Careers and equal opportunities at Ypsomed

Within the framework of human resources development, Ypsomed endeavors to develop employees’ skills further, through internal and external training courses. Within the company, Ypsomed offers three career path models: man-agement, project management and specialist careers. The different management careers promote equality of opportu-nity, and allow specialists and women to achieve manage-ment status within Ypsomed.

“ In the 2011/12 business year, 30 em-ployees have progressed to a new role, more than half into a management position.”

45

Ypsomed – Sustainability Report

Sust

ain

abil

ity

Rep

ort

Innovation-driving and family-friendly corporate culture

Great importance of employee surveys and the improvement system

As the regular employee surveys show, Ypsomed offers an innovation-driving and family-friendly corporate culture. Ypsomed offers exciting and challenging positions in the development of medical technology products, in complex projects together with pharmaceutical and biotech customers, or operating ultra-modern production and assembly plants.Ypsomed’s management takes the feedback from the em-ployee surveys and the suggestions for improvement very seriously, and together with the employees, it endeavors continually to optimize and improve the structures and busi-ness processes. Every year, Ypsomed awards prizes for the best suggestions for improvement.

Occupational health promotion yields measurable successes

Ypsomed places great value on occupational health promo-tion, and every year it invests a large, five-figure sum in the health and safety of Ypsomed employees. The successes of health promotion and accident prevention are measurable: since 2006, it has been possible to reduce the number of days of absence due to sickness and accidents by 4.7 days, from 12.2 days to 7.5 days at present. In this connection, we are pleased to report that the number of accidents at Ypsomed overall has settled at a low level, and around 70.0% of ac-cidents are merely minor. In the context of health promotion, Ypsomed offers its employees free entry to the fitness training facility and indoor swimming pool, the opportunity to take part in company sports events, as well as preventive flu vac-cinations. Ypsomed is continually improving workplace ergo-nomics, and has once again been involved in the “bike to work” campaign, as well as National Future Day (Nation-aler Zukunftstag). Furthermore, employee car parking spaces are subject to a fee, and this is intended to motivate employees to use public transport, or to get to work on foot or by bicycle.

Ypsomed offers attractive employment conditions and a family-friendly working environment

In order to win and retain well-educated, talented and moti-vated employees, Ypsomed offers attractive employment conditions, different paths to management careers, and a family-friendly working environment. Ypsomed supports equal opportunities and a good mix of ages. Accordingly, Ypsomed also offers jobs to older people, and people with a disabil-ity. Compared with the industry, the workforce at Ypsomed tends to be young, at 42 years. 40.0% of employees have a family with children. But a good work/life balance is impor-tant not just for fathers and mothers, but for all employees at Ypsomed. Ypsomed supports this through flexible working hours in the framework of a defined annual working time, and offers the opportunity for part-time working, as well as unpaid leave. Ypsomed also enables parental leave, and makes financial contributions to childcare.

“Ypsomed is convinced that the individuality of employees and the social diversity of staff at Ypsomed make an important contribution to success.”

Daycare center for Ypsomed employees in Burgdorf

For the children of Ypsomed employees at the Burgdorf site, places are available at the Bucher Areal daycare center. At present, all the places are filled, and feedback from parents is very positive in every respect. The Bucher Areal daycare center in Burgdorf is run by the LeoLea organization (for more information, see www.leolea.ch). The Ypsomed Innovation Fund foundation, which is supported by annual contributions from Ypsomed, supported the non-profit LeoLea organization with a loan when it started up.

46


Ypsomed assumes social responsibility in the adjustment of staffing structures

As of March 31, 2012, the Ypsomed Group employed a total staff of 1,026, compared with 1,097 the previous year. In Switzerland, Ypsomed employed 785 people (previous year: 879) and 241 abroad (previous year: 218). In the 2011/12 business year, Ypsomed laid off a total of 23 people in Burg-dorf and Solothurn for economic reasons. A redundancy program was put in place for the affected staff, in order to manage the economic consequences of the redundancies and to alleviate the human and financial hardship. In working out the redundancy program in cooperation with the Personnel Commission, the emphasis was placed on the reorientation of the affected staff. Ypsomed provided affected employees with support in analyzing their current situation and finding new employment faster and more successfully.

Commitment to society and to the region

In addition to its commitment to its employees, Ypsomed also has a commitment to society and to the region. For years, Ypsomed has been making financial contributions to the Ypsomed Innovation Fund, to support innovative enterprises in the Swiss Mittelland region. Furthermore, Ypsomed has established the Ypsomed innovation prize, worth CHF 50 000.00, to promote knowledge and technology transfer at the University of Bern and the Bern University of Applied Sciences. Ypsomed also traditionally uses around 1.0% of the consolidated net profit for regional sponsorship at the Burgdorf, Solothurn and Grenchen locations, in the areas of social and cultural affairs, specialist training, and sports for all. Furthermore, through the Franz Gertsch Museum, Ypsomed supports the arts, offering young Swiss artists a platform and opportunities for exhibitions and work-shops. With the Franz Gertsch Museum, Burgdorf has acquired a lasting attraction and a great deal of positive publicity for the region.

The Swiss Federal Council in front of a painting by Franz Gertsch

47


Sust

ain

abil

ity

Rep

ort

Environment

Environmentally sensitive use of energy and resources is an important concern for Ypsomed, and an integral part of management decisions, particularly in the case of new invest-ment in fixed assets, operating infrastructure and buildings. For this reason, Ypsomed provides training to raise employees’ awareness of the subject of the environment, and actively endeavors continually to improve Ypsomed’s energy effi-ciency. Ypsomed’s most important environmental key data for the calendar years 2007 to 2011 are listed below, with comments.

Low energy consumption in an industry comparisonOverall, Ypsomed uses very little in the way of energy and natural resources in production compared with other sectors or industries. In the 2011 calendar year, thanks to optimiza-tion of costs and changes in production, Ypsomed once again reduced its energy requirement by 1.8% (see diagram on energy consumption). Compared with the previous year, Ypsomed used 14.8% less natural gas and 8.5% less heating oil, but due to increasing demands relating to indoor air quality, it used 5.0% more electricity. Overall, investments made in recent years in order to improve energy efficiency have paid off, such as for example the modernization of the shell of the building and building services in Solothurn, or the introduction of electrical injection molding machines with 50.0% less energy requirement. Investment in energy effi-ciency makes sense not only for environmental reasons, but is also financially necessary against the background of continually rising energy prices. For the 2012/13 business year, Ypsomed is therefore planning fresh measures to reduce energy consumption, including increased use of waste heat from production processes and air conditioning processes, as well as through the optimization of compressed air produc-tion and more intelligent monitoring and control of the systems for lighting, ventilation and air conditioning.

Lower burden on the environ-ment through reduced business travelConsistent cost management at Ypsomed has yielded not only considerable savings on travel costs, but has also sig-nificantly reduced the burden on the environment caused by business travel by Ypsomed staff and flights. In the 2011 calendar year, business travel as measured in kilometers traveled was reduced by 14.4% overall. The kilometers traveled using our own vehicles were reduced by 24.1%, and the kilometers traveled by vehicles belonging to Ypsomed staff were even reduced by more than 34.0%.

100 000

80 000

60 000

40 000

20 000

02011 2010 2009 2008 2007

Natural gas –14.81% Heating oil –8.48% Electricity 5.09%

Energy in business years

Business travel (CH) in km

2 500 000

2 000 000

1 500 000

1 000 000

500 000

0

Own vehicles –24.15% Vehicles of employees –34.29% Air travel –6.69%

2011 2010 2009 2008 2007

48


Financial results 2011/12

Financial reporting now in accordance with Swiss GAAP FERDuring the 2011/12 business year, Ypsomed switched its financial reporting from IFRS (International Financial Report-ing Standards) to Swiss GAAP FER (Accounting and Reporting Recommendations). The effects of the conversion and reclas-sification are explained in detail in the notes from page 57 onward.

Ypsomed increases net profit despite lower sales of goods and servicesIn the 2011/12 business year, the Ypsomed Group generated consolidated sales of goods and services totaling CHF 248.6 million and increased net profit by 55.5% from CHF 5.5 mil-lion to CHF 8.5 million. Sales of goods and services in the 2011/12 business year were CHF 13.2 million (5.1%) lower than in the same period in the previous year (CHF 261.8 million). The pleasing growth in sales of goods and services in the “Diabetes Direct Business” (up 7.7% from CHF 72.6 million to CHF 78.2 million) and in the “Others” segment (up 11.0% from CHF 15.3 million to CHF 17.0 million), largely thanks to Ypsotec, only went some way toward offsetting a fall in sales in the “Delivery Device Business” (down 11.8% from CHF 173.9 million to CHF 153.4 million). The “Delivery Device Business” had to contend with the loss of proceeds from the manufacture of adapters for Roche infusion systems, while the proceeds generated with Ypsomed pens for Sanofi were once again lower than in the previous year, as had been expected. Overall, the share of total revenue attribut-able to Sanofi fell from 22.0% to 20.5%. Because the OptiSet® Pen was delivered for the last time in March 2012, sales with Sanofi will reduce by some 40% in the 2012/13 business year. Consolidated sales of goods and services in the 2011/12 business year were also adversely affected by fluctuations in the Swiss franc exchange rate and lower remuneration for research and development services.

Delivery Device Business expands customer baseThe Ypsomed Group stuck rigorously to its company strategy in the 2011/12 business year, further diversifying the Group’s earnings base. In the Injection Systems segment, Ypsomed won several new customers for the ServoPen insulin pen, including more insulin providers from Asia in the shape of Square Pharmaceuticals Ltd. and Incepta Pharmaceuticals Ltd. Particularly gratifying was the increase in earnings gen-erated with Ypsomed’s China-based pharmaceuticals partner Tonghua Dongbao Pharmaceutical.

mylife™ Diabetescare products enjoy earnings growthDuring the 2011/12 business year, Ypsomed also expanded the geographical reach of its mylife™ Diabetescare customer base in the Diabetes Care business segment and launched new products. The mylife Roto infusion set, which offers 360 degrees of freedom of movement, was brought onto the market in spring 2011 and a new distribution company was

49

Ypsomed – Financial Report

Fin

anci

al R

epor

t

Sales of goods and services Currency effect

Delivery Devices2011/12 2010/11

In million CHF

Sales development

180

160

140

120

100

80

60

40

20

0

Diabetes Direct Business

2011/12 2010/11 2010/11Others2011/12

Gross profit of 22.7% despite non-recurring special circumstances

In the 2011/12 business year, Ypsomed cut manufacturing costs from CHF 200.8 million to CHF 192.2 million, generating a gross profit of CHF 56.4 million as against CHF 61.0 million in the previous year. The fall in gross profit year-on-year was due to amortization, currency effects in the pen needle business, and higher pen needle production costs. Needle production in Solothurn has now been optimized and expanded cost-effec-tively through the use of additional facilities provided by an-other manufacturer. The gross profit was also negatively af-fected by an impairment of CHF 1.3 million on capitalized development costs. CHF 1.0 million of this figure relates to Pfizer’s and Biocon’s decision to abandon their cooperation. It is therefore all the more pleasing that, by rigorously adjusting its cost structure in line with lower sales volumes in the pen needle business, Ypsomed nevertheless generated a gross profit margin of 22.7%, only 0.6% below last year’s figure of 23.3%.

Rigorous cost savings result in an operating profit before depreciation and amortization of CHF 32.9 millionDuring the past business year, Ypsomed carried out a cost analysis commissioned by the Board of Directors, and most of the resulting cost-cutting measures have already been imple-mented. Overall, personnel expenses fell by 7.8% (CHF 8.4 million) from CHF 108.0 million to CHF 99.6 million. Total ex-penditure (incl. capitalized development activities) for research and development remained high in the 2011/12 business year, accounting for some 10.0% of net proceeds, but this was also reduced year-on-year, from CHF 27.5 million to CHF 25.2 million. Administrative expenses were reduced from CHF 13.6 million to CHF 12.8 million. At CHF 40.6 million, expenditure on sales and marketing remained more or less the same as in the previous year (CHF 40.5 million) but increased in percentage terms from 15.5% to 16.3% of sales of goods and services. This illustrates Ypsomed’s determination to further diversify its earnings base and further expand its strategic mylife Diabetes care business segment. Overall, despite a CHF 13.2 million decrease in sales

set up in Austria toward the end of the year. In addition, summer 2012 will see the launch of mylife™ DailyDose™, the smallest insulin syringe to date, and distribution of second-generation mylife™ OmniPod® insulin patch pumps will begin. Expenditure on sales and marketing has paid off, with mylife™ Diabetescare products posting earnings growth of 7.7% in the 2011/12 business year. Especially pleasing was the growth in earnings enjoyed by the mylife™ OmniPod® insulin pump and the mylife™ Orbit® infusion set. Overall, the strategic Diabetes Care business segment continued to gain in impor-tance, contributing as much as 31.5% to the Ypsomed Group’s consolidated sales of goods and services in the 2011/12 business year (previous year: 27.1%).

Adjusted for currency effects, sales of goods increase by 2.5%In the course of the 2011/12 business year, the Swiss franc rose 9.5% against the euro and 13.0% against the US dollar, knocking CHF 10.8 million off Ypsomed’s sales of goods and services. Adjusted to take account of these currency effects, Ypsomed would have increased sales of goods in the 2011/12 business year by 2.5%.Foreign exchange effects also had a significant impact on profit. In the pen needle business, the strong Swiss franc cut profitability by CHF 3.0 million. The remaining products mainly generate sales proceeds and incur purchasing costs in the same currencies. This operational currency hedge prevented the strong Swiss franc from doing even greater damage to Ypsomed’s profitability.

”Adjusted for the negative currency effects caused by the strong Swiss franc, Ypsomed increased net sales from goods by 2.5% in the 2011/12 business year compared to the previous year.„

50


Personnel expenses2011/12 2010/11

In million CHF

Cost development

120

100

80

60

40

20

0

R & D expenses2011/12 2010/11

Capital expenditure(capex)

2011/12 2010/112010/11Marketing & Salesexpenses

2011/12 2010/11Administrationexpenses

2011/12

of goods and services, in the 2011/12 business year Ypsomed recorded an operating profit before depreciation and amortiza-tion (EBITDA) of CHF 32.9 million and an EBITDA margin of 13.2%, slightly higher than the previous year’s figure of 12.9%.

“Despite lower sales of goods and services, in the 2011/12 business year Ypsomed succeeded in achieving an EBITDA margin slightly higher than the previous year’s level, thanks to rigorous cost savings.”

Net profit increased by 55%Depreciation of fixed assets in the 2011/12 business year remained unchanged on the previous year at CHF 19.6 mil-lion, while amortization of intangible assets increased from CHF 5.4 million to CHF 6.9 million. Due to the negative cur-rency effects and the impairment, operating profit amounted to a still unsatisfactory CHF 5.1 million, a fall on the previous year’s figure of CHF 8.8 million. Stringent cost management and process optimizations will therefore remain top priorities and the focus of Ypsomed’s efforts.

In the 2011/12 business year, financial expenses increased only slightly year-on-year, up from CHF 2.6 million to CHF 3.4 million. Financial income, on the other hand, rose markedly by CHF 6.3 million from CHF 1.7 million in the previous year to CHF 8.0 million, due to the sale of the stake in Insulet Corp. at a profit. The good financial result and slightly lower taxes had a positive impact on net profit, which improved by 55.5% in the 2011/12 business year, up from CHF 5.5 million to CHF 8.5 million. Profit per share in the 2011/12 business year thus stood at CHF 0.67 per registered share as against CHF 0.43 per registered share in the previ-ous year.

Ypsomed boosts cash flow from operating activities to CHF 31.1 million

In the 2011/12 business year, Ypsomed generated cash flow from operating activities of CHF 31.1 million, up by 7.5% on the previous year. Thanks to the substantial investments made over the past few years and free capacity, Ypsomed was able to cut investments in fixed assets by nearly 50% in the past business year. By contrast, Ypsomed increased its stake in Taiwan-based Bionime Corp. by CHF 1.7 million and used its own funds to acquire the infusion business of ICU Medical Inc. for CHF 14.3 million.

51


Fin

anci

al R

epor

t

Strategically important acquisition of the infusion set business of ICU Medical Inc.The acquisition of the patents and infusion set business of the US firm ICU Medical Inc. in November 2011 was a very important strategic step for Ypsomed as it turned the com-pany into a manufacturer of infusion sets and thus further strengthened the Diabetes Care business segment. Ypsomed intends to increase its market share in the extremely promis-ing growth market for infusion sets, and improve its profit margin by taking over production activities. Ypsomed has thus secured a key accessory with a view to the launch of its own low-cost economical and user-friendly insulin pump.

“With the acquisition of the infusion set business of ICU Medical Inc., Ypsomed is becoming a manufacturer of infusion sets and is strengthening the strategic Diabetes Care business segment.”

Positive cash flow in the 2011/12 business yearTotal cash flow from investing activities amounted to CHF -19.8 million in the 2011/12 business year, a fall of CHF 8.1 million on the previous year (CHF -27.9 million). In the past business year, Ypsomed increased its bank loans by CHF 6.5 million, while at the same time repaying a further CHF 10.0 million of the current shareholder loan and paying shareholders a dividend of CHF 2.5 million from capital reserves in June 2011. Cash flow from financing activities thus stood at CHF -6.4 million as against CHF -3.2 million in the previous year. The Ypsomed Group’s total cash flow improved from CHF -3.0 million in the previous year to CHF 4.7 million in the 2011/12 business year.

High equity ratio despite offset goodwill

Even with the switch in reporting standards from IFRS to Swiss GAAP FER, Ypsomed has maintained an extremely solid balance sheet. Cash and cash equivalents increased from CHF 5.0 million to CHF 9.7 million in the 2011/12 busi-ness year, while trade receivables fell from CHF 32.2 million to CHF 24.5 million. At CHF 50.1 million, inventories dipped only slightly below the previous year’s level of CHF 51.6 million. Financial assets fell in the past business year from CHF 13.1 million to CHF 9.1 million due to the sale of the stake in Insulet Corp. at a profit. With depreciation remaining at the same level as the previous year but investment lower, fixed assets declined from CHF 179.1 million to CHF 166.4 million. When the reporting standards were switched, capital-ized goodwill was offset in full against equity and thus eliminated from the balance sheet. The Ypsomed Group’s equity ratio increased by 3.0% in the 2011/12 business year from 63.6% to 66.6%. On the liabilities side of the balance sheet, the shareholder loan was reduced from CHF 34.5 million to CHF 24.5 million, while bank loans increased from CHF 40.0 million to CHF 46.5 million. Overall, the balance sheet total decreased in the 2011/12 business year from CHF 353.8 million to CHF 327.3 million as of the reporting date, 31 March 2012.

Dividend payment from capital reservesFor the 2011/12 business year, the Ypsomed Board of Direc-tors will propose to the General Meeting of Shareholders, to be held on June 27, 2012 in Bern, that a dividend payment of CHF 0.20 per registered share be made from tax-beneficial capital reserves. At CHF 2.5 million in total, the dividend paid to shareholders for the 2011/12 business year will thus be the same as in the previous year.

52


(Audited Swiss GAAP FER figures) in thousand CHF Notes 1 April 2011 31 March 2012

in % 1 April 2011 31 March 2011

(Adjusted*)

in %

Sales of goods and services 20 248 593 100 261 822 100

Cost of goods and services sold –192 221 –77.3 –200 835 –76.7

Gross profit 56 373 22.7 60 987 23.3

Marketing and sales expenses –40 580 –16.3 –40 467 –15.5

Administration expenses –12 754 –5.1 – 13 553 –5.2

Other operating income 3 979 1.6 3 838 1.5

Other operating expenses –1 877 –0.8 – 1 988 –0.8

Operating profit 20 5 140 2.1 8 817 3.4

Financial income 17 7 955 3.2 1 666 0.6

Financial expenses 18 –3 357 –1.4 –2 601 –1.0Profit before income taxes 9 738 3.9 7 882 3.0

Income taxes 19 –1 238 –0.5 –2 414 –0.9

Net profit 8 500 3.4 5 468 2.1

Earnings per share (basic and diluted) in CHF 24 0.67 0.43

Operating profit 5 140 8 817

Depreciation of fixed assets 20 19 578 19 645

Amortization of intangible assets 20 8 146 5 436

EBITDA (operating profit before depreciation and amortization) 32 865 13.2 33 898 12.9


Consolidated income statement

– –

53


Fin

anci

al R

epor

t

Consolidated balance sheet

(Audited Swiss GAAP FER figures) in thousand CHF

AssetsNotes 31 March 2012 in % 31 March 2011

(Adjusted*)in %

Cash and cash equivalents 4 9 735 3.0 5 022 1.4

Trade receivables 5/14 24 528 7.5 32 246 9.1Other current assets 6 130 1.9 5 024 1.4Prepayments and accrued income 3 713 1.1 8 073 2.3

Current income tax assets 123 0.0 185 0.1

Inventories 6/14 50 147 15.3 51 576 14.6

Customer machinery 228 0.1 5 258 1.5

Total current assets 94 604 28.9 107 385 30.3

Financial assets 7 9 054 2.8 13 094 3.7

Deferred income tax assets 19 7 063 2.2 4 911 1.4

Fixed assets 8 166 361 50.8 179 052 50.6

Intangible assets 9 50 191 15.3 49 386 14.0Total non-current assets 232 668 71.1 246 443 69.7

Total assets 327 273 100.0 353 829 100.0

Liabilities and equityNotes 31 March 2012 in % 31 March 2011

(Adjusted*)in %

Financial liabilities 46 500 14.2 40 000 11.3

Current financial liabilities to major shareholder 11 10 000 3.1 10 000 2.8

Trade payables 13 461 4.1 13 080 3.7

Prepayments from customers 14 2 284 0.7 7 333 2.1

Current income tax payable 2 198 0.7 4 593 1.3

Other payables 2 477 0.8 3 733 1.1

Accrued liabilities and deferred income 12 714 3.9 20 621 5.8

Provisions 12 1 262 0.4 1 418 0.4

Total current liabilities 90 895 27.8 100 777 28.5

Non-current liabilities to major shareholder 11 14 500 4.4 24 500 6.9

Other non-current financial liabilities 2 308 0.7 7 0.0

Provisions 12 989 0.3 973 0.3

Deferred income tax liabilities 577 0.2 2 503 0.7

Total non-current liabilities 18 374 5.6 27 983 7.9

Share capital 13 178 994 54.7 178 994 50.6

Capital reserves 178 558 54.6 181 091 51.2

Own shares/Translation exchange differences –8 496 –2.6 –6 005 –1.7

Goodwill acquired offset –322 892 –98.7 –312 350 –88.3

Retained earnings 191 839 58.6 183 339 51.8

Total equity 218 004 66.6 225 069 63.6

Total liabilities and equity 327 273 100.0 353 829 100.0


54


Consolidated statement of cash flows

(Audited Swiss GAAP FER figures) in thousand CHF Notes 1 April 011 31 March 2012

1 April 2010 31 March 2011

(Adjusted*)

Net profit 8 500 5 468

Depreciation of fixed and intangible assets 26 455 25 081

Loss from impairment 1 269 0

Change in provisions (incl. deferred income taxes) –1 270 1 132

Other expenses/income that do no not affect the fund 1 590 –256

Gain (–)/loss (+) of fixed and financial assets –5 261 –43

Increase (–)/decrease (+) in trade receivables 6 942 –1 643

Increase (–)/decrease (+) in other receivables and prepayments and accr. income 3 102 –1 928

Increase (–)/decrease (+) in inventories –242 –6 223

Increase (–)/decrease (+) in customer machinery 5 030 –4 080

Increase (+)/decrease (–) in trade payables 725 46

Increase (+)/decrease (–) in prepayments from customers –5 049 5 445

Increase (+)/decrease (–) in other payables and accr. liabilities and deferred income –10 736 5 878

Cash flow from operating activities 31 055 28 876

Purchases of financial assets –1 175 0

Disposals of financial assets 11 446 0

Purchases of fixed assets 8 –7 501 –14 485

Disposals of fixed assets 8 586 2 002

Purchases of intangible assets 9 –8 424 –11 739

Disposals of intangible assets 9 4 0

Final payment acquisition prev. year/Acquisitions, net of cash acquired 1 –14 717 –3 681

Cash flow from investing activities –19 781 –27 903

Repayment of financial liabilities to major shareholder 11 –10 000 –10 000

Proceeds from borrowings 6 500 10 000

Outflows from borrowings 0 –648

Distribution of capital reserves/Par value repayment 25 –2 532 –3 190

Purchase of treasury shares 13 –392 0

Cash flow from financing activities –6 425 –3 838

Effect of foreign currency translation –136 –178

Total Cash Flow 4 713 –3 043

Cash and cash equivalents as of April 1 5 022 8 065

Cash and cash equivalents as of March 31 9 735 5 022Net increase (+)/decrease (–) in cash and cash equivalents 4 713 –3 043


– –

55


Fin

anci

al R

epor

t

Consolidated statement of changes in equity

(Audited Swiss GAAP FER figures) in thousand CHF Sharecapital

Groupreserves

and sharepremium

Treasuryshares

Cumulativetranslation

reserve

Fluctuationin value of

financialinstruments

Goodwilloffset

Retainedearnings

Total

Balance as of 1 April 2010 IFRS 182 156 181 125 –1 951 –1 615 6 679 171 349 537 743

Change from IFRS toSwiss GAAP FER –6 679 –308 878 6 522 –309 036

Balance as of 1 April 2010 Swiss GAAP FER 182 156 181 125 –1 951 –1 615 0 –308 878 177 871 228 707


Par value repayment –3 162 –34 6 –3 191

Translation exchange differences –2 445 –2 445

Goodwill acquired offset –3 471 –3 471

Balance as of 31 March 2011 (after adjustment) 178 994 181 091 –1 945 –4 060 0 – 312 350 183 339 225 069


Distribution of dividends fromcapital contribution reserves –2 532 – 2 532

Purchases of own shares –392 –392

Translation exchange differences –2 099 –2 099

Goodwill due to akquisition offset –10 542 –10 542Balance as of 31 March 2012 178 994 178 558 –2 337 –6 159 0 –322 892 191 839 218 004

56


Basis for the consolidated financial statements

1. General information

Ypsomed Holding AG is a limited company (Aktiengesellschaft) established on 29 December 2003 under Swiss law with registered offices in Burgdorf (canton of Berne, Switzerland).

Operating in the field of medical technology, the Ypsomed Group is a leading independent manufacturer of injection pens for pharmaceutical and biotech companies, as well as a supplier of pen needles. Ypsomed’s core manufacturing business consists of developing and marketing prod-ucts and services allowing patients to administer their own medication. The Group operates production sites in Burgdorf, Solothurn, Grenchen (all CH) and Tabor (CZ) and has a sales and distribution network across Europe. The shares of Ypsomed Holding AG have been traded on the SIX Swiss Exchange since 2004, and since 2007, on the BX Bern eXchange.

The company was created as a result of the split-up of the Disetronic group in 2003. Disetronic had been founded in 1984 to develop, manufacture and sell infusion pumps and had expanded into the injection systems business in 1986.

The consolidated financial statements were approved for issue by the Board of Directors on 15 May 2012 and recommended for acceptance to the General Meeting of 27 June 2012.

2. Fundamental accounting and assessment methods

BasicsThe consolidated financial statements have been prepared in accordance with the Swiss accounting and reporting recommendations of Swiss GAAP FER according to the principle of “true and fair view.” They are based on the financial statements of the company prepared for the same reporting period using consistent accounting policies. The Group’s reporting cur-rency is the Swiss franc (CHF). The period under review comprises twelve months and ends 31 March. The accompanying consolidated financial statements are published in German and English. The German version is legally binding. All figures included in these financial statements and notes to the financial statements are rounded to the nearest CHF 1 000 except where otherwise indicated.

Change in accounting policiesUp to March 31 2011, the Ypsomed Group used the IFRS accounting system (International Financial Reporting Standards). The ever-increasing regulatory scope of IFRS, which is based on formal, complex, detailed regulations, has become too elaborate for Ypsomed Holding AG. In addition, disclosure obligations, which by and large do not provide stake-holders with a better understanding of the company’s financial position and earnings situation, increase the risk of revealing trade secrets. Swiss GAAP FER also ensures a meaningful accounting framework built around the guiding principle of presenting a true and fair view of a company’s net assets, financial position and earnings situation. Due to this reason, the Board of Directors decided to accomplish the switch to Swiss GAAP FER (accounting and reporting recommendations) as of 1 April 2011.

The switch from IFRS to Swiss GAAP FER has necessitated adjustments to the Group’s accounting policies in terms of how goodwill, pension obligations and financial assets are treated, and in the presentation and structure of the annual financial statements. The figures for the previous year have been adjusted to make it possible to draw comparisons with the previous year.

GoodwillUnder IFRS, goodwill is reported under intangible assets, is subjected to an annual impairment test and is shown in the balance sheet at cost less accumulated impairment. Under Swiss GAAP FER, goodwill is reported either as an intangible asset at cost less accumulated amortization, or is offset against equity at the time of acquisition. The Board of Directors has decided to offset goodwill against equity.

Pension benefit obligationsWith the adoption of Swiss GAAP FER, the economic impact of pension benefit obligations is now reported in accordance with Swiss GAAP FER 16. The pension benefit obligations of the Group companies in respect of retirement, death and disability comply with the statutory provisions and regulations in the respective countries. Two Swiss companies have a legally independent pension fund financed by employer and employee contributions (defined contribution plan). The actual economic impact of pension plans on Ypsomed’s consolidated financial statement is calculated as of the balance sheet date. An economic benefit is capitalized provided it will be available to reduce the company’s future pension expenses. An economic obligation is recognized as a liability if the conditions for establishing a provision are met. Any unconditionally available employer contribution reserves are recognized as assets. The economic impacts of surpluses or deficits in the pension funds on the Group, as well as a change in any employer contribution reserves are recognized as income and reported as personnel expenses in addition to the contributions deferred to the reporting period. Based on the existing pension agreements and the actual circumstances as of April 1, 2010, March 31, 2011, and March 31, 2012, no economic benefits or economic obligations were recognized in the Group’s consolidated financial statements.

Financial assetsUnder IAS 39, financial assets available for disposal were initially reported in the balance sheet at cost and were then valued at fair value. Changes in fair value were included in equity until any such financial instrument was either reduced in value or sold. Under Swiss GAAP FER 2, financial assets must be valued at cost, less any impairment of value.

Presentation and structureThe structure and presentation of the balance sheet, the income state-ment, the statement of changes in equity and the statement of cash flows have been adjusted to reflect the requirements of Swiss GAAP FER. In this process, only the income statement has been adjusted to any significant extent: all revenue from sales and services has now been included under “Sales of goods and services,” which now also comprises income from the provision of research, development, industrialization and marketing services. The items “Real estate income,” “Gains from disposal of fixed assets” and “Licensing revenue,” which were listed individually under IFRS, are combined under “Other operating income.” The costs required for the generation of real estate income are included in “Other operating costs.” Research and development expenses are now included under “Cost of goods and services sold.” The effects of the accounting adjustments indicated above on equity, the income statement and the presentation and structure of the income statement are summarized in the table shown (see page 58).

57


Fin

anci

al R

epor

t

IFRS IFRS Reclassi-fication

Valuationeffects

Swiss GAAP FER

Swiss GAAP FER

Sales of goods and services 240 261 21 561

Real estate income 2 200 –2 200

Total sales of goods and services 242 461 19 361 261 822 Total sales of goods and services

Cost of goods andservices sold

–175 737 –25 249 152 –200 835Cost of goods andservices sold

Gross profit 66 724 –5 888 152 60 987 Gross profit

Profit from disposal offixed assets

381 –381

Licensing revenues 1 119 –1 119

Research and developmentreimbursed

8 261 –8 261

Research and development expenses –17 508 17 490 18

Research and developmentexpenses net

–9 247 9 229 18

Marketing and sales expenses –36 928 –3 553 13 –40 467 Marketing and sales expenses

Administration expenses –13 439 –138 24 –13 553 Administration expenses

3 838 3 838 Other operating income–1 988 –1 988 Other operating expenses

Operating profit 8 610 207 8 817 Operating profit

Financial income 1 666 1 666 Financial income

Financial expenses 2 601 –2 601 Financial expenses

Profit before income taxes 7 675 207 7 882 Profit before income taxes

Income taxes –2 469 55 –2 414 Income taxes

Net profit 5 206 262 5 468 Net profit

Equity underIFRS

Adjustment ofgoodwill*

Adjustment ofpension obligations*

Adjustment offinancial

instruments*

Equity under Swiss GAAP FER

1 April 2010 537 743 – 308 878 6 522 – 6 679 228 707

31 March 2011 538 056 – 311 063 6 710 – 8 634 225 069

Net profit underIFRS

Adjustment of taxeson goodwill

Adjustment ofpension obligations*

Adjustment offinancial instruments

Net profit underSwiss GAAP FER

Total 2010/2011 5 206 74 189 5 468

*After taxes

Figures in thousand CHF

Income statement 1 April 2010 – 31 March 2011

58


ConsolidationSubsidiariesSubsidiaries are all entities over which the Group has the power to govern the financial and operating policies, generally accompanying a sharehold-ing of more than one half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or tradable can also determine whether the Group controls another entity. Subsidiaries are fully consolidated from the date on which control is obtained. They are de-consolidated from the date that control ceases.Subsidiaries are recognized using the purchase method. The considera-tion encompasses the compensation transferred in exchange for obtaining control over the identifiable assets, liabilities and contingent liabilities of the company acquired. The compensation encompasses cash payments as well as the fair market value of both the transferred assets, the incurred or assumed liabilities, and in addition the equity instruments as of the trade date that have been issued by the Group. The net assets acquired compris-ing identifiable assets, liabilities and contingent liabilities are recognized at their fair value. Goodwill is recognized as of the acquisition date and is measured as the excess of the consideration transferred as described over and above the fair value of the identified net assets. If the Group does not acquire 100% of the shares of a company, the minority interest in equity is to be disclosed separately under the equity.Transactions, balances and gains on transactions between subsidiaries are eliminated. Losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset.

AssociatesAssociates are those companies that are significantly influenced but not controlled by the Group. This normally applies to investments in which the Group owns between 20% and 50%. Investments in associates are accounted for using the equity method. The Group’s investment in associates includes goodwill identified on acquisition. Ypsomed does not currently have any investments in associates.

Foreign currency translationForeign currency transactions are translated to the functional currency using the exchange rate prevailing at the date of the transaction. Foreign exchange gains and losses resulting from the settlement of such transac-tions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of comprehensive income as financial income or expenses.In the consolidated financial statement, assets and liabilities of foreign subsidiaries are converted into Swiss francs at year-end exchange rates. Equity is converted with historical exchange rates. The statement of comprehensive income and the statement of cash flows are translated at annual average exchange rates. The effects of this conversion as well as foreign exchange gains and losses arising from the translation of non-currency congruent financed equity-like corporate loans denominated in foreign currencies are to be recognized in the equity, with no effect on the income statement.

CashCash and cash equivalents comprise cash on hand, demand deposits and time deposits with a residual term to maturity from the balance sheet date of 90 days at the most. They form the basis of the consolidated statement of cash flows.

Trade receivables/other receivablesTrade receivables and other receivables are valued at par value less impairment, if any. An allowance is set aside if objective indications show that receivables cannot be collected. Allowances are based on individual valuations.

InventoriesRaw materials and merchandise purchased are recognized at cost, semi-finished and finished goods at their cost of conversion. Discounts are rec-ognized as a reduction in the purchase price. Manufacturing costs include the associated direct production costs and production overheads. If the acquisition or manufacturing costs are higher than the net market value, an impairment loss is recorded on the income statement in the current

period to write the inventories down to the net market value (lower of cost or market principle). Net market value is equivalent to the current market price less the usual sales deductions, marketing costs, and administrative costs yet to be incurred. Inventories that cannot be sold are written off in full. The costs of inventories are determined by using the FIFO method.

Customer machinery/Prepayments from customersYpsomed receives prepayments from pharma partners in order to acquire production machinery for these pharma partners. Ypsomed coordinates the manufacturing of the machineries with suppliers and makes contractual advance payments to the suppliers. After installation and successful test runs, the machinery is accepted by Ypsomed. From a legal and commercial viewpoint, once the machinery has been accepted by Ypsomed the title is transferred to the pharma partners. The advance and final payments made by Ypsomed to suppliers are disclosed in the consolidated balance sheet as current assets until acceptance of the machinery. The prepayments from customers are recognized in current liabilities. Once the machinery is accepted, the advance and final payments from Ypsomed are settled with the prepayments from the customer.

Fixed assetsFixed assets are carried at historical acquisition or manufacturing cost, with depreciation calculated using the straight-line method based on the following estimated useful lives: • Buildings 20to40years • Technicalassets 6to20years • Machineryandcompanyfacilities 3to12years • Fixtures,fittingsandvehicles 3to8years • Otherfixedassets 2to10yearsDepreciation is included in the following income statement categories: manufacturing costs of goods sold, marketing and distribution costs, admin-istration costs and other operating expenses. Should an asset be impaired as a result of impairment testing, the corresponding impairment charge is included in depreciation and reported separately as an impairment loss.Value-enhancing expenditures are capitalized if the market value or the value in use increases as a result.Long-term leasing contracts, which are, in substance, equivalent to the pur-chase of assets with long-term financing (financial leasing), are recognized at the beginning of the lease as an asset and measured at net market value/acquisition cost or, if lower, at the present cost of the leasing payments. The asset is depreciated in line with its useful economic life.Investment properties are reported at cost of acquirement minus depreciation. The period of depreciation is calculated according to the category of asset.

Intangible assetsGoodwillNet assets taken over in an acquisition are to be valued at actual values, any surplus of acquisition cost over the newly valued net assets is to be designated as goodwill (purchase price allocation). The goodwill is to be offset at the date of acquisition. The effects of a theoretical capitalization are to be disclosed in the notes.

Development costsDevelopment costs are capitalized if an intangible asset can be identified, finished, marketed, or used internally, if it is controlled by the Ypsomed Group, if it is expected to provide the Ypsomed Group with an economic benefit over several years, and if its costs can be reliably determined.Capitalized development costs are amortized straight-line over their useful economic lives. The amortization is included in the manufacturing costs of products and services sold. Costs accrued for development projects are tested for impairment on an annual basis.

Other intangible assetsPatents are carried at acquisition cost and amortized over their estimated useful lives of 15 to 20 years. Amortization is included in the costs of research and development that are integrated in the manufacturing costs of products and services sold.Software is capitalized on the basis of the costs incurred to acquire the software and bring the software to use. These costs are amortized over the estimated useful life of three to four years using the straight-line method.

59


Fin

anci

al R

epor

t

Amortization is mainly included in administration expenses. Intangible assets, such as brand names or customer relationships that were acquired through a business combination and can be identified separately, are reported if they fulfill the definition of an intangible asset. The acquisition costs of such intangible assets correspond to their fair value at the time of acquisition. The value thereafter is measured at acquisition cost minus accumulated amortization and depreciation. The useful life is estimated at five to eight years. Amortization is included in marketing and distribu-tion costs.

Financial assets Financial assets are recognized at acquisition cost less impairment, if any. Impairment is recorded in profit or loss for the current period.

Impairment of assetsAll assets are reviewed as of each balance sheet date for indications of impairment. If there are indications that an asset may be impaired, the recoverable amount of the asset is determined and the impairment loss is estimated. Should the estimated recoverable amount of the asset, which is equivalent to the higher of net market value and the useful value of the asset, be lower than the asset’s book value, an adjustment is made to the income statement to reduce the book value of the asset to the estimated recoverable amount in the same period in which the impairment was discovered. Net market value is the price obtainable between independent third parties less the associated selling expenses. Useful value is based on the estimated future cash flows resulting from the use of the asset, including any possible cash flow at the end of the useful life, discounted using an appropriate long-term interest rate.

Long-term financial liabilities to shareholdersThe loan to the major shareholder is measured at its nominal amount.

ProvisionsProvisions are established when a legal or de facto obligation arising from previous events exists that will likely result in a cash outflow and this cash outflow can be reliably estimated. The provisions established represent the best possible estimate of the final obligation. Long-term provisions are discounted to their present values, provided that the impact is material. The subdivision into short-term and long-term provisions is based on whether utilization is assumed to be probable within one year or at a later time. Possible obligations whose existence requires confirmation by future events, or obligations whose amount cannot be reliably estimated, are disclosed in the notes to the financial statements as contingent liabilities.

Pension benefit obligations The pension benefit obligations of the Group companies in respect of old age, death and disability comply with the statutory provisions and regulations in the respective countries. The employees of the Swiss com-panies have a legally independent pension fund for retirement, death and disability. The pension funds are financed by employer and employee contributions (defined contribution plan). The actual economic impact of pension plans on the company is calculated as of the balance sheet date. An economic benefit is capitalized provided it will be available to reduce the company’s future pension expenses. An economic obligation is recognized as a liability if the conditions for establishing a provision are met. Any unconditionally available employer contribution reserves are recognized as assets. The economic impacts of surpluses or deficits in the pension funds on the Group, as well as a change in any employer contribu-tion reserves, are recognized as profit or loss and reported as personnel expenses in addition to the contributions deferred to the reporting period.

Current income taxes Income taxes are calculated based on reported profits and in conformity with the tax laws prevailing in the individual countries and recognized in profit or loss of the current period.Deferred taxes are taken into account on temporary differences between tax bases and the carrying amounts in the consolidated financial state-ments and are calculated using the liability method based on effective

or expected effective local tax rates. Deferred tax assets are recognized for loss carry-forwards where it is highly probable that they can be offset against future taxable income. The changes in deferred tax assets and liabilities are recognized in the consolidated income statement. Taxes on transactions that are reported in equity are also recognized in equity.

Net sales and sales recognitionNet salesSales consists of all sales proceeds attained from the delivery of goods and provision of services to third parties after deducting discounts, rebates, cash discounts and value-added taxes. Sales proceeds are always included in the income statement as soon as the delivery of the goods has taken place and benefit and risk have been transferred to the buyer, or the service has been rendered.

Other operating incomeOther operating income primarily includes rental income arising from the leasing of properties owned by the Ypsomed Group, licensing income aris-ing from the use of Ypsomed assets by external third parties, and proceeds from the disposal of property, plant, and equipment.

Long-term contractsDevelopment and industrialization projects are accounted for according to the percentage-of-completion method (PoCM). Services and costs are correspondingly considered according to the degree of completion (cost-to-cost method) so that any profit is taken into consideration propor-tionally. The degree of completion for the services provided is calculated by determining the difference between the costs incurred and the costs expected for the whole order. Long-term contracts are accounted for under inventories, customer machinery and prepayments from customers.

Research and development costsResearch costs are routinely included in the manufacturing costs of the products and services sold.Development costs are capitalized if an intangible asset can be identified, finished, marketed, or used internally, if it is controlled by the Ypsomed Group, if it is expected to provide the Ypsomed Group with an economic benefit over several years, and if its costs can be reliably determined.Capitalized development costs are amortized straight-line over their useful economic lives. The amortization is included in the manufacturing costs of products and services sold. Costs accrued for development projects are tested for impairment on an annual basis.

Borrowing costsBorrowing costs in connection with the construction of property, plant, and equipment are capitalized under certain conditions. All other borrowing costs are charged directly to the income statement.

60


3. Risk assessment

The management of the Ypsomed Group carries out a comprehensive risk assessment at least once a year. This standardized process is based on a risk inventory that encompasses the relevant risk categories such as strategic risks, management risks, general risks in operating business, legal risks, systemic risks, financial risks (including market, credit and liquidity risks) and event risks (including political, regulatory, fiscal and external risks). The fundamental risks are assessed with regard to probability of occurrence and impact, and both management and the Board of Direc-tors decide on measures to be taken and monitor their implementation according to predetermined criteria.

4. Legal risks

The Ypsomed Group develops, manufactures and sells innovative medical technical devices, based on technical expertise and technologies protected by intellectual property rights. The Group is either owner of the required rights or license holder of the property rights of a third party. In the medi-cal devices market, disputes over patent rights and patent infringements occur fairly frequently and can involve costly and time-intensive patent infringement suits.

The development, manufacture and sale of medtech products involve product liability risks and can lead to product recall. There is no guarantee that the present liability insurance is sufficient to cover all damage cases con-nected with the development, manufacture and sale of medical products and that the insurance companies will still be prepared in future to insure Ypsomed Group business activities against liability risks at viable conditions.

The risk of patent infringement or product liability claims by a third party, risks in connection with the recall of products and negative develop-ments in the reimbursement of costs of Ypsomed products through state-prescribed cost-saving measures in the area of healthcare or by health insurance schemes as well as problems with authorization and upholding of authorization of drugs used together with Ypsomed products can also result in lasting detrimental effects, not only on the business performance of the Ypsomed Group but also on its financial situation and competitive position in the marketplace.

5. Key estimates and assumptions

The preparation of the consolidated financial statements in accordance with generally accepted accounting principles assumes that management makes certain estimates and assumptions which have an impact on the reported carrying amounts of assets and liabilities shown in the balance sheet on the balance sheet date and income and expenses accounted for in the period under review. These estimates and assumptions are based on future expectations and are held reasonable at the time of preparation of the financial statements. The actual amounts can deviate from these assumptions. The most important influential factors on positions based on estimates and assumptions are expressed as follows:

Capitalized development expensesThe development expenses are capitalized when the requirements for the capitalization are met. Ypsomed’s estimation of future economic benefits is based on management’s assumptions with regard to the economic baseline conditions, expected prospective cash flows, the discount rates to be applied and the expected period of time in which economic benefits are targeted. Capitalized development expenses amounted to CHF 45.3 million as of 31 March 2012 (prior year CHF 41.4 million).

Provisions for warrantiesWhen determining the provisions for warranties, management takes into account currently marketed own products and sets the provisions neces-sary to cover all callable claims based on the maturity and characteristics of the products as well as experience. Provisions for warranties as of 31 March, 2012, amount to CHF 1.6 million (prior year CHF 1.8 million).

Income taxesWhen accruals for income taxes are made for a period, uncertainties regarding final tax payments remain. Estimates that vary from the definitive tax amount have an impact on current and deferred income taxes. In par-ticular, with the capitalization of deferred tax assets from losses carried forward, the value of these tax loss carry-forwards and the tax rates to be applied must be estimated. Deferred income tax assets related to tax loss carry-forwards amount to CHF 4.7 million (prior year CHF 3.9 million).

61


Fin

anci

al R

epor

t

In thousand CHF, unless otherwise stated

1. Acquisitions

On 2 November 2011, Ypsomed AG, Burgdorf acquired the assets of the infusion-set-business Orbit™ of the american company ICU Medical Inc. In the previous period Ypsomed Ltd., UK acquired the assets of the diabetes

business of its existing distributor in Great Britain and Ypsomed GmbH Germany acquired 100% of the shares of DIABETIC SERVICES Vertriebs- und Beratungsgesellschaft GmbH in Ulm.

Assets

Book valueafter acquisition

2011/12

Book valueafter acquisition

2010/11

Cash and cash equivalents 5

Trade receivables 126

Inventories 509

Fixed assets 106

Intangible assets 660

Other assets 4

Total assets 766 644

Liabilities

Trade payables 75

Other liabilities 76

Total liabilities 0 152

Net working capital 766 492

Goodwill acquired offset 13 568 4 468

Total purchase consideration 14 334 4 960

Cash and cash equivalents acquired –5

Deferred purchase consideration –383

Offsetting of receivables –891

Net cash outflow 14 334 3 681

Notes to the consolidated financial statements

After the transfer of the production of the infusion sets, inventories will be overtaken to the fair value. At the acquisition date, the inventories had a fair value of CHF 1.6 million. The goodwill is attributable to the stronger market position and the expected synergies resulting in a higher profitability. The goodwill is completely deductible for tax purposes.

62


2. Consolidation scope Interest held

Capital /Votes

Share capital Research &Development

Production Marketingand Sales

Financingand Services

Ypsomed Holding AG, CH-Burgdorf CHF 178 993 807 •

Ypsomed AG, CH-Burgdorf 100 % CHF 10 000 000 • • • •

Ypsomed Distribution AG, CH-Burgdorf 100 % CHF 6 000 000 •

TecPharma Licensing AG, CH-Burgdorf 100 % CHF 100 000 •

Ypsotec AG, CH-Grenchen 100 % CHF 1 000 000 • •

Ypsotec s.r.o., CZ-Tábor 100 % CZK 200 000 • •

Ypsomed GmbH, DE-Sulzbach 100 % EUR 100 000 •

DiaExpert GmbH, DE-Sulzbach 100 % EUR 50 000 •

Feelfree GmbH, DE-Sulzbach 100 % EUR 25 000 •

Ypsomed AB, SE-Bromma 100 % SEK 100 000 •

Ypsomed S.A.S., FR-Paris 100 % EUR 50 000 •

Ypsomed BV, NL-Vianen 100 % EUR 50 000 •

Ypsomed India Private Ltd., IN-Gurgaon 100 % INR 36 657 470 •

Ypsomed Limited, GB-Selby 100 % GBP 300 000 •

Ypsomed GmbH, A-Wien 100 % EUR 35 000 •

3. Foreign currencies Balance sheet year-end rates Income statement average rates

31 March 2012 31 March 2011 2011/12 2010/11

Euro (EUR) 1.20 1.30 1.21 1.34

US-Dollar (USD) 0.90 0.91 0.88 1.01

Swedish krona (100 SEK) 13.64 14.52 13.44 14.43

Norwegian krone (100 NOK) 15.86 16.57 15.68 16.87

Danish krone (100 DKK) 16.20 17.42 16.29 17.98

Czech koruna (100 CZK) 4.87 5.29 4.90 5.37

Indian rupee (100 INR) 1.77 2.05 1.83 2.22

British pound (GBP) 1.44 1.47 1.41 1.58

4. Cash and cash equivalents31 March 2012 31 March 2011

Cash 24 15

Postal accounts 350 586

Bank accounts 9 361 4 421

Total 9 735 5 022

On January 26, 2012 Ypsomed incorporated the affiliated company Ypsomed GmbH in Austria for the purpose of enhancing the sales- and marketing organization of the European Diabetes Diarect Business. It’s business activities have started in the same month.

63


Fin

anci

al R

epor

t

5. Trade receivables31 March 2012 31 March 2011

Trade receivables 25 096 32 721

Provision for bad and doubtful debts –569 –474

Total 24 528 32 246

Provision for bad and doubtful debts 2011/12 2010/11

At 1 April 474 566

Addition 138 12

Use –17 –53

Reversal –18 –41

Currency translation differences –8 –10

At 31 March 569 474

6. Inventories31 March 2012 31 March 2011

Raw materials and supplies 5 636 5 227

Goods in process 19 083 15 774

Finished products 26 902 32 627

Gross inventories 51 621 53 628Valuation allowance –1 474 –2 052

Total 50 147 51 576

7. Financial assets31 March 2012 31 March 2011

Bionime Corp. Taiwan and Insulet Corp. USA 8 936 12 985

Other financial assets 118 109

Total 9 054 13 094

64


8. Fixed assets

Cost

Landand buildings

Machineryand equipment

Otherfixed assets

Assets under construction

Buildings forinvestment purposes

Total

At 1 April 2010 75 997 234 693 13 019 13 319 17 122 354 150

Additions 990 5 017 1 113 5 545 2 069 14 734

Disposals –16 151 –1 126 –17 277

Transfers 517 7 694 –314 –8 353 14 –442

Currency translation differences –10 –269 –183 –462

At 31 March 2011 77 495 230 985 12 508 10 510 19 206 350 703

Accumulated depreciation

At 1 April 2010 –21 819 –136 451 –8 240 –1 368 –167 878

Depreciation –2 653 –14 661 –1 693 –638 –19 645

Disposals 14 309 1 009 15 319

Transfers 125 201 327

Currency translation differences 5 121 101 226

At 31 March 2011 –24 467 –136 557 –8 621 –2 006 –171 651

Net book value at 1 April 2010 54 179 98 242 4 779 13 319 15 755 186 273

Net book value at 31 March 2011 53 027 94 428 3 887 10 510 17 200 179 052

Cost

At 1 April 2011 77 495 230 985 12 508 10 510 19 206 350 703Additions 925 3 313 631 2 347 285 7 501

Disposals –16 –6 723 –433 –7 172

Changes in consolidation scope 106 106

Transfers 111 10 016 42 –10 306 –137

Currency translation differences –17 –274 –153 –1 –445

At 31 March 2012 78 497 237 423 12 594 2 550 19 490 350 556

Accumulated depreciation

At 1 April 2011 –24 467 –136 557 –8 621 0 –2 006 –171 651Depreciation –2 743 –14 558 –1 575 –703 –19 578

Disposals 7 6 360 406 6 772

Transfers 10 32 42

Currency translation differences 5 129 87 220

At 31 March 2012 –27 198 –144 617 –9 672 0 –2 708 –184 195

Net book value at 1 April 2011 53 027 94 428 3 887 10 510 17 200 179 052

Net book value at 31 March 2012 51 299 92 807 2 923 2 550 16 782 166 361

There are no fixed assets pledged to secure loans and there are no long-term leasing agreements (financial leasing). The fire insur-ance value of fixed assets at March 31, 2012, amounted to CHF 506.9 million (previous year: CHF 514.4 million).

Gains from the sale of fixed assets in the 2011/12 business year amounted to CHF 0.2 million (previous year: CHF 0.4 million). Gains from the sale of fixed assets are included in the income statement under other operating income.

65


Fin

anci

al R

epor

t

11. Intangible assets

Cost

Development costs Patents

Software

Client base Total

At 1 April 2010 32 844 11 447 13 323 57 613

Additions 10 046 1 693 11 739

Disposals –161 –161

Transfers 115 115

Currency translation differences –72 –527 –600

At 31 March 2011 42 889 13 022 12 795 68 707

Accumulated amortization

At 1 April 2010 0 –7 200 –7 081 –14 281

Amortization –1 452 –2 160 –1 825 –5 436

Transfers 161 161

Currency translation differences 49 187 236

At 31 March 2011 –1 452 –9 150 –8 719 –19 321

Net book value at 1 April 2010 32 844 4 247 6 242 43 332

Net book value at 31 March 2011 41 437 3 872 4 077 49 386

Cost

At 1 April 2011 42 889 13 022 12 795 68 707Additions 7 906 518 8 424

Disposals –118 –118

Change in consolidation scope 660 660

Transfers 90 90

Currency translation differences –56 –392 –448

At 31 March 2012 50 795 660 13 456 12 404 77 315


At 1 April 2011 –1 452 –9 150 –8 719 –19 321Amortization –2 806 –2 317 –1 754 –6 877

Impairment –1 269 –1 269

Disposals 114 114

Transfers 6 6

Currency translation differences 42 180 222

At 31 March 2012 –5 527 –11 305 –10 293 –27 125

Net book value at 1 April 2011 41 437 0 3 872 4 077 49 386

Net book value at 31 March 2012 45 269 660 2 152 2 110 50 191

Due to the cancellation of development projects by pharmaceutical partners, CHF 1.3 million of capitalized development costs was written off. Development costs capitalized include CHF 23.3 million (prior year CHF 18.3 million) for products in the development phase, CHF 0.1 million

(prior year CHF 1.0 million) for products in the industrialization phase, CHF 0.0 million (prior year CHF 0.0 million) for products in the pre-launch phase and CHF 21.8 million (prior year CHF 22.1 million) for products in the phase of commercialization.

66


Acquired goodwill – the difference between acquisition costs and the recalculated current value of all net assets acquired – is offset directly against equity at the time of acquisition of a participation or business.

10. Goodwill not reported in the balance sheet

Cost 2011/12 2010/11

At 1 April 312 158 308 994

Additions before taxes 13 568 4 118

Accumulated currency translation differences –781 –954

At 31 March 324 945 312 158


At 1 April –306 418 –304 312

Amortization, scheduled amortization over 5 years –3 627 –2 760

Change in accumulated currency translation differences 537 654

At 31 March –309 508 –306 418

Net book value at 1 April 5 741 4 682

Net book value at 31 March 15 438 5 741

Net profit and equity would change as follows:


Scheduled amortization over 5 years –3 627 –2 760

Tax effects 433 240

Net profit on reporting goodwill 5 306 2 948

Equity at 31 March

Equity at 31 March 218 004 225 069

Effect of reporting goodwill in the balance sheet 15 438 5 741

FX effects on goodwill 244 299

Equity on reporting goodwill at 31 March 233 686 231 109

Theoretical capitalization of goodwill and amortization over five years would produce the following stated values under assets and scheduled amortization of goodwill in the income statement:

67


Fin

anci

al R

epor

t

11. Financial liabilities to major shareholder31 March 2012 31 March 2011

Loan from Techpharma Management AG, Burgdorf

Current 10 000 10 000

Non-Current 14 500 24 500

Since April 1, 2010 the interest is based on CHF 12-month LIBOR rate as published by the Swiss National Bank plus a margin of 0.5 % with semi-annual interest rate fixing. At any time Ypsomed Holding AG is eligible to amortize the loan in full or partially. Techpharma Management AG for its part may call for an amortization of CHF 10 million per annum start-

ing April 1, 2011 by applying a term of notice of 3 months. Techpharma Management AG is controlled by Willy Michel.

In the 2011/12 business year, interest amounting to CHF 0.3 million (prior year CHF 0.4 million) was paid on the loan.

Warranties Restructuring Other Total 12. Provisions

At 1 April 2010 1 690 0 635 2 325

Additions 687 0 0 687Release –581 0 –581Utilization –40 0 0 –40

At 31 March 2011 1 756 0 635 2 391

of which current 1 418 1 418

At 1 April 2011 1 756 0 635 2 391Additions 158 66 0 224

Release –279 0 0 –279

Utilization –85 0 0 –85At 31 March 2012 1 550 66 635 2 251

of which current 1 196 66 1 262

WarrantiesThere is a risk that medical products developed, distributed and produced by Ypsomed could have material defects or product faults, resulting in legal liability and product liability in particular, as well as other liabilities, such as the withdrawal or recall of products. Provisions are recorded based on management`s best estimate and relate to guarantees and also to replace-ment costs for withdrawn products. The company’s management bases these provisions on the estimated potential guarantee claim for each product.Ypsomed holds insurance policies with third parties to cover material damages, interruption of operation, product liability and other risks, with worldwide cover. Ypsomed believes that its insurance cover and provisions with regard to business activities and the associated operative risks involved with this are appropriate and sensible. However, events can arise that are not covered, or only partly covered by insurance policies or provisions made by Ypsomed. The closing of an insurance contract, covering product liability, depends on the development of the insurance

market, in particular on the general development of the pharmaceutical industry, in which high claims for compensation are typical. Although no such losses are presently expected at Ypsomed, there is no guarantee that the company might not be subjected to damage claims in the future that are in excess of the cover available.Provisions for warranties cover any guarantee claims that may occur for products on the market. The provisions extend for the average life of the products, which is between 1 and 4 years, depending on the product, and are also determined by the best possible assessment of the risk of a claim for each product category.

Other provisionsOther provisions are based on estimates and have the purpose of com-plying with requirements for disposal of waste related to the upcoming conversions of buildings.

68


13. Share capital

Share capital (in thousand CHF) 2011/12 2010/11

At 1 April 178 994 182 156Repayment of nominal value CHF 0.00 per share (prior year CHF 0.25) 0 –3 162

At 31 March 178 994 178 994

Shares issued as at 31 March 12 649 739 12 649 739Treasury shares as at 31 March 35 013 27 877

Shares outstanding as at 1 April 12 621 862 12 621 863

Purchases –7 136 –1

Average price in CHF 55 52

Shares outstanding as at 31 March 12 614 726 12 621 862

Ypsomed Holding AG was founded on 29 December 2003 with originalshare capital of CHF 250 000, consisting of 2 500 shares with a nominalvalue of CHF 100 each. There exist a total of 12 649 739 shares, eachwith a par value of CHF 14.15. The General Meeting of Shareholders resolved on 24 June 2009 an increase of the par value of CHF 5.25 to CHF 15.00. As a result the share capital has increased in the amount of CHF 59.0 million by debiting the group reserves. Within the scope of

the capital increase that took place in June 2009 the share capital wasincreased in the amount of CHF 21.1 million. As of September 30, 2010, thepar value was reduced by CHF 0.25 to CHF 14.15 and repaid to the shareholders. The total reduction of the par value was CHF 3.2 million. On 31 March 2012, Ypsomed Holding AG and its Group companies held a total of 35 013 own shares (prior year: 27 877).

Conditional share capital (in thousand CHF) 2011/12 2010/11

At 1 April 2 264 2 304Repayment of nominal value CHF 0.00 per share (prior year CHF 0.25) 0 –40

At 31 March 2 264 2 264

The company has a conditional share capital totaling CHF 2.3 million (prior year CHF 2.3 million). The company may issue a maximum of 160 000 fully

paid up registered shares of nominal value CHF 14.15 (prior year CHF 14.15) each to selected employees and members of the Board of Directors.

69


Fin

anci

al R

epor

t

14. Long-term contracts2011/12 2010/11

Revenue from development and industrialization services 5 538 11 122

Long-term contracts in the balance sheet 31 March 2012 31 March 2011

Trade receivables 0 1 692

Inventories 0 1 416

Prepayments from customers 1 295 2 700

15. Personnel expenses2011/12 % 2010/11 %

Wages and salaries 84 102 84.4 91 260 84.5

Social security expenses 13 749 13.8 15 113 14.0

Other personnel expenses 1 783 1.8 1 681 1.6

Total 99 634 100.0 108 054 100.0

Personnel at 31 March (full-time equivalents) 31 March 2012 31 March 2011

Switzerland 756 849

Germany 151 145

Netherlands 6 5

France 23 21

Scandinavia 3 5

Czech Republic 27 19

United Kingdom 7 6

Austria 1 0

India 6 6

Total 980 1 056

Headcount 1 026 1 097

70


Surplus/Deficit Economical benefit/Economic obligation

Contributions concerning the

business period

Pension benefit expenses within personnel expenses

31 March 2012 31 March 2012 31 March 2011 2011/12 2011/12 2010/11

Pension institutions with surplus 10 011 0 0 4 033 4 033 4 735

Within the Group, there are various employee pension plans, of which most employees are members. For the companies abroad and one company in Switzerland, there are pension plans for which the obligation to provide benefits such as retirement, death or invalidity benefits lies with a state institution and/or an insurance company. For the pension plan for two companies in Switzerland representing a proportion of 67% of the Group’s workforce as at March 31, 2012, there is a separate pension scheme set up in accordance with the Swiss Federal Act on Occupational Retirement, Survivors’ and Disability Pension Plans (BVG) and independent of the Group. In the year under review, the actuarial surplus for this pension scheme amounted to CHF 10.0 million (previous year: CHF 10.2 million). This

corresponds to a calculated level of cover within the meaning of Art. 444 of the Ordinance on Occupational Retirement, Survivors’ and Disability Pension Plans (BVV2) of 111.4% based on a technical interest rate of 2.5% and BVG 2010 (previous year: 111.43%, technical interest rate 3.5% and BVG 2010). As it has not yet been possible to set aside value fluctuation reserves to the target value of 15% of assets, the pension scheme does not have any freely disposable resources available to it. Free resources of this kind would be the prerequisite for an economic benefit in accordance with Swiss GAAP FER 16, so there is no economic benefit in this case. Pension costs as part of personnel expense correspond to the standard contribution payments by the Group companies involved.

16. Employee pensions

17. Financial income2011/12 2010/11

Interest income 36 32

Gains from marketable securities 5 118 0

Foreign exchange gains 1 340 1 218

Other financial income 1 461 416

Total 7 955 1 666

18. Financial expenses2011/12 2010/11

Interest expenses 785 944

Losses from marketable securities 44 0

Foreign exchange losses 2 448 1 478

Other financial expenses 80 179

Total 3 357 2 601

Per end of the business years 2011/12 and 2010/11 there were no employer contribution reserves existing.

The gains from marketable securities result from sales of financial assets.

71


Fin

anci

al R

epor

t

19. Income taxes31 March 2012 31 March 2011

Current income taxes 2 369 3 718

Deferred income taxes –1 131 –1 304

Total 1 238 2 414

Average tax rate in % 12.7% 30.6%

Tax-loss carryforwards are only recognized if it is probable that the associated tax benefits can be realized.

For the purposes of company management, the Ypsomed Group is organ-ized into business sectors according to products and services. The seg-ment “Delivery Devices” comprises the product groups pen systems, pen neeedles, infusion sets and other injection moldings produced by Ypsomed.

The business segment “Diabetes Direct Business” covers the direct trade in a range of diabetes articles. “Others” contains the business segment precison turned parts» and currently unused real estate for operational purposes. Intersegmental sales are executed at arm’s length.

20. Segment information

The Group benefits from reduced tax rates for individual companies. These rates are subject to annual changes. Changes to these tax rates and dif-ferences in the allocation of profits to these companies affect the effective

tax rate. The lower tax rate in comparison with the previous year is mainly due to the gains made from securities held in a tax-privileged company.

Business year 2010/11Delivery Devices Diabetes Direct

BusinessOthers Eliminations Group

Sales of goods and services to third party customers 173 917 72 584 15 321 261 822

Intersegmental sales 2 739 –2 739 0

Total sales of goods and services 173 917 72 584 18 060 –2 739 261 822

Operating profit 22 181 –12 908 –456 8 817Investments in fixed and intangible assets 23 029 582 2 862 26 473

Depreciation/Amortization/Impairment 19 618 2 384 3 079 25 081

Business year 2011/12Delivery Devices Diabetes Direct

BusinessOthers Eliminations Group

Sales of goods and services to third party customers 153 404 78 186 17 003 248 593

Intersegmental sales 2 519 –2 519 0

Total sales of goods and services 153 404 78 186 19 522 –2 519 248 593

Operating profit 13 804 –9 059 395 5 140Investments in fixed and intangible assets 12 865 460 2 600 15 925

Depreciation/Amortization/Impairment 22 973 1 773 2 978 27 724

31 March 2012 31 March 2011

Capitalized deferred tax assets 7 063 4 911

of which temporary differences 2 388 940

of which not yet utilized tax-loss carryforwards 4 674 3 971

72


22. Contractual obligations31 March 2012 31 March 2011

Contractual obligations from consultancy and researchand development projects 0 300

Contractual purchase commitments for products 10 662 5 907

Contractual obligations from rental contract with Techpharma Management AG until 31.12.2015 3 400 4 681

Contractual obligations from rental contract with GBUK Healthcare until 31.03.2013 366 659

Contractual obligations from rental contract with Exel Medical GmbH until 30.10.2015 93 0

Contractual obligations from contract for work and services to build a factory and office building for Ypsotec CZ by 31.03.2013 1 755 0

Total contractual obligations 16 276 11 546

Sales of goods and services

2011/12 2010/11

Switzerland 15 840 23 086

Europe 211 476 215 336

North America 19 232 22 480

Rest of the World 2 046 920

Total 248 593 261 822

Sales of goods and services are reported by geographical location in accordance with the invoice address. The sales of injection systems to biotech and pharmaceutical partners are made mainly to their European group companies. These companies market the products worldwide.

21. Contingent liabilities

The Group has contingent liabilities of kCHF 699 (prior year kCHF 803) toward third parties arising in the ordinary course of business. Ypsomed doesnot anticipate that any material liabilities will arise from the contingent liabilities.

Sales of goods and services are reported by geographical location

The rental contract between Ypsomed AG and Techpharma Management AG, a company controlled by Willy Michel, was signed at arm’s length. Rental interest is based on an independent rental value estimate and was per 1 January 2012 reduced from CHF 985 402 to CHF 906 570 annu-ally plus VAT. It is linked to the consumer price index. The rental contract arranges for small and normal maintenance work on the building to be

paid by the tenant up to a maximum amount of 2% of the annual rent per calendar year.As at 31 March 2012 contractual obligations for the purchase of fixedassets amount to CHF 6.7 million (prior year CHF 2.4 million), and forthe purchase of intangible assets these amount to CHF 0.05 (prior yearCHF 0.08 million).

73


Fin

anci

al R

epor

t

2011/12 2010/11

Techpharma Management AG (interest according to note 11) 258 400

Techpharma Management AG (compensation for rented business premises) 966 985

Techpharma Management AG (amounts in accordance with service contract) 78 50

Adval Tech Group 127 598

Finox AG –30 –24

Finox AG 99 69

Faes Bau AG (not a related party any more in 2011/12) 0 364

Total 1 498 2 442

2011/12 2010/11

Net profit in thousand CHF 8 500 5 468

Number of outstanding shares weighted on a monthly basis 12 615 303 12 621 863

Earnings per share in CHF (basic and diluted) 0.67 0.43

25. Proposal for the appropriation of retained earnings

Willy Michel (respectively his company Techpharma Management AG) has been renting out the building on Buchmattstrasse in Burgdorf (Ypsomed Nord) to Ypsomed since 1 January 2006. The parties signed a rental contract set at an indexed market rent, based on a rental assessment performed by an independent party (see figure 22). The rental contract can be terminated for the first time on 31 December 2015, conditional upon 24 months’ notice. The tenant has unlimited first right of refusal for purchasing the property for the entire rental period, but for a maximum of 25 years from the start of the rental. Willy Michel (respectively his company Techpharma Management AG) and Ypsomed have concluded a framework service contract that can be terminated by either side at any time. This contract allows for Techpharma Management AG to provide occasional services to the Ypsomed Group (e. g. hotel, catering and transport services) as well as selected management support services (including temporary personnel leasing) and, for its part, for the Ypsomed Group to offer occasional services to Techpharma Management AG (e. g. management and IT support, including temporary personnel leas-ing). The services are invoiced at normal market conditions. The mutual supply of temporary personnel is invoiced at the personnel cost rate. This contract was discussed and approved by the Board of Directors, in whose opinion this is a cooperation agreement at normal market conditions. The framework service contract has been expanded inasmuch as Willy Michel has been performing the function of CEO since August 2011. The amount of remuneration hitherto for the management services provided personally to the company by Willy Michel was for this reason not adjusted. In June 2007, Ypsomed AG and Adval Tech Holding AG signed an agreement

on strategic cooperation in tool construction with a fixed contract term of 5 years. The services purchased are in line with normal market conditions. A cooperation contract existed between Ypsomed Holding AG and two of its subsidiaries on the one hand, and Techpharma Management AG (which is controlled by Willy Michel) and its subsidiary Finox AG on the other hand. This contract was terminated on 20 December 2011, and replaced by a licensing agreement. Finox AG primarily develops pharmaceuticals, in particular fertility hormones as well as devices for their administration. The licensing agreement regulates the rights to the technology and the industrial property rights developed under the cooperation contract with regard to the administration devices. Ypsomed AG is granted a license for the use of two administering technologies outside of the specified areas of application. Finox AG may use the industrial property rights developed under the cooperation contract on an exclusive basis within specified areas of application. Furthermore, under the licensing agree-ment, a former employee who has held key positions at Finox AG during the last three and a half years, rejoins Ypsomed AG. Under the licensing agreement, Finox AG can continue to use consultancy services provided by Ypsomed employees at hourly and daily rates that are in accordance with the prevailing market rates. Finally, the termination of the coopera-tion contract means that the former first right of refusal of Ypsomed AG to purchase the shares of Finox AG now no longer applies. The termina-tion of the cooperation contract and the conclusion of the new licensing agreement were discussed and approved by the Board of Directors and, in the opinion of the Board, represent a cooperative relationship that is usual in the market.

The Board of Directors proposes to the General Meeting of Shareholderson 27 June 2012 a tax-free distribution of capital reserves in the amount of CHF 0.20 per share (prior year CHF 0.20 per share). The total distri-

bution based on the actual share capital as per 31 March 2012 will be approximately CHF 2.5 million (prior year CHF 2.5 million). This amount will be credited to shareholders.

23. Transactions with related parties

Related Group parties are Techpharma Management AG, Adval Tech Group and Finox AG. Services are remunerated in line with industry standards. Receivables from related parties amounted to kCHF 527 (prior

year kCHF 23) on the balance sheet date. Liabilities amounted to kCHF 0 (prior year kCHF 53). In the year under review the following transactions were made with related parties:

24. Earnings per share

Earnings per share are calculated by dividing net profit through the weighted monthly number of shares outstanding during the period. The average number of treasury shares is deducted from the number of shares issued.

74


Report of the group auditors

75


Fin

anci

al R

epor

t

76


In thousand CHF

Assets 31 March 2012 31 March 2011

Cash and cash equivalents 336 125

Marketable securities 1 924 1 589

Accrued income and prepaid expenses 20 25

Other receivables 20 4

Total current assets 2 300 1 743

Loans to Group companies 185 498 171 088

Investments 323 902 327 951

Expenditures related to capital increase 746 1 103

Total non-current assets 510 146 500 142

Total assets 512 446 501 885

Liabilities and equity 31 March 2012 31 March 2011

Trade payables 18 45

Accrued expenses and deferred income 966 890

Current financial liabilities to major shareholder 10 000 10 000

Bank loans 43 500 35 000

Current income taxes payable 209 264

Total current liabilities 54 692 46 200

Non-current financial liabilities to major shareholder 14 500 24 500

Total non-current liabilities 14 500 24 500

Share capital 178 994 178 994

Capital contribution reserves1 181 151 193 802

Disagio –150 –150

Legal reserves 50 50

Reserves for own shares 2 343 1 952

Retained earnings 66 274 48 229

Net profit 14 592 8 308

Total equity 443 253 431 185

Total liabilities and equity 512 446 501 885

1 The classification as capital contribution reserves was undertaken as at 31 March 2011, subject to the approval of the Swiss Federal Tax Administration (FTA). In the 2011/12 reporting year, the capital contribution reserve in the amount of kCHF 183 673 was approved, with kCHF 10 129 being reclassified from capital contribution reserves to retained earnings. In addition, kCHF 2 529 was paid out to shareholders in the 2011/12 reporting year.

Balance sheet of Ypsomed Holding AG – statutory financial statements

77


Fin

anci

al R

epor

t

Income statement of Ypsomed Holding AG – statutory financial statements

In thousand CHF

Income1 April 2011

31 March 20121 April 2010

31 March 2011

Financial income 18 459 11 911

Total income 18 459 11 911

Expenses

Depreciation and amortization –367 –366

Financial expenses –1 400 –981

Administration –1 793 –1 877

Income tax expenses –307 –379

Total expenses –3 867 –3 603

Net profit 14 592 8 308

Proposal for the appropriation of retained earningsThe Board of Directors proposes to the General Meeting of Shareholder that the retained earnings be appropriated as follows:

In thousand CHF 31 March 2012 31 March 2011

Retained earnings 56 537 48 229

Increase reserve for own shares –392

Net profit for business year 14 592 8 308

Non-approved capital contribution reserves from the Swiss Federal Tax Administration1 10 129

Retained earnings at disposal of the General Meeting 80 866 56 537

Allotment from capital contribution reserves 2 523 2 529

Distribution of dividend from capital contribution reserves2 –2 523 –2 529

Carried forward to the next year 80 866 56 537

––

1 See balance sheet of Ypsomed Holding AG page 77.2 The Board of Directors proposes to the General Meeting of Shareholders on 27 June 2012 a tax free distribution of capital contribution reserves

in the amount of CHF 0.20 per share. The total distribution based on the actual share capital as per 31 March 2012 will be approximately CHF 2.5 million (prior year CHF 2.5 million). This amount will be credited to shareholders.

78


Notes to the financial statements 2011/12 of Ypsomed Holding AG

Significant shareholdersand shareholder groups 31 March 2012 31 March 2011

Number of shares Capital and vote share

Number of shares Capital and vote share

Shareholder group Michel family 9 650 194 76.3 %

Patinex AG 301 395 5.2 %

Investments 31 March 2012 31 March 2011

Interest held Book value (CHF) Interest held Book value (CHF)

Ypsomed AG, CH-Burgdorf 100 % CHF 277 180 644 100 % CHF 277 180 644

Share capital CHF 10 000 000

Ypsotec AG, CH-Grenchen 100 % CHF 13 643 520 100 % CHF 13 643 520


Techpharma Licensing AG, CH-Burgdorf 100 % CHF 18 161 816 100 % CHF 18 161 816

Share capital CHF 100 000

Ypsomed Distribution AG, CH-Burgdorf 100 % CHF 6 000 000 100 % CHF 6 000 000


Bionime Corporation, Taiwan 9.7 % TWD 8 905 138 8.7 % TWD 6 581 976

Share capital TWD 439 467 940 (Prior year TWD 399 516 310)

Insulet Corporation, Bedford, MA, U.S.A. 0.0 % USD 10 638 1.3 % USD 6 382 622

Share capital USD 45 441Total Investments 323 901 756 327 950 578

Own shares 31 March 2012 31 March 2011

Number of shares Ø price Number of shares Ø price

Purchase of own shares 7 136 55 1 52

Disposal of own shares 0 0

Own shares held 35 013 27 877

Claim subject to subordination clause against subsidiaries 31 March 2012 31 March 2011

Loan to Ypsomed Distribution AG, CH-Burgdorf 27 094 872 17 167 872

In addition there is letter of comfort with unlimited amount in favor of a group company.

Income Financial income mainly consists of dividends, interest income and gains on securities. Share capital The share capital of CHF 178 993 806 (prior year CHF 178 993 806) consists of 12 649 739 (prior year 12 649 739) registered shares with a nomi-nal value of CHF 14.15 (prior year CHF 14.15). Conditional share capital The company has a conditional share capital totalling CHF 2.2 million (prior year CHF 2.2 million). The company may issue a maximum of 160 000 (prior year 160 000) fully paid-up registered shares with a nominal value of CHF 14.15 (prior year CHF 14.15) each to selected employees and members of the Board of the Directors.

The Michel family shareholder group was set up in the year under review. The participation held by Patinex AG was reported in the year under review in accordance with the provisions of stock exchange law. See also Corporate Governance, page 90. In the previous year, the significant shareholders were Willy Michel, who held 8 946 834 shares (share of capital/voting rights 70.7%), and Techpharma Management AG, a company controlled by him, which held 507 125 shares (4.0%).

79


Fin

anci

al R

epor

t

Risk assessment

Ypsomed Holding AG performs an extensive risk assessment at least once a year. This standardized process is based on an inventory of risks, which covers the relevant categories of risks such as strategic risks, management risks, general risks of the business areas, legal risks, systemic risks, financial risks including market-, credit- and liquidity risks and event risks including

political, regulatory, fiscal and external risks. The significant risks are valuated regarding the probability of occurrence and impact, and both Management and the Board of Directors determine measures and monitor the implementation according to established criteria.

Management remuneration

(Gross, in thousand CHF)

Highest remuneration to: Basic Salary Variable Salary

Payments

Employercontributions toSocial Insurance

Total

11/12 10/11 11/12 10/11 11/12 10/11 11/12 10/11 11/12 10/11

Richard Fritschi, CEO until August 2011

620.1 607.1 172.4 214.2 97.3 100.2 889.8 921.5

Add. members of management 1 158.8 1 508.0 177.2 133.8 2.0 52.0 194.6 244.4 1 532.6 1 938.2

Total management remuneration 2 422.3 2 859.7

Board of Directors remuneration

(Gross, in thousand CHF, exclusive of VAT)

Board of Directors remunerationWilly Michel(Chairman)

Anton Kräuliger(Vice-Chairman)

Prof. em. Dr. Dr. h. c. mult. Norbert Thom

(Member)

Gerhart Isler(Member)

Total

11/12 10/11 11/12 10/11 11/12 10/11 11/12 10/11 11/12 10/11

Fixed amount 150.0 150.0 90.0 90.0 90.0 90.0 90.0 90.0 420.0 420.0

Variable amount 7.5 11.7 4.5 7.0 4.5 7.0 4.5 7.0 21.0 32.7

Attendance fee / Others 6.0 9.0 6.0 9.0 6.0 7.5 6.0 9.0 24.0 34.5

Total remuneration and attendance fee 163.5 170.7 100.5 106.0 100.5 104.5 100.5 106.0 465.0 487.2

Techpharma Management AG: for consultancy services Dr. h. c. Willy Michel 140.0 140.0 140.0 140.0

Total remuneration Board of Directors 303.5 310.7 100.5 106.0 100.5 104.5 100.5 106.0 605.0 627.2

Highest remuneration to Willy Michel 303.5 310.7

Further transactions to affiliated persons of Willy Michel

Techpharma Management AG: for loan (interest) 258.2 400.5

Techpharma Management AG: for rented business premises (rent) 965.7 985.4

Securities, reserve for guarantees and collateral order in favor of third parties 31 March 2012 31 March 2011

Credit Suisse, CH-ZurichGuarantee in the context of credit business for Ypsomed AG 22 500 000 22 500 000

80


As of 31 March members of the non-executive and executive boards held the following shares. No Ypsomed share options were held.

Share ownership of Board of Directors excl. Michel family groupShares as of

31 March 2012Shares as of

31 March 2011

Willy Michel, Chairman 8 574 114 8 946 834

Techpharma Management AG as related party to Willy Michel, Chairman 649 055 507 125

Total of Willy Michel and Techpharma Management AG combined 9 223 169 9 453 959Gerhart Isler, Member 5 000 3 000

Anton Kräuliger, Vice-Chairman 1 225 225

Prof. em. Dr. rer. pol. Dr. h.c. mult. Norbert Thom, Member 0 0

Total 9 229 394 9 457 184

Share ownership of Management excl. Michel family group

Willy Michel, CEO since August 2011 8 574 114 8 946 834

Techpharma Management AG as related party to Willy Michel 649 055 507 125

Simon Michel, Senior Vice President Marketing & Sales 144 888 8 528

Dr. Beat Maurer, Senior Vice President Legal Services & Intellectual Property 3 000 3 000

Yvonne Müller, Senior Vice President Human Resources 800 800

Niklaus Ramseier, Senior Vice President Finance/IT (CFO) 1 069 1 069

Hans-Ulrich Lehmann, Senior Vice President Technology 50 0

Dr. Benjamin Reinmann, Senior Vice President Operations 50 0

Total 9 373 026 9 467 356

At 31 March 2012, Richard Fritschi, CEO until August 2011, held 3 500 shares (previous year: 3 500). For details of the Michel family shareholder group, see also Corporate Governance, page 90.For further details of shareholdings, see also Corporate Governance, page 102.

81


Fin

anci

al R

epor

t

Report of the statutory auditors

82


83


Fin

anci

al R

epor

t

In thousand CHF 2011/12 2010/11 2009/10 2008/09 2007/08

Sales of goods and services1/Total Sales2 248 593 261 822 254 014 275 058 287 468

Gross profit 56 373 60 987 66 446 84 310 90 197

Gross profit in % 22.7 % 23.3 % 26.2 % 30.7 % 31.4 %

Operating profit 5 140 8 817 13 449 30 735 30 976

Operating profit in % 2.1 % 3.4 % 5.3 % 11.2 % 10.8 %

Net profit 8 500 5 468 9 425 26 166 26 583

Net profit in % 3.4 % 2.1 % 3.7 % 9.6 % 9.2 %

Depreciation of fixed assets 19 578 19 645 23 946 24 753 22 678

Amortization of intangible assets 8 146 5 436 3 532 1 770 1 667

EBITDA3 32 865 33 808 40 926 57 258 55 322

EBITDA in % 13.2 % 12.9 % 16.1 % 20.8 % 19.2 %

Current assets 94 604 107 385 100 152 98 461 144 164

Non-current assets 232 668 246 443 561 858 533 755 494 066

Current liabilities 90 895 100 777 77 953 43 391 48 056

Non-current liabilities 18 374 27 983 46 314 151 793 172 595

Balance sheet total 327 273 353 829 662 010 632 216 638 230

Capital expenditure –7 501 –14 485 –32 487 –43 698 –42 741

Cash flow from operating activities 31 055 28 876 22 480 48 404 70 155

Cash flow from investing activities –19 781 –27 903 –43 739 –49 589 –52 306

Cash flow from financing activities –6 425 –3 838 20 489 –28 041 –20 130

Issued shares as of 31 March 12 649 739 12 649 739 12 649 739 11 244 213 11 244 213

Average shares outstanding 12 615 303 12 621 863 11 975 054 11 223 971 11 233 080

Earnings per share in CHF (basic / diluted) 0.67 0.43 0.79 2.33 2.37

Dividend per share (in CHF) 0.20 0.00 0.00 0.00 0.00

Par value repayment per share (in CHF) 0.00 0.25 0.60 0.60 0.00

Book value per issued share (in CHF)4 17.23 17.79 42.51 38.87 37.14

Share price: year’s highest (in CHF) 58.00 70.00 79.00 101.00 120.30

Share price: year’s lowest (in CHF) 43.50 51.50 58.75 64.80 75.00

Share price: year-end (in CHF) 55.00 57.00 68.00 76.90 92.00

Market capitalization (in million CHF) 696 721 860 865 1 034

Average headcount 1 062 1 150 1 228 1 209 1 208

Average fulltime equivalent 1 018 1 104 1 176 1 152 1 157

Year-end headcount 1 026 1 097 1 199 1 209 1 210

Year-end fulltime equivalent 980 1 056 1 149 1 153 1 150

Sales per average fulltime equivalent (in CHF) 244 197 237 158 215 998 238 766 248 629

Five-year overview 1 April – 31 March

1 See basis for the consolidated financial statements on page 57. 2 Since 1 April 2008, Real Estate income has been included in Total Sales (IFRS).3 Operating profit before depreciation and amortization.4 The Goodwill was offset with equity under Swiss GAAP FER.

IFRSSwiss GAAP FER

84


Ypsomed – Corporate Governance Report

Corporate Governance

This Corporate Governance report describes the management and control principles at the highest corporate level of Ypsomed Holding AG and its subsidiaries according to the directive of the SIX Swiss Exchange concerning information on corporate governance.

Ypsomed, which is headquartered in Burgdorf, Switzerland, is a world leader in the field of injection systems for the self-administering of pharmaceutical substances. Ypsomed de-velops and produces its products primarily in Switzerland. Ypsomed injection systems are largely marketed by biotech and pharmaceutical partners around the world. As part of its diabetes care business segment, Ypsomed focuses on self-medication products for patients with diabetes. The company’s own injection systems and pen needles as well as infusion sets and commercial products purchased from third parties – in particular devices for the self-monitoring of blood glucose levels as well as infusion pumps, accessories and many day-to-day items for diabetics – are sold through the company’s own distribution network and by independent distributors. The Ypsomed Group also includes Ypsotec, headquartered in Grenchen, Switzerland, a supplier of precision turned parts and subassemblies.

The Ypsomed Group’s rules and regulations on Corporate Governance are defined in the Articles of Association, in the Organizational Policy of Ypsomed Holding AG and in the

Code of Conduct of the Ypsomed Group and correspond to the Corporate Governance Directive of October 29, 2008, issued by the SIX Swiss Exchange. The Board of Directors has issued an organizational policy that stipulates the duties, powers and responsibilities of the executive bodies of the Ypsomed Group. The main features of this policy are set out on page 96 under the section on regulations concerning authority. A copy of Ypsomed Holding AG’s Articles of Association (in the German version) can be ordered in print form from the company or can be viewed in its current version on the company’s website at www.ypsomed.com (under Company/Investors/Corporate Governance). A copy of the Code of Conduct of the Ypsomed Group (in German, English and French versions) can be ordered in print form from the company or can be viewed in its current version on the com-pany’s website at www.ypsomed.com (under Company/Inves-tors/Corporate Governance). Compliance with the basic principles and values laid down in the Code of Conduct is reviewed on an ongoing basis during the company’s day-to-day business. In addition, the Board of Directors receives information on a periodic basis regarding experiences with the Code of Conduct.

85

Cor

pora

te G

over

nan

ce


as of 31 March 2012 as of 31 March 2011

Market capitalization in CHF 695 735 645 721 035 123

in % of equity 319.1* 320.4*

Share price in CHF 55.0 57.0

Price-earnings ratio 82.1** 132.6**

* Equity on 31 March 2012: TCHF 218 004 Equity on 31 March 2011: TCHF 225 069 ** Profit per share 31 March 2012: CHF 0.67 Profit per share 31 March 2011: CHF 0.43

Group structure

Ypsomed Holding AG is organized as a holding company pursuant to Swiss law and directly or indirectly owns or controls all companies that are part of the Ypsomed Group worldwide. None of Ypsomed Holding AG’s subsidiaries are listed com-panies.

History of Ypsomed’s development

Ypsomed was formed from what was previously Disetronic, which was founded in 1984 and which developed and pro-duced infusion systems and also, starting in 1986, injection systems. On April 30, 2003, Roche Holding AG acquired the infusion business of Disetronic through a public tender offer. Willy Michel continued the injection business under the Ypsomed trade name.

Listed holding company

Ypsomed Holding AG, which has its headquarters in Burgdorf, is the holding company of the Ypsomed Group. It has a share capital of CHF 178 993 806.85, divided into 12 649 739 registered shares with a par value of CHF 14.15 each. Shares in Ypsomed Holding AG were traded on the Main Standard of the SIX Swiss Exchange from September 22, 2004, to September 28, 2011. Since September 29, 2011, shares in Ypsomed Holding AG have been traded on the Domestic Standard of the SIX Swiss Exchange. The shares have also been traded since June 27, 2007, on the BX Berne eXchange. The move from the Main Standard to the Domestic Standard of the SIX Swiss Exchange is associated with the switch in accounting standards from IFRS (International Financial Reporting Standards) to Swiss GAAP FER (see page 97), which, in accordance with SIX Swiss Exchange’s accounting guidelines, results in a change of segment. Security Number 1 939 699/Ticker symbol: YPSN

86

Ypsotec AGGrenchen

100 %

TecPharmaLicensing AG

Burgdorf100 %

DiaExpert GmbHLiederbach, DE

100 %

Ypsomed GmbHLiederbach, DE

100 %

feelfree GmbHLiederbach, DE

100 %

Ypsomed BVVianen, NL

100 %

Ypsomed ABBromma, SE

100 %

Ypsomed SASParis, FR100 %

Ypsomed GmbHVienna, AT

100 %

Ypsomed Holding AGBurgdorf

Ypsotec s.r.oTábor, CZ

100 %

Ypsomed AGBurgdorf / Solothurn

100 %

Ypsomed Distribution AG

Burgdorf100 %

Ypsomed India Private Ltd.

New Delhi, IN 100 %

Ypsomed Ltd. Selby, UK

100 %


Corporate structure at March 31, 2012

Operating organization

The Ypsomed Group’s operating organization is based on a parent company structure. It is divided into the following departments: Delegate of the Board of Directors and CEO, Operations (including Production, Logistics and Quality Management & Regulatory Affairs), Technology, Corporate Finance/IT, Marketing & Sales, Human Resources, and Legal & Intellectual Property. As a rule, two members of Ypsomed Group management sit on the Board of Directors of each subsidiary. In terms of operations, the Ypsomed Group is divided into two business segments: The Delivery Devices segment consists of business with the product group’s pen systems, pen needles, infusion sets and other injection-molded parts that are developed and manufactured by Ypsomed. The Diabetes Direct Business segment consists of the sales and direct trade business with various supplies for diabetes care, for example, devices for the self-monitoring of blood glucose levels as well as infusion pumps, accessories and other day-to-day items for diabetics. The “Other” seg-ment brings together precision-turned parts and real estate not currently in operational use.

87

Cor

pora

te G

over

nan

ce

Ypsomed – Corporate Governance Report Ypsomed – Corporate Governance Report

Capital structure

Capital

Ypsomed Holding AG has a share capital of CHF 178 993 806.85, divided into 12 649 739 fully paid-up registered shares, each with a par value of CHF 14.15. All shares entitle the holder to receive dividends. Ypsomed Holding AG does not have an authorized share capital amount. The company has issued neither profit certificates nor participation certificates. There are no convertible bonds outstanding, and no options have been issued for participa-tion rights in Ypsomed Holding AG or any Group companies.

Conditional share capital

Ypsomed Holding AG has conditional share capital totaling CHF 2 264 000. The company may issue to selected employees and members of the Board of Directors up to a maximum of 160 000 registered shares, to be paid up in full, with a par value of CHF 14.15 each. Shareholders’ purchase and advance subscription rights are excluded. Pursuant to the Articles of Association, shares and option rights may be issued at a price below the stock market value. The acquisi-tion of shares through the exercising of subscription or option rights is subject to the statutory recording limitation and the statutory voting right limitation (see below). The company has not issued any shares or option rights to date.

Changes in capital

Capital has changed in recent years as follows: Changes in equity capital up to March 31, 2012, pursuant to the accounts of Ypsomed Holding AG produced in accordance with com-pany law.

General statutory reserves

Date Issue Number of shares Nominal value Share capital Capital reserves Retained earnings Reservesfrom equity

Generalreserves

Reserves for own shares

Total

29.12.03 Founding 2 500 100.00 250 000.00 250 000.00

31.03.04 Net profit 11 096 910.20 11 346 910.20

01.04.04 Balance 2 500 100.00 250 000.00 11 096 910.20 11 346 910.20

01.07.04 Reverse merger with Finox Beteiligungen AG –150 000.00 6 315 915.24 17 512 825.44

28.07.04 Capital increase settled with shareholder loan 997 500 100.00 99 750 000.00 117 262 825.44

18.09.04 Split 1 : 8 8 000 000 12.50 117 262 825.44

20.09.04 Capital increase IPO 3 016 000 12.50 37 700 000.00 165 143 042.21 320 105 867.65

28.09.04 Capital increase IPO over-allotment 228 213 12.50 2 852 662.50 12 495 951.29 335 454 481.44

31.03.05 Net profit 825 726.81 336 280 208.25

31.08.05 Nominal value reduction CHF 0.90 per share –0.90 –10 119 791.70 326 160 416.55

31.03.06 Net profit 1 187 206.38 327 347 622.93


31.03.07 Reserves for own shares –2 223 985.21 2 223 985.21 313 292 356.68

31.03.07 Net profit 1 020 967.85 314 313 324.53

31.03.08 Reserves for own shares 873 759.26 –873 759.26 314 313 324.53

31.03.08 Net profit 6 099 149.38 320 412 473.91


31.03.09 Reserves for own shares –392 705.90 392 705.90 313 665 946.11

31.03.09 Net profit 11 968 630.02 325 634 576.13

03.07.09 Nominal value increase 5.25 59 032 118.25 384 666 694.38

Capital increase 1 405 526 21 082 890.00 16 163 522.75 421 913 107.13



31.03.10 Net profit 11 715 880.66 426 039 144.39


31.03.11 Reserves for own shares –51.50 51.50 422 876 709.64

31.03.11 Reassignment of capital reserves to reserves as capital investments –193 802 516.25 193 802 516.25 422 876 709.64

31.03.11 Reassignment of capital reserves to reserves as capital investments 150 000.00 –150 000.00 422 876 709.64

31.03.11 Reclassification of general reserves –50 000.00 50 000.00 422 876 709.64

31.03.11 Net profit 8 308 089.98 431 184 799.62

15.07.11 Reassignment of capital reserves to reserves as capital investments –2 522 945.20 428 661 854.42

30.09.11 Adjustment capital contribution reserves –150 000.00 10 129 024.25 –9 979 024.25 428 661 854.42


31.03.12 Net profit 14 591 564.24 443 253 418.66

31.03.12 Balance 12 649 739 14.15 178 993 806.85 –150 000.00 80 865 605.61 181 150 546.80 50 000.00 2 343 459.40 443 253 418.66

Share premium of IPO 20. + 28.09.2004 Capital in % IPO costs Share premium gross Share premium net

18.09.04 Capital increase 37 700 000.00 92.97 % 10 189 057.47 165 143 042.21 154 953 984.74

28.09.04 Capital increase 2 852 662.50 7.03 % 770 979.90 12 495 951.29 11 724 971.39

Total 40 552 662.50 100.00 % 10 960 037.37 177 638 993.50 166 678 956.13

The costs for the IPO have been capitalized in the statutory accountsand have been amortized over five years since September 2004.

88 89

Cor

pora

te G

over

nan

ce


Shareholder structureRegistered shareholders

There were 5 186 shareholders registered in the Share Register on March 31, 2012 (prior year: 5 789 shareholders). Of these shareholders, 98% report Switzerland as their place of residence. The distribution of shareholdings is as follows:

Number of sharesNumber of shareholders

as of 31 March 2012Number of shareholders

as of 31 March 2011

1 to 100 2 954 3 234

101 to 1000 2 067 2 357

1001 to 10 000 144 178

10 001 to 100 000 15 16

more than 100 000 6 4

Significant shareholders and significant shareholder groups

Willy Michel, Chairman of the Board of Directors and CEO of Ypsomed Holding AG and the Ypsomed Group, who was listed as a significant shareholder in reports from previous years on the basis of his shareholding, formed a share-holder group in the year under review together with his children for the purposes of holding shares in family ownership. The group comprises Willy Michel, who owns shares both directly and also indirectly via the company Techpharma Management AG, over which he exerts control, and his children Simon Michel, Serge Michel and Lavinia Camilla Nussio, who all hold their shares directly. As of March 31, 2012, the “Michel Family” shareholder group together holds 9 650 194 registered shares of Ypsomed Holding AG, which corresponds to 76.3% of the company’s total shares. In the prior year (as of March 31, 2011), the “Michel Family” shareholder group had not yet been formed. At that time, Willy Michel held directly and also indirectly (via Techpharma Management AG, which he controls) a total of 9 453 959 shares, equating to 74.7%.

The formation of the group, together with the fact that the shareholding of Willy Michel as an individual has, as a result, fallen below the threshold of 3.0%, was notified to the SIX Swiss Exchange on January 4 and January 11, 2012, pursuant to Article 20 of the Swiss Federal Act on Stock Exchanges and Securities Trading (SESTA) and Article 10 in conjunction with Article 21 of the FINMA Stock Exchange Ordinance. At that point in time, the “Michel Family” share-holder group held a total of 9 641 104 shares, comprising 76.2%.During the year under review, Patinex AG, Egglirain 24, 8832 Wilen, controlled by Martin and Rosmarie Ebner, also reported shareholdings in the company of 3.0% (notification of August 13, 2011) and 5.2% (notification of February 23, 2012) in accordance with the aforementioned provisions under stock exchange law. No further significant shareholders or significant share-holder groups are known.

Cross participations

There are no cross participations.

90


Limitation on the transferability of sharesNo share certificates are issued for Ypsomed Holding AG shares. Any shareholder may ask the company at any time to issue a confirmation regarding the registered shares entered in the Share Register in his name. Any person validly entered in the Share Register as an owner or beneficiary is considered to be a shareholder of the company. Any person acquiring registered shares or the beneficial entitlement to registered shares must apply in writing to be entered in the Share Regis-ter. Approval is given by the Board of Directors, which may delegate this power. The transfer is then entered in the Share Register. Applicants will be entered in the Share Register as shareholders with voting rights provided they expressly declare that they have acquired the registered shares in their own name and for their own account. If this declaration is not made, the Board of Directors may refuse the entry. The Board of Directors may draw up guidelines for the entry of nominees and may permit nominees to be entered in the Share Register with voting rights for shares up to a maximum of 5.0% of the nominal share capital. The Board of Directors may also allow nominees to be entered in the Share Register with voting rights for shares exceeding this limit if the nominees disclose the names, addresses, nationality, domicile and shareholdings of the natural persons and legal entities on whose account they hold 1.0% or more of the nominal share capital. The 5.0% limit also applies to nominees who are related to one another through capital ownership or voting rights by virtue of a common management or otherwise. If a shareholder has been entered in the Share Register on the basis of incorrect information then the Board of Directors may, after having given the parties involved the right to be heard, remove from the Share Register the entry as a shareholder with voting rights and replace it instead with an entry as a shareholder without voting rights. In the year under review, no applica-tions for the entry of nominees were made.

Restrictions on the transfer of registered shares may only be amended by a resolution passed at the General Meeting of Shareholders with a qualified majority of at least two-thirds of the votes represented and an absolute majority of the nominal share capital represented at such a meeting.

Board of Directors

Members of the Board of Directors

The Board of Directors consists of a minimum of three and a maximum of five members elected for a term of office of three years with the possibility of re-election. The members of the Board of Directors were re-elected in globo on the occasion of the 2010 General Meeting of Shareholders. The Board of Directors is self-constituting. Willy Michel was a member of the executive management of Disetronic Holding AG until April 2003, non-executive Chairman of the Board of Directors of Ypsomed Holding AG between 2003 and August 2011, and since August 2011 has been Delegate of the Board of Directors and CEO of both Ypsomed Holding AG and the Ypsomed Group. The other directors are non-executive members of the Board of Directors.

The main task of the Board of Directors is the overall manage-ment of the company and the supervision and control of executive management. As Delegate and CEO, Willy Michel represents both the Board of Directors of Ypsomed Holding and the Ypsomed Group externally. The other members of the Board of Directors are not actively employed in operative functions at either Ypsomed Holding AG or at any of its subsidiaries, nor have they held any such positions in the past three years. With the exception of Willy Michel, no business relationships exist between the individual members of the Board of Directors and Ypsomed Holding AG or any of its subsidiaries. The following business relationships between Willy Michel and affiliated persons and Ypsomed Holding AG and/or its subsidiaries existed in the year under review (information relating to the actual remuneration paid directly or indirectly in the 2011/2012 business year that is s t ipulated by Ar t. 663b bis of the Swiss Code of Obligations can be found in the Notes to the 2011/2012 financial statement, see page 80).

Executive loan

Willy Michel made a loan to the company that he assigned to his company Techpharma Management AG. In the year under review, an amount of CHF 10 million was paid off. As of March 31, 2012, a loan amount of CHF 24.5 million was still outstanding. The key terms of the loan agreement are: Since April 1, 2010, the loan has borne interest at a rate

91

Cor

pora

te G

over

nan

ce


based on the CHF 12-month LIBOR as published by the Swiss National Bank plus 0.5% and it is adjusted in line with the prevailing rate as at the end of March and the end of September every year. Ypsomed Holding AG may repay the loan in full or partially at any time. However, it is repayable by March 31, 2014, at the latest. Starting April 1, 2011, Techpharma Management AG may each year demand repayment of a maximum of CHF 10 million at three months’ notice. There are no further executive loans.

Rental contract

Willy Michel (respectively his company Techpharma Manage-ment AG) has been renting out the building on Buchmattstrasse in Burgdorf (Ypsomed Nord) to Ypsomed since January 1, 2006. The parties signed a rental contract set at an indexed market rent, based on a rental assessment performed by an independent party. The rent was reduced on January 1, 2012, to CHF 906 570 plus VAT (excluding additional costs). The rental contract can be terminated for the first time on Decem-ber 31, 2015, conditional upon 24 months’ notice. The tenant has unlimited first right of refusal for purchasing the property for the entire rental period, but for a maximum of 25 years from the start of the rental. The rental contract dictates that small and normal maintenance work on the building be paid by the tenant up to a maximum amount of 2.0% of the annual rent per calendar year. Major maintenance work and repairs necessary for safeguarding the asset value of the building are at the lessor’s expense. On termination of the contract, the tenant will be reimbursed for the alterations carried out to the leased property with the lessor’s consent in application of Swiss GAAP FER depreciation rates at the residual book value. The rental contract was discussed and approved by the Board of Directors, in whose opinion this is regarded as a rental contract at normal market conditions.

Other contractual relationships

Willy Michel (respectively his company Techpharma Manage-ment AG) and Ypsomed have concluded a framework service contract that can be terminated by either side at any time. This contract allows for Techpharma Management AG to provide occasional services to the Ypsomed Group (e. g. hotel, catering and transport services) as well as se-lected management support services (including temporary personnel leasing) and, for its part, for the Ypsomed Group to offer occasional services to Techpharma Management AG (e. g. management and IT support, including temporary per-sonnel leasing). The services are invoiced at normal market conditions. The mutual supply of temporary personnel is in-

voiced at the personnel cost rate. This contract was discussed and approved by the Board of Directors, in whose opinion this is a cooperation agreement at normal market conditions. The framework service contract has been expanded inasmuch as Willy Michel has been performing the function of CEO since August 2011. The amount of remuneration hitherto for the management services provided personally to the company by Willy Michel was for this reason not adjusted. It remains at CHF 140 000 incl. VAT (previous year: CHF 140 000). This amount represents the full remuneration for all consulting and other work carried out by Willy Michel, including his activity as CEO in the year under review. Willy Michel has expressly waived the right to any more extensive remuneration for his operating activities as CEO in the year under review. Willy Michel no longer holds any shares in Faes Bau AG, which is headquartered in Burgdorf.

Contractual relationship with Finox AG

A cooperation contract existed between Ypsomed Holding AG and two of its subsidiaries on the one hand, and Tech-pharma Management AG (which is controlled by Willy Michel) and its subsidiary Finox AG on the other hand. This contract was terminated on December 20, 2011, and replaced by a licensing agreement. Finox AG primarily develops pharma-ceuticals, in particular fertility hormones as well as devices for their administration. The licensing agreement regulates the rights to the technology and the industrial property rights developed under the cooperation contract with regard to the administration devices. Ypsomed AG is granted a license for the use of two administering technologies outside of the specified areas of application. Finox AG may use the indus-trial property rights developed under the cooperation contract on an exclusive basis within specified areas of application. Furthermore, under the licensing agreement, a former em-ployee who has held key positions at Finox AG during the last three and a half years rejoins Ypsomed AG. Under the licensing agreement, Finox AG can continue to use consult-ancy services provided by Ypsomed employees at hourly and daily rates that are in accordance with the prevailing market rates. Finally, the termination of the cooperation contract means that the former first right of refusal of Ypsomed AG to purchase the shares of Finox AG now no longer applies. The termination of the cooperation contract and the conclusion of the new licensing agreement were discussed and approved by the Board of Directors and, in the opinion of the Board, represent a cooperative relationship that is usual in the mar-ket.

92


Dr. h. c. Willy Michel, Chairman of the Board of Directors and CEO of Ypsomed Holding AG and the Ypsomed Group, founded Disetronic together with his brother in 1984. They were together until his brother’s departure from the business in 1995, and thereafter Willy Michel was solely responsible for the development, production, distribution and sale of Disetronic products (until 1999). Within the scope of the sale of Disetronic to Roche Holding AG in 2003, Willy Michel repurchased the injection business of Disetronic, which has since then traded under the name Ypsomed. He has held the post of Chairman of the Board of Directors of the Disetronic Group and now of the Ypsomed Group without interruption. Prior to the founding of Disetronic, Willy Michel, who holds a professional qualification as a pharmaceutical consultant with a federal diploma, obtained a broad range of experi-ence with several industrial and pharmaceutical companies in the fields of development, sales and marketing, and he was the head of novo Nordisk Switzerland for six years (from 1978 until 1984). For three years (from 1998 until 2001) he was a member of the Burgdorf City Council, and in 2004 the city awarded him its Medal of Honor. In addition, he is the owner of a number of companies including several well-known firms involved in the fields of art, watchmaking and gastronomy as well as Finox AG, which is active in the de-velopment, manufacturing and sale of pharmaceuticals. He is currently Vice-Chairman of the Board of Directors of BV Holding AG (Chairman from 2001 until March 2008), a member of the Board of Directors of Adval Tech Holding AG (since 2007), and is a member of the Boards of Directors of various non-listed companies operating in different sectors from the Ypsomed Group and of no significance to its busi-ness activities (Faes Bau AG and others). In 2005, Willy Michel was declared the “Master Entrepreneur of the Year” for his overall business performance by Ernst & Young AG, and in 2006 he was awarded an honorary doctorate (Dr. h. c.) by the Economic and Social Science Faculty of the Uni-versity of Bern.

Prof. em. Dr. rer. pol. Dr. h. c. mult. Norbert Thom, Mem-ber of the Board of Directors of Ypsomed Holding AG since 2005. After studying economics and social sciences, he became a scientific assistant, project manager and lecturer at the University of Cologne, Acting Professor at the Univer-sity of Giessen and then full Professor of management, or-ganization and human resources studies at the University of Fribourg, Switzerland. Prof. em. Thom is the founder (in 1991) and director of the Institute for Organization and Human Resources at the University of Bern (until 2012) as well as Emeritus Professor of Business Management Studies. From 1995 until 1997 he was Vice-Rector for Finance and Planning and a member of the Board of Governors at the University of Bern. From 1997 until 2000 he was a member of the Swiss Scientific Board, which is the advisory body of the Federal Council for questions concerning science policy. Prof. em. Thom has three honorary doctorates for his academic achieve-ments in the areas of public management, organization and human resources management. He received these awards from universities in Lithuania (Vilnius), Austria (Linz) and Germany (Halle-Wittenberg). He has many years of practical experience as, among other things, an organizational and human resources advisor to companies, authorities and governments. He was further a member of the Board of Direct-ors at WIFAG Polytype Holding AG, Bern (until 2011). He has been extensively involved in the further training of man-agers, is a lecturer for several executive master level courses and is Vice-President of the Volkswirtschaftliche Gesellschaft of the canton of Bern and Vice-President of the Schweizerische Gesellschaft fur Organisation und Management (SGO).

Members of the Board of Directors

93

Cor

pora

te G

over

nan

ce

Name Nationality Year of birth Position Member since* Elected until the GV

Dr. h. c. Willy Michel Swiss 1947 Chairman of the Board of Directors 1984 2013

as CEO 2011 2013

Gerhart Isler Swiss 1949 Member of the Board of Directors 2008 2013

Prof. em. Dr. rer. pol. Dr. h. c. mult. Norbert Thom German 1946 Member of the Board of Directors 2005 2013

Swiss

Anton Kräuliger Swiss 1946 Vice-Chairman of the Board of Directors 2007 2013

* Including membership of the Board of Directors of Disetronic


Gerhart Isler, Member of the Board of Directors of Ypsomed Holding AG since 2008. After completing his studies in economics at the University of Zurich, Gerhart Isler joined the family newspaper publishing company Finanz und Wirtschaft AG as an editor in 1976. In 1980 he managed the company’s editorial department in New York, was head of foreign correspondents from 1981 until 1986, and then held the position of manager of the publishing house until 1989. He then became the owner of Finanz und Wirtschaft, which enjoyed strong growth up to 2000 and became the country’s most important financial newspaper. Mr. Isler subsequently sold the publishing firm but continued as its editor until the end of 2004. From 2005 until the end of 2008, Mr. Isler was a member of the Board of Directors of the listed company PubliGroupe and from 2008 to spring 2012 he was a member of the Board of Directors of the listed investment company New Value. In 2005, he was elected to the Board of Directors of Grand Casino Baden. Mr. Isler has been a member of the Board of Trustees of the move>med Foundation, which is involved in the field of sports, since 2005. Furthermore, Mr. Isler has been head of the Bergdietikon municipal council since early 2010.

Anton Kräuliger, Vice-Chairman of the Board of Directors of Ypsomed Holding AG (member of the Board since 2007). After completing his studies at ETH Zurich with a degree in Mechanical Engineering, Anton Kräuliger joined the family business in 1971 and in 1978 took over the majority share-holding in Lyss AG (today Metalyss AG), a metal foundry and fittings factory. He developed this company into the leading fittings group on the Swiss market, the Similor Group. Within the scope of the sale of the fit tings division to Madison Private Equity Holding AG in 2002 and 2005, Mr. Kräuliger repurchased the Industrial Division, which today is combined into Metalyss AG once more. Between 1993 and 2004, Mr. Kräuliger was a member of the Board of Directors of the listed Berner Kantonalbank BEKB | BCBE and continues to be an active member of several Boards of Directors including serving as Chairman of the Board of Directors of Metalyss AG (since 1978), Chairman of the Board of Directors of Sécheron SA (since 2005) as well as a member of the Board of Directors of the parent company Sécheron-Hasler Holding AG (since 2005). Anton Kräuliger is also the owner of Moospinte AG, a restaurant in Munchenbuchsee. As a member of the City Council for the town of Kappelen he is director of the Finance Department.

94

Dr. h. c. Willy Michel Prof. em. Dr. rer. pol. Dr. h. c. mult. Norbert Thom

Anton Kräuliger Gerhart Isler95

Cor

pora

te G

over

nan

ce


Interrelated companies

Willy Michel is also Vice-Chairman of the Board of Directors of BV Holding AG, which is listed on the BX Berne eXchange. On March 31, 2012, BV Holding AG held a total of 22 500 shares in Ypsomed Holding AG (previous year: 22 500 shares), representing a shareholding of 0.18% (previous year: 0.18%).Willy Michel is also a member of the Board of Directors of Adval Tech Holding AG, a company listed on the SIX Swiss Exchange and with headquarters in Niederwangen. In June 2007, Ypsomed AG and Adval Tech Holding AG signed an agreement on strategic cooperation in tool construction with a fixed contract term of five years. The objective of this co-operation is to bring together the respective strengths and core competencies of both companies and to use them for the efficient manufacturing of high-quality products. As part of this agreement, Ypsomed from time to time has tools manufactured by Adval Tech or its group companies at fair market prices based on standard industry conditions and existing competitive offers. Ypsomed and Adval Tech have also entered into a subcontracting agreement in May 2012. Under this agreement, Adval Tech, in its capacity as a sub-contractor for Ypsomed, will manufacture infusion sets for insulin pumps.

How the Board of Directors operates

The Board of Directors holds regular meetings four times per year at which it accepts management’s written report and the verbal comments of the Delegate and CEO, deliberates and also decides on management proposals. The auditors participate in the May meeting of the Board of Directors at which they give information on the comprehensive report and on other questions. The Board of Directors meets on one ad-ditional occasion per year for two to three days within the context of a strategy meeting with management. Occasion-ally the Board of Directors makes additional decisions by correspondence. The agendas for the meetings are set by the chairman; any member may ask for points to be included on the agenda. The members receive the agenda and the necessary basis for decision-making generally seven to ten days before each meeting. Any member of the Board of Dir-ectors may request information about any aspect of the Group’s affairs. Votes and resolutions within the Board of Directors are taken by majority decision; if the vote is tied, the Chairman, or in his absence the Vice-Chairman, has the deciding vote. Votes may not be taken by proxy. Meetings of the Board of Directors are regularly attended by the CFO

and, depending on the business to be discussed, by other members of management. Simon Michel, the son of Willy Michel and a member of management, also takes part in Board of Directors’ meetings with an advisory role.Given the size and composition of the Board of Directors, it may advise and decide on all matters in plenary. However, it may delegate individual powers to a committee of the Board of Directors. There is also a monitoring committee consisting of three members of the Board of Directors, but not the Chair-man of the Board of Directors. The members of the monitoring committee are Anton Kräuliger, Gerhart Isler and Prof. em. Norbert Thom. In the year under review, the Board of Directors met a total of five times and passed several resolutions by correspond-ence. During the Board of Directors’ meeting in May 2011, the lead auditor participated. The Board of Directors addition-ally met in March 2012 for two and a half days as part of the strategy meeting with executive management. All members of the Board of Directors participated in all Board of Direc-tors’ meetings, in the General Meeting of Shareholders of June 2011, and in the strategy meeting of March 2012.

Regulations concerning authority

The Board of Directors by law has certain non-transferable and irrevocable duties. It has the highest decision-making power in the company, under restriction of those matters on which shareholders must decide in accordance with the law. In particular, it defines company policy, the mission statement – consisting of a mission and a vision – and the strategic direc-tion of the Ypsomed Group, sets its targets and priorities, and allocates the resources for achieving the targets set. The Board of Directors defines the organization of the Ypsomed Group, supervises business activities, controls the finance and accounting divisions and is responsible for appointments and dismissals as well as the supervision of the individuals entrusted with management duties. It is responsible for the Annual Report, issues the Code of Conduct, approves the budget and the mid-term planning for executive management and also monitors the business activities of the Group com-panies. It periodically assesses strategic, operational and financial risks. The Board of Directors approves individual business affairs. This includes, in particular, decisions on the purchase or sale of companies and properties as well as the conclusion of contracts regarding strategic cooperation and contracts with other financial significance. The Board of Direct-ors approves securities obligations and employment contracts with members of management. At least once a year, the

96


members of the monitoring committee speak individually with the persons in charge of the internal control system, risk management and compliance on the topics of monitoring the internal control system, risk management, compliance and internal audit planning. They report on their findings to the entire Board of Directors. The responsibilities of the Board of Directors and of the other decision-makers within the Ypsomed Group are fixed in the assignment of authority. Otherwise, the Board of Directors has delegated responsibility for run-ning the company to its Delegate and CEO.

Instruments for information and control with regard to management

The Ypsomed Group’s information and control instruments (Management Information System, “MIS”), which are at the disposal of the Board of Directors, consist of written manage-ment reporting, which is produced quarterly (management review, quarterly reports), and financial reporting. The Chair-man of the Board of Directors and CEO has access at all times to the MIS. As Chairman of the Board and CEO of Ypsomed, Willy Michel chairs the management meetings that regularly take place every two weeks and also participates in them. The CFO and Simon Michel (member of manage-ment) regularly participate in the meetings of the Board of Directors. Furthermore, the entire Board of Directors meets for two to three days within the context of a strategy meeting with management and other employees during which there is also a focus on risk management. The officer responsible for risk management takes part in all meetings of manage-ment, of the whole Board of Directors and in the strategy meeting.Furthermore, the Board of Directors uses strategic planning documents as management instruments for steering the com-pany. Responsibility for risk management and monitoring rests with management, which reports on these matters peri-odically to the Board of Directors, but at least once a year. In addition to these documents, further selected financial figures are at management’s disposal on a monthly basis. Risk assessment is based on a risk inventory that encom-passes the relevant risk categories such as strategic risks, management risks, general risks in operating business, legal risks, systemic risks, financial risks (including market, credit and liquidity risks) and event risks (including political, regula-tory, fiscal and external risks). These risks are assessed with regard to probability of occurrence and impact.The Internal Auditing function, for which the Board of Direct-ors is directly responsible, is commissioned with the constant

expansion of the documented, internal control system. The auditing plans are based on a risk-oriented procedure that relates to business processes and are geared towards the following goals and tasks: reviewing the fulfillment of business goals and objectives; evaluation of the effectiveness of risk management, control and corporate management processes; optimization of business processes; improvement of controls and processes with regard to the information systems; verifi-cation of controls and processes for accounting systems and financial reporting; confirmation and guarantee of authorized business transactions; safeguarding of assets; support with regard to complying with legal and regulatory requirements; and reviewing significant or particular business cases and transactions. The Board of Directors can determine add-itional areas to be reviewed. The officer responsible for in-ternal auditing provides the auditors four times per year with appropriate documentation on his internal auditing activities and coordinates these with the auditing to be carried out by the auditors in the framework of the intermediate and year-end audits.

Accounting

With effect from September 30, 2011, Ypsomed changed its accounting standard from IFRS to Swiss GAAP FER. The half-year financial statement at the end of September 2011 was prepared for the first time in line with the new standard. The foremost principle of Swiss GAAP FER is to promote a true and fair view of the assets, liabilities, financial position and profit or loss, so informative and reliable accounting remains guaranteed under Swiss GAAP FER. Group accounting in accordance with Swiss GAAP FER comprises comprehensive consolidated accounts including profit and loss statement, balance sheet, cash flow statement, statement of changes in equity, as well as selected management statistics.

97

Cor

pora

te G

over

nan

ce

Dr. h. c. Willy MichelChief Executive Officer, CEOand Chairman of the Board of Directors


Executive ManagementThe Delegate and CEO as well as the executive management team are responsible for the operational management of the Ypsomed Group within the scope of the guidelines laid down by the Board of Directors.

Name Nationality Year of birth Position Acting for Ypsomed (or pre-2003 for Disetronic)

Dr. h. c. Willy Michel Swiss 1947 as Chairman of the Board of Directors 1984

as CEO 2011

Dr. Benjamin Reinmann Swiss 1969 Senior Vice-President Operations 2011

Hans Ulrich Lehmann Swiss 1966 Senior Vice-President Technology 2011

Simon Michel Swiss 1977 Senior Vice-President Marketing & Sales 2006

Niklaus Ramseier Swiss 1963 Chief Financial Officer (CFO) 2002

Yvonne Müller Swiss 1969 Senior Vice-President Human Resources 2003

Dr. Beat Maurer Swiss 1958 Senior Vice-President Legal & Intellectual Property,Secretary of the Board

1992

98

Niklaus RamseierChief Financial Officer (CFO)

Dr. Beat MaurerSenior Vice-President Legal & Intellectual Property

Dr. Benjamin ReinmannSenior Vice-President Operations

Simon MichelSenior Vice-President Marketing & Sales

Yvonne MullerSenior Vice-President Human Resources

Hans Ulrich LehmannSenior Vice-President Technology

99

Cor

pora

te G

over

nan

ce

Organisation of Ypsomed

CEO and Chairman of the Board of DirectorsDr. h. c. Willy Michel

Board of Directors

Finance & ITCFO

N. Ramseier

Legal & IPDr. B. Maurer

TechnologyH. U. Lehmann

Marketing & SalesS. Michel

OperationsDr. B. Reinmann

Human ResourcesY. Muller


Dr. h. c. Willy Michel, has been Chairman of the Board of Directors of Ypsomed Holding AG since its creation (1984) and CEO of Ypsomed Holding AG and the Ypsomed Group since August 2011. Further details about Willy Michel can be found in the section “Members of the Board of Directors” on page 93.

Simon Michel, Senior Vice-President Marketing & Sales, with Ypsomed since October 2006. Member of management since 2008 and responsible for Marketing & Sales. From 2003 until 2006, he worked for Orange Communications AG in Zurich and Lausanne where he was responsible for, among other things, the introduction and marketing of UMTS. Simon Michel studied economics at the University of St. Gallen and completed a Masters with a focus on media and communications manage-ment. Since 2006, he has been a member of the Board of Direct-ors of Sphinx Werkzeuge AG and since 2008 a board member of the local trade and industry association.

Benjamin Reinmann, Dr. med., Dr. phil. med., Senior Vice- President Operations, has carried out a number of different roles at Ypsomed (and at Disetronic prior to 2003) since joining the company in 2002, in the areas of Marketing & Sales, Technol-ogy and Production. Previously a medical practitioner at the Universitätskinderspital (University Children’s Hospital) Bern (2001 – 2002) and research associate at the University of Bern and the University of Indianapolis, USA (1997 – 2001). He studied medicine, took his doctorate in medicine and structural biology at the University of Bern, then did postgraduate studies in business management at PHW Bern.

Hans Ulrich Lehmann, Senior Vice-President Technology. He has been with Ypsomed since 2000 (and at Disetronic prior to 2003) in different positions, initially as Senior Project Manager for R&D projects, before spending several years as Vice-President Manufacturing and Vice-President Technology. Previously he

worked at various medical device manufacturing and injection molding companies in Switzerland and the USA. He graduated as a mechanical engineer and completed the postgraduate program in business administration at the University of Applied Sciences in Bern and also completed the Program for Leadership Development PLD at Harvard Business School in Boston, USA.

Niklaus Ramseier, CFO, with Ypsomed (pre-2003 with Disetronic) since 2002, prior to that Head of Finance and Con-trolling for the industrial services product line of the Von Roll Group (from 1995 until 2002) and various advisory and ac-counting functions within a trust and auditing company. Educa-tion: Swiss certified expert in accounting and controlling.

Yvonne Müller, Senior Vice-President Human Resources, with Ypsomed since 2003, prior to that responsibility for training at Berner Kantonalbank (BEKB I BCBE (from 2002 until 2003) and for human resources at X-Media and Scout24 (from 2000 until 2002) as well as at IKEA (from 1996 until 2000). Education: graduated as a human resources specialist.

Beat Maurer, Dr. iur., attorney-at-law, Senior Vice-President Legal & Intellectual Property, Secretary to the Board of Directors of Ypsomed Holding AG, with Ypsomed (pre-2003 with Disetro-nic) since 1992, prior to that tax and legal consultant with a trust and auditing company. Education: degree in law from the University of Fribourg, studied at the Free University of Berlin, took a doctorate in law at the University of Bern and was admit-ted to the bar in the canton of Bern. Beat Maurer has been a judge specializing in issues relating to business law and intel-lectual property law at the commercial court of the canton of Bern since 2002. He is also a member of the Board of Directors of FASMED, the Federation of Swiss Medical Devices Trade and Industry Associations, based in Muri near Bern.

100


Management contractsThere are no management contracts.

Board of Directors’ remunerationThe members of the Board of Directors draw a remuneration that is discussed and established by the complete Board of Directors at its own discretion and during a plenary session without any external advisers present. All remunerations are paid in cash. Share or option plans do not exist.

The Board of Directors’ remuneration (consisting of a fixed amount, a variable amount and an attendance fee) is reviewed each year by the Board of Directors and set anew at its own discretion. The fixed sum amounts to CHF 150 000 (prior year: CHF 150 000) for the Chairman of the Board of Direct-ors and CHF 90 000 (prior year: CHF 90 000) per member of the Board of Directors. The variable sum amounts to between 0% and 331/3 % of the fixed sum. The variable amount depends on achieved vs. budgeted targets based on two-thirds of the consolidated EBIT margin and one-third of the consolidated sales, and in the year under review comprises 5.0% of the fixed sum. The attendance fee amounts to CHF 1 500 per meeting of at least half a day in duration (prior year: CHF 1 500). For shorter meetings and for the participation in the strategy meeting and the General Meeting of Share-holders, no attendance fee is paid. The Board of Directors’ remuneration and attendance fees are paid after the Gen-eral Meeting of Shareholders.

In addition, for consulting services, the Chairman of the Board of Directors (respectively the company Techpharma Management AG controlled by him) receives a flat fee of CHF 140 000 incl. sales tax (prior year: CHF 140 000). This amount represents the full remuneration (in addition to the aforementioned Board of Directors’ remuneration and attend-ance fee) for all consulting and other work carried out by Willy Michel, including his activity as CEO in the year under review. The relationship to affiliated persons is described in the section Board of Directors, Members of the Board of Directors, page 91.Information relating to all actual remuneration paid to present and former members of the Board of Directors in the 2011/2012 business year as stipulated by Art. 663bbis of the Swiss Code of Obligations can be found in the Notes to the 2011/2012 financial statement, page 80.

101

Cor

pora

te G

over

nan

ce


Management remunerationThe amount paid to Willy Michel and to his company Tech-pharma Management AG for consulting as Chairman of the Board of Directors (see page 80) is the full remuneration (in addition to the aforementioned Board of Directors’ remunera-tion and attendance fee) for all consulting and other work carried out by Willy Michel, including his activity as CEO in the year under review. Willy Michel has expressly waived the right to any more extensive remuneration for his operating activities as CEO in the year under review.

Remuneration for other members of management consists of a base salary and a variable amount depending on the suc-cess of the company and the achievement of individual goals. The Chairman of the Board of Directors reviews the base salary of each individual member of management on an an-nual basis and effects any adjustments at his own discretion. The variable portion of salary lies between 0% and 31.25% of the total annual salary (gross) of the individual members of management. It depends on achieved vs. budgeted targets based on 50% of the consolidated EBIT margin, 25% on consolidated sales and 25% on the individual performance of the member of management in terms of achieving individ-ual targets. All remunerations are paid in cash. Share or option plans do not exist.

The payment of lump sum expenses is based on the expense regulation approved by the canton of Bern; according to this, lump sum expenses only cover effective expenses and are thus not reported separately. Likewise, additional payments (such as discounts for purchasing Reka vacation checks, etc.) are not listed as long as they do not exceed a total amount of CHF 2 000 per person per year.

No severance payments have been agreed upon with direct-ors, nor have any long-term contracts of more than six months duration been agreed with members of management.

In the year under review, former CEO Richard Fritschi resigned from management. His employment with Ypsomed ended on 31 March 2012. No severance payments were paid to former directors in the year under review.

Information relating to the actual remuneration paid directly and indirectly to members of management and former members of management in the 2011/2012 business year as stipulated by Art. 663b bis of the Swiss Code of Obligations can be found in the Notes to the 2011/2012 financial statement, page 80.

Allocation of shares in the year under review

No shares were allocated in the year under review.

Share ownership

Information relating to the actual shares held directly and in-directly by members of the Board of Directors, management and affiliated persons in the 2011/2012 business year as stipulated by Art. 663c of the Swiss Code of Obligations can be found in the Notes to the 2011/2012 financial statement, page 81. Prof. em. Norbert Thom holds management courses that draw on practical examples; in order to avoid any conflicts of interest, he does not hold any shares in the company.

There were no options issued by the company on equity rights of Ypsomed Holding AG or Group companies.

102


Shareholders’ rights of participation

Voting-right restrictions and representation

All shareholders who are entered in the Share Register with voting rights are entitled to vote at the General Meeting of Shareholders. Shareholders may arrange to be represented at the General Meeting of Shareholders by written proxy. In exercising his voting rights, no shareholder may directly or indirectly amalgamate more than 5% of the total voting rights in the form of his own shares and those he is representing. Legal entities and partnerships that are related to one an-other through capital ownership or voting rights or by virtue of a common management or otherwise, as well as natural persons, legal entities or partnerships that adopt a coordi-nated approach in order to circumvent the restrictions on voting rights, will be considered as one person. However, the restriction on voting rights will not apply to the exercise of voting rights by the company representative, a depositary representative or the specially designated independent shareholder representative, nor to Willy Michel because more than 5% of all voting rights were registered to him in the Share Register at the time the Articles of Association were drawn up (Art. 16 of the Articles of Association).

Quorums according to the Articles of Association

Unless otherwise stipulated by law or by the Articles of As-sociation, the General Meeting of Shareholders will adopt resolutions and conduct votes on the basis of an absolute majority of the votes cast, excluding blank and invalid votes. The Chairman will also vote and, if the vote is tied, he will have the deciding vote. The quorums laid down in the Articles of Association reflect statutory quorums.

Convening the General Meeting of Shareholders

The General Meeting of Shareholders will be convened at least 20 days prior to the meeting by way of a letter to the shareholders who are entered in the Share Register, as well as by publishing a notice in the Swiss Official Gazette of Commerce (SOGC).

Agenda items

Shareholders holding shares with a nominal value of at least CHF 1 million have the right to request that a specific matter be put on the agenda by specifying the items of the agenda and the proposals. Such requests must be submitted in writing to the Chairman of the Board of Directors at least 45 days before the meeting.

Entries in the Share Register

Entries in the Share Register will be made until six days prior to the General Meeting of Shareholders.

Change of control and blocking mechanismsIn the event of a public takeover bid, the bidder is required pursuant to Art. 32 of the Swiss Stock Exchange Act to make an offer for all of the company’s listed shares as soon as he acquires shares directly, indirectly or in concert with third parties, which along with the shares already held exceed the threshold of 49% of the voting rights of the company, wheth-er exercisable or not (Art. 10 Articles of Association).

There are no change-of-control clauses with members of the Board of Directors, of management and/or other management personnel.

103

Cor

pora

te G

over

nan

ce


AuditorsTerm of mandate of auditors and term of the lead auditor

On June 27, 2007, the General Meeting of Shareholders of Ypsomed Holding AG selected Ernst & Young AG, Bern, as auditors for the first time. The lead auditor, Mr. Christian Schibler, has been in office at Ypsomed Holding AG since June 2007 and will be replaced in 2014 at the latest due to the rotation obligation. The auditors are each appointed for a term of one year by the General Meeting of Shareholders, the last time being on the occasion of the 2011 General Meeting of Shareholders.

Revisionshonorare

The total auditing fees charged by the auditor for Ypsomed Holding AG and its Group companies in the course of the year under review amount to TCHF 262. Ypsomed Holding AG and its Group companies were invoiced TCHF 97 for additional so called non-auditing services in respect to tax advisory and interpretation of Swiss GAAP FER and disclosure requirements.

Instruments for supervision and control of auditing

The complete Board of Directors undertakes the supervision and control of the auditor. The lead auditor is in attendance during the discussion and acceptance of the consolidated and annual financial statements by the Board of Directors. The auditor compiles a comprehensive report annually for the attention of the Board of Directors, and it is discussed by the Board of Directors with the lead auditor in attendance.

104

Information policyYpsomed Holding AG maintains an open and transparent communication policy towards shareholders, potential invest-ors, financial analysts, the media, customers and other inter-ested people, based on the principle of equality. The com-pany uses the following instruments: annual report, half-year report, presentation of the annual results to the media and financial analysts ahead of the shareholders’ meeting, as well as media briefings and company publications that have potential relevance to the share price. Responsibility for com-munication with investors rests with the Chairman of the Board of Directors.

The following banks monitor the development of the Ypsomed Group:

Bank am Bellevue, Zurich (www.bellevue.ch), Gina Francioli

BZ-Bank, Wilen (www.bzbank.ch), Florian Gaiser

Credit Suisse, Zurich (www.credit-suisse.com), Christoph Gretler

Vontobel, Zurich (www.vontobel.com), Carla Bänziger

Zurcher Kantonalbank, Zurich (www.zkb.ch), Sibylle Bischofberger Frick

On our website at www.ypsomed.com (under Company/In-vestors) any interested person can access up-to-date and potentially market-relevant information (pull system) without charge. Furthermore any interested person can register at www.ypsomed.com/ch/unternehmen/investoren (push system) to be added to an e-mailing list to receive the publications mentioned about the company (push system). The official publication organ of Ypsomed Holding AG is the Swiss Of-ficial Gazette of Commerce (SOGC). Company publications with potential relevance to the share price are usually com-municated at the end of daily trading. Such publications are initially reported to the SIX Swiss Exchange Regulation and thereafter installed on the above-mentioned website and simultaneously communicated to a number of national news-papers, electronic information systems and to persons regis-tered on the e-mail distribution list.

Stock listingThe registered shares of Ypsomed Holding AG are traded at the SIX Swiss Exchange and at the BX Bern eXchange.

Ticker symbols:YPSN (Telekurs)YPSN.S (Reuters)YPSN SW (Bloomberg)Securities numer 1939 699ISIN CH 001 939 699 0

Key forthcoming dates27 Juni 2012General Meeting of Shareholders, Bern

1 November 2012Press conference and presentation of thehalf-year figures 2012/13, Burgdorf

28 Mai 2013Press conference and presentation of theannual results 2012/13, Burgdorf

ContactYpsomed Holding AGBenjamin Overney, Head of Investor & Public RelationsUrsula Rytz, Head of Marketing Communication

Tel. +41 34 424 41 59Tel. +41 34 424 41 55

[email protected]


105

Cor

pora

te G

over

nan

ce

Glossary

Ampule / CartridgeA drug reservoir containing the drug to be administered used with, for example, reusable pens. Some substances need pens with two-chamber cartridges, which contain lyophilized drug and diluent that are mixed automatically in the pen before use (see also Cartridge).

AmylinHormone produced together with insulin in the pancreas. Like insulin, it is no longer produced in the case of a functional inability of the pancreas. According to latest research, amylin complements the effect of insulin in the treatment of diabetes and allows the blood sugar level to be controlled more effectively.

AnemiaAnemia means an insufficiency of blood. This can manifest itself in a reduction in hemoglobin concentration (red blood pigment), in the hem-atocrit (measurement of blood thickness, packed cell volume) and / or in the number of erythrocytes (red blood cells) in the blood compared with the age norm. Among its effects is a reduction in the transport capacity for oxygen in the blood. The classic symptoms include loss of energy and rapid fatigue as well as pallor, fatigue, breathlessness and palpitations (the heart beats irregularly, faster or more forcefully than it should in rela-tion to the level of activity demanded of it). Anemia can have a number of different causes.

AutoinjectorIn autoinjectors, needle insertion into the skin and / or injection of the drug are automatic, usually being driven by means of a spring mechanism.

Biomolecule injectablesDrugs manufactured using biotechnology. Such biomolecules cannot be delivered using traditional methods (e. g. orally) because they would be destroyed by the digestive tract and thus require the injectable route of administration.

BiosimilarThe term “biosimilar” refers to a protein-based mimetic drug that has been produced using biotechnology and which is approved after the expiration of the patent period of an original active substance. Unlike the classic drugs defined in terms of molecular structure, the active substances of these novel biotechnology products are not completely identical to the original active substance and therefore require more extensive approval and monitoring procedures than the classic generics. The main reasons for these differences are the different organisms (for example E. coli bac-teria) on which the target protein is expressed, and the different methods applied, such as separation and cleansing.

Blood sugar (blood glucose)Blood sugar means, in general, the level of glucose in the blood. Glucose is an important source of energy for the body and represents a significant measured value in medicine. If the blood sugar is high over a sustained period of time (hyperglycemia), diabetes mellitus typically exists. In intensi-fied insulin therapy, the blood sugar or blood glucose should be mea s-ured at least four times a day so that the amount of insulin administered can be adjusted to actual requirements. A person’s insulin requirements change over the course of the day due to the varying levels of hormones that influence blood sugar, the consumption of food, physical activity or febrile infectious diseases.

Blood sugar monitoring (blood glucose monitoring)Diabetics normally measure their blood sugar levels themselves using a portable blood sugar monitor. To carry out the measurement, a small blood sample must first be placed on a test strip. Through an enzymatic reaction with the test strip, the blood sugar is converted into a measur-able product that is then measured on the basis of a photometric or an electrochemical process and displayed by the monitoring device. In the case of intensive insulin therapy, the measuring of the blood sugar takes place a minimum of four times daily.

CannulaSee Pen needle.

CartridgeA drug reservoir containing the drug to be administered used with, for example, reusable pens. Some substances need pens with two-chamber cartridges that contain a lyophilized drug and diluent that are mixed automatically in the pen before use (see also Ampule/Cartridge).

CM (Contract Manufacturing)Contract Manufacturing refers to the assigning of several or individual stages in the manufacture of a product to a contractor (outsourcing manu-facturing). There are cost benefits for the OEM / ODM manufacturer as the infrastructure is not just utilized for a single product line / assembly line or product, but for several manufacturers or products. The specialization of the contractor with specific infrastructure leads to larger production volumes (numbers of units). Thus both parties benefit.

ComplianceIn medicine we talk about the compliance of the patient. This means that, in many illnesses, for healing to occur the patient must have a cooperative attitude. In the medical sense, compliance can therefore be described as sticking to one’s therapy, taking one’s medicine as prescribed; in short, following the doctor’s recommendations. Compliance is particularly important for diabetics with regard to taking their medicine, following a diet or making lifestyle changes.

CO2 equivalentIndicator of the greenhouse gas potential of substances in the earth’s atmosphere, such as methane (CH4), nitrous oxide (N2O), HCFC / CFC or sulfur hexafluoride (SF6). The greenhouse effect of carbon dioxide serves as a reference value. Calculations use factors as defined in IPC C2001.

Depot formulation“Depot form / formulation» is synonymous with the terms “long-acting” or “sustained release formulation”; in other words, the fact that the substance that is taken orally or with an injection is released into the bloodstream in a delayed manner, e. g. in order to achieve a longer duration of effect or to permit an active ingredient to be supplied on a continuous basis.

Ypsomed – Glossary

106

Diabetes mellitusDiabetes mellitus is a chronic metabolic disorder involving increased blood sugar levels. In people with diabetes mellitus, the blood sugar is no longer absorbed from blood cells in the requisite quantity for the production of energy. As a result, there is excess glucose in the blood (hyperglycemia / excess sugar), which is then excreted in part through the kidneys. In Type 1 diabetes mellitus, the body produces insufficient insulin, if any insulin at all (absolute insulin deficiency), because most or all of the insulin-producing cells in the pancreas have become damaged by an autoimmune disease. It generally manifests itself in persons up to 35 years old and requires the regular subcutaneous administration (injection) of insulin. Type 1 diabetes mellitus accounts for about 10 % of all cases of diabetes mellitus and, thanks to its clear principal symptoms, is generally correctly diagnosed and treated by physicians. In Type 2 diabetes mel-litus, which is much more common, the pancreas continues to produce insulin, however its effectiveness is reduced by an insulin resistance (insulin insensitivity) of the somatic cells. As a rule, this leads to an increased release of insulin (hyperinsulin anemia) in order to compensate for the deficient insulin effectiveness. Risk factors, such as being overweight or lack of exercise, promote the development of Type 2 diabetes, therefore it frequently has the designation of an illness of affluence. Type 2 diabetes mellitus is generally diagnosed in people over the age of 40 and who are overweight. As a first step, it is often successfully treated by follow-ing a healthy diet and by getting more physical exercise. In later phases, tablets and insulin injections may be considered. According to estimates, about half of all people who currently have Type 2 diabetes mellitus are unaware of that fact. If both types of diabetes are not diagnosed at an early stage or if they are inadequately treated, this can lead to serious secondary diseases affecting the kidneys, nerves, eyes or blood vessels.

Dual chamber ampuleThe dual chamber ampule was developed primarily for lyophilized substances. Dual chamber technology enables efficient use of the active substance through careful product reconstitution. The dual chamber technology was thus designed specifically for sensitive drugs that are preserved through freeze drying. One of the two chambers contains the lyophilized active substance (freeze-dried active substance) and the other contains the solvent. The two are mixed together only immediately before use. This “all-in-one” design facilitates both a higher degree of accuracy in dosage and easier handling.

EIP (Environmental impact points)Quantitative expression of environmental impact in the form of a measure-ment based on the principle of ecological scarcity. Environmental impact points are determined on the basis of the extent to which environmental quality targets for air, water, soil and resources have been met.

EPO (erythropoietin)Natural hormone mainly produced by the kidney that regulates the forma-tion of red blood cells (erythrocytes) in the bone marrow.

FDA (Food and Drug Administration)US health agency.

FSH (follicle-stimulating hormone)FSH is a germ line hormone (a hormone excreted by the anterior pituitary gland and placenta) that stimulates follicle growth in females and activates sperm-forming cells in males. FSH is used for treating infertility.

GLP-1Glucagon-like peptide-1 (GLP-1) is a peptide hormone formed in the intestines that plays an important part in glucose metabolism as part of the “incretin effect” – the insulin response of beta cells in the pancreas to the supply of sugar through the intestines and the blood. GLP-1 is released directly into the bloodstream when food is eaten. It is broken down within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4) and therefore must be constantly produced. It stimulates the production of insulin in the pan-creas and slows the emptying of the stomach contents into the intestine, thereby suppressing hunger pangs and thirst. It also reduces glucagon levels. Glucagon helps the release and synthesis of glucose from the liver. In this way, secretion in sufficient quantities or subcutaneous injection of GLP-1 prevents excessively high levels of blood sugar.

Greenhouse gasesGases in the air that contribute to climate change (global warming) and that may be of either natural or anthropogenic origin. They emit thermal radiation corresponding to their temperature (infrared radiation) that acts as atmospheric counter-radiation and heats the surface of the earth in addition to the heat from sunlight. On the other hand, greenhouse gases also absorb some of the infrared radiation given off by the earth that would otherwise escape into space.

HGH (human growth hormone – somatropin)One of the body’s natural hormones used today primarily to treat growth disorders.

HeparinMedication with anticoagulation properties. An anticoagulant is a sub-stance that delays or stops blood clotting.

HyperglycemiaHyperglycemia (excess sugar) is an increased blood sugar value (glucose value) with clinical values above 110 mg / dl (6.1 mmol / l) on an empty stomach or above 140 mg / dl (7.8 mmol / l) two hours after eating. The cause of the hyperglycemia is a relative or absolute insulin deficiency (dia-betes mellitus). This has the effect that the glucose cannot be transported from the blood into the cells and at the same time glucose is released from the liver, for example. The result: blood sugar increases. The body attempts to excrete the blood sugar through the kidneys, thereby losing vital amounts of liquid, and affected parties react with strong thirst and frequent urination. Slight increases in blood sugar remain unnoticed for the most part because the initial symptoms, such as fatigue and lethargy, are not recognized as resulting from high levels of blood sugar. A complete insulin deficiency and a prolonged increase in blood sugar may lead to nausea, vomiting, a smell of acetone on the breath, the appearance of glucose and acetone in the urine and finally to a life-threatening diabetic coma. Insulin is administered and the intake of liquids is increased for the treatment of hyperglycemia.

HypoglycemiaHypoglycemia is low blood sugar with a blood sugar value of less than 40 mg / dl (2.2 mmol / l) without the presence of symptoms. Hypoglycemia can occur in all diabetics who are treated with sulfonylurea, glinides or insulin. Low blood sugar can occur when the factors reducing blood sugar (e. g. insulin, tablet effectiveness, physical activity) outweigh the factors increasing blood sugar (e. g. food intake, sugar regeneration in the liver). The symptoms include, among other things, trembling and sweating, increased appetite, headaches, weakness, a loss of concentration and blurred vision. It can be treated by the immediate administration of glucose or drinking fruit juice. Severe hypoglycemia can lead to unconsciousness and requires immediate medical attention.


107

Glo

ssar

y

IncretinsIncretins are hormones produced in the small intestine (peptide hormones) that are released after food is eaten and stimulate insulin secretion by the pancreas. At the same time, they prevent the insulin antagonist, glucagon, from being released. Patients with Type 2 diabetes release lower levels of incretin than healthy individuals. The incretins GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitor peptide) are of particular inter-est in the treatment of diabetes. There are two new classes of drugs that act on incretin metabolism: the “incretin mimetics” that imitate the action of incretins, and the “DPP-4 inhibitors” that delay the breakdown of endogenous incretins.

InjectionAdministration of liquid substances with a syringe.

Injection systems / injection devicesInjection systems or injection devices include self-injection devices such as pens and autoinjectors as well as pen needles.

InsulinA vital peptide hormone that is produced by the pancreas in the beta cells of the islets of Langerhans. The primary effect of insulin is the fast reduc-tion of the blood sugar concentration in that it supports the transport of glucose from the blood into the cells’ interior. Insulin was first discovered in 1921 by two Canadians, Dr. Frederick Banting and Charles Best, and has since been used to treat diabetes. Today, it is produced mainly by means of biotechnological processes and must be either injected or infused. It cannot be administered orally because the peptide hormone insulin would be destroyed by gastric acid.

Insulin analogsInsulin analogs are insulins with a modified amino acid sequence that have an altered metabolization compared with human insulin. The motivation for developing insulin analogs was to improve the ability to control the insulin treatment. In the case of normal insulin, the effect sets in after about 30 minutes, and the maximum effect is reached after one to two hours. Through the exchange of certain amino acids, the metabolization (pharmacokinetics) of the insulin can be altered without affecting its ac-tion, i. e. binding to the insulin receptors.

Insulin pumpInsulin pumps are small, battery-operated devices (about the size of a pager or cell phone) that can replace regular insulin injections for patients man-aging diabetes. They contain an insulin ampule / cartridge with fast-acting insulin. The insulin is delivered at regular intervals into the subcutaneous fatty tissue of the body by means of a catheter, for which the cannula is under the skin. The catheter and cannula are changed every one to three days. The infusion pump allows for an almost normal adjustment of blood sugar by continuously delivering small doses of insulin, preprogrammed by the patient, around the clock, even while a patient sleeps. In addition, the patient can deliver additional insulin doses at the touch of a button in order to be able to cover additional insulin requirements, for example at meals. The treatment with an insulin pump requires the patient to continue to take regular blood sugar measurements so that the insulin dose can be adjusted, if necessary.

Insulin patch pumpsPatch pumps represent a new generation of pumps; patch pumps are dis-posable pumps usable for up to three days, after which they are disposed of. They consist of a plastic case containing the insulin reservoir, and, with a small cannula that is placed under the skin, are adhered directly to the body. The tubing system connecting the pump and body is therefore no longer required. The pump system is operated via a remote control that is carried externally. The first patch pump available on the American market was the Omnipod®, which will be distributed in Europe from June 2010 as the mylife OmniPod.

Interferon alphaInterferons play an important role as messengers and cues for different defense mechanisms in the immune system. They are released by cells that are afflicted with viruses. In this way, defense cells of the immune system, such as macrophages, natural killer cells and cytocidal T lymphocytes, are activated. In addition, interferons inhibit the growth and the division of healthy as well as malignant cells. Alpha interferon is used for the treatment of acute and chronic hepatitis C infections.

Lantus®

Lantus® from Sanofi-Aventis is a long-acting insulin analog injected one to two times daily that lowers glucose levels for up to 24 hours. Lantus® is a basal insulin in that it provides for a slow and steady release of insulin.

Monoclonal antibodiesMonoclonal antibodies are highly specialized and targeted antibodies – active protein molecules that are produced by the immune system in response to a foreign substance (e. g. foreign bodies, pathogens) and can render it harmless – that are created synthetically using biotechnological processes. What is special about them is that they are able to activate the body’s own natural defense mechanisms to combat a disease. Until now, monoclonal antibodies have been used in cancer therapy in particular and for the suppression of adverse immune reactions, e. g. in cases of psoriasis. This may also involve autoimmune diseases or even the preven-tion of rejection reactions after organ transplants.


108

ODM (Original Design Manufacturer)A company is described as an Original Design Manufacturer (ODM) if it undertakes make-to-order production for another company. An ODM manufactures products commissioned by other companies, some of which it develops itself. The products are then sold under the buying company’s brand name. This method enables a customer of an ODM to offer branded products without having to run its own factory for this product. “Design” is significant in the definition of an ODM, as an ODM also carries out the planning and design of the parts produced. This is in contrast to a CM (Contract Manufacturer), which only undertakes the make-to-order production.

OncologyThe branch of medicine / science concerned with the prevention, diagnosis, treatment, follow-up care and study of cancer / tumor diseases.

Pen (injection pen)Injection device that externally looks like a fountain pen or ballpoint pen. The dose of medication prescribed by a doctor is set by adjusting a dosage knob and is injected from a cartridge through a cannula (pen needle) into the body.

Pen needle (cannula)A fine hollow needle for one-time use attached to the tip of the injection pen in order to inject the drug into the body. Ypsomed’s pen needles feature a click-on mechanism that makes the pen needle easy to attach to the pen.

PsoriasisPsoriasis is a non-communicable autoimmune disorder that affects the skin, resulting in lesions over various areas of the body. The most common form (accounting for 80 % of all cases) is plaque psoriasis, characterized by red, raised skin covered with scales.

® / ™

The ® or ™ symbols, when used in this document, indicate that the relevant name is a registered trademark of the relevant pharma partner of Ypsomed or Ypsomed itself.

Rheumatoid arthritisRheumatoid arthritis (also chronic polyarthritis) is the most common condi-tion that leads to inflammation in the lining of the joints. Most commonly, the chronic condition develops episodically, with an episode lasting typically between several weeks and a few months. The pain recedes between individual episodes. The cause of the condition has not been fully explained although it is thought to result from an autoimmune condition.

Self-injection devicesWhen used in this document, self-injection devices include pens (disposable, reusable and semi-disposable pens), autoinjectors, motor-driven injection systems, safety products, and needle-free technology.

Subcutaneous(from Lat. sub = under, cutis = skin, abbr. s. c.)A subcutaneous injection is an injection into the fatty tissue under the skin. Using pens or other injection systems, drugs can, for example, be administered intramuscularly, subcutaneously or intravenously.

ThrombosisThrombosis is the presence or accumulation of a blood clot (thrombus) in a blood vessel. In principle, thrombosis can develop in all vessels (arter-ies, veins). Colloquially, however, we commonly refer to thrombosis of the deep leg veins even when we mean phlebothrombosis. Arterial thrombosis occurs significantly less frequently. An embolism is a dangerous complica-tion of thrombosis. In this case, the thrombosis has detached from its point of origin in the vessel and is transported (embolism) in the body through the blood flow. Should the embolism block a narrow point in the vascular system, the tissue behind the affected location will no longer be properly supplied with blood and will be damaged. This is called an infarction. Infarctions can damage all organs (myocardial infarction, apoplexy, pulmonary embolism).


109

Glo

ssar

y

Editor and Design:Ypsomed Holding AG, Burgdorf

Concept:KOMET Werbeagentur AG BSW, Bernwww.komet.ch

Printing:Stämpfli Publikationen AG, Bern

Photography:Janosch Abel, Photography, Bern

The Group publishes its annual reports in English and German. The German version is legally binding.

Disclaimer

This annual reports contains certain forward-looking statements. These can be identified by terms such as “should”, “accept”, “expect”, “anticipate”, “intend” or similar terms and phrases. The actual future results may differ materially from the forward-looking statements in this annual report, due to various factors such as legal and regulatory developments, exchange rate fluctuations, changes in market conditions, as well as the activities of competitors, the non-introduction or delayed introduction of new products for various reasons, risks in the development of new products, interruptions to production, the loss of or inability to obtain intellectual property, litigation and administrative proceedings, adverse publicity and news coverage.

Links to third party websites and other references to the information of third parties are offered as a courtesy; we accept no responsibility for any third party information.

All product names mentioned in this report are trademarks owned by or licensed to the Ypsomed Group. Third-party trademarks are marked with ® combined with the product name.

Ypsomed Holding AG – Annual Report 2011/12

Ypsomed Holding AG

Brunnmattstrasse 6Postfach3401 BurgdorfSchweiz

Telefon +41 34 424 41 11Fax +41 34 424 41 22

[email protected]

Ypso

med

Hol

ding

AG

– A

nnua

l Rep

ort 2

011/

12

ypsomed holding ag – annual report 2011/12 · “diabetes care” and broaden our customer base....

Documents